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ABSTRACT 
 
The role and functions of Urotensin II (UII), Urotensin II-related peptide (URP) and 
proangiotensin-12 (PA12) are currently ambiguous, either due their relatively new 
identification and isolation from their host species, or due to contrasting and 
conflicting reports observing the physiological and pathophysiological role of these 
spasmogens within the mammalian cardiovascular system. Accordingly, we sought to 
determine the true physiological functions of these peptides in both healthy and 
diseased states.  
 
The initial task was to reveal potential reasons for the contrasting responses to UII, 
and to define the role of UII within the isolated rat heart. UII and URP retain a highly 
conserved cyclic region, shown to be necessary in receptor binding and activation, 
with the high inter-species variance within the N-terminus reported to be of little 
importance. Our research revealed UII to be highly species-specific, stimulating 
potent, sustained vasodilation of the coronary arteries in response to the native form 
infused, while non-native UII peptides had either no effect, or caused significant 
vasoconstriction. UII-induced vasodilative effects were found to be mediated by nitric 
oxide and prostaglandin activity combined. Reviewing publications to date it was 
evident that many studies employed UII foreign to the host species, reporting 
potentially untrue effects, based on our findings. 
 
Recent studies have identified UII as a potent agent in developing and promoting 
atherosclerosis and coronary artery disease through UII-induced mitogenic activity 
and promoting foam cell formation. Hence, we observed the effect of infusing the 
native species of UII and URP into a model of cardiac ischemia-reperfusion. Both 
preconditioning the heart with UII or URP, or infusing UII or URP upon reperfusion 
caused significant coronary vasodilation following ischemia, and significantly 
attenuated ischemic-induced myocardial injury. These studies indicated elevating UII 
and URP provided a level of cardioprotection, not only when administered into 
healthy hearts prior to an ischemic event, but also in hearts having already undergone 
ischemia and the resultant endothelial damage.  
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PA12 was the third peptide tested in the current thesis. Being newly identified and 
suggested to be a new component of the renin-angiotensin system (RAS) it was 
important to define the physiological role of PA12 upon the cardiovasculature, as the 
RAS is heavily associated with the development and progression of cardiovascular 
disease. Utilising the Langendorff isolated rat heart technique, PA12 was found to 
cause potent vasoconstriction of the coronary arteries, mediated by the angiotensin II 
type 1 receptor (AT1R). Furthermore, using subjecting the perfusate samples to 
radioimmunoassay and RP-HPLC revealed PA12 was converted to AngII. Both 
PA12-induced vasoconstriction and generation of AngII were found to be dependent 
upon chymase activity, with inhibition of ACE1 having little effect. Myography was 
employed to further study the vascular response to PA12 throughout the rat arterial 
system from the common carotid to the femoral arteries. PA12-induced 
vasoconstriction displayed a potency gradient, with greatest constriction observed in 
vessels closest to the heart, with potency reduced and eventually lost further from the 
heart. PA12-induced vasoactivity was shown to be dependent upon both chymase and 
ACE1 activity, with ACE1 regulating PA12 activity with greater potency.  
The intracellular pathways stimulated in response to PA12 were defined using western 
blotting, with PA12 stimulating phosphorylation of ERK1/2, JNK, p38 and PKCα/βII, 
but having no influence on PKCδ/θ. Stimulation of these pathways is consistent with 
the observed PA12-induced vasoconstriction, and also indicates that PA12 activation 
of AT1R and the subsequent cytokines, could potentially stimulate hypertrophy, 
apoptosis, cell growth and differentiation, and inflammation, promoting cadiovascular 
remodelling and progressing atherosclerosis, hypertension and other vascular diseases 
if not sufficiently regulated.  
Taken together, these studies indicate PA12 may have a primary role within the local, 
tissue-based RAS, providing an alternate substrate to angiotensin I, while ACE1 is the 
primary regulatory enzyme within the circulation. Our findings also display the 
chymase-dependent PA12/AT1R pathway as potential novel targets for 
pharmacological inhibition of RAS activity to ameliorate hypertension and 
maladaptive vascular remodelling. 
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1.  General Introduction and aims 
 
 
Peptides are short chains of amino acids joined together in a specific sequence capable 
of exerting effects either on neighbouring cells (paracrine), or at a distance from their 
point of synthesis (endocrine). Research into peptides has exploded in recent times 
and they have become recognised as controlling a vast amount of homeostatic 
regulation from hunger to blood pressure. Peptides can also be highly specific markers 
of health, providing practitioners with an otherwise invisible insight into the health of 
an individual. For example, natriuretic peptides are now widely used as a specific 
marker of cardiac health (Potter et al. 2009, Troughton et al. 2006), and growth 
hormone levels provide a measure of cellular reproduction and growth (Brooks et al. 
2008). Furthermore, once the physiological role of a specific peptide has been 
ascertained, pharmacological agonistic or antagonistic agents can then be designed to 
alter the peptides activity, providing therapeutic benefits in diseased states where: 1) 
the peptides beneficial effects may be lacking, or 2) the peptides detrimental effects 
may be in excess. Therefore, the greater number of peptides identified and isolated, 
the further our understanding of our homeostatic processes, and the greater power we 
have in controlling these. It was recently estimated that the human circulation contains 
more than 106 different proteins with approximately 1173 of those proteins currently 
identified (Anderson L. 2005). Whilst the acceleration in technological advancements 
in recent times has aided isolation and identification of new peptides from many 
species, it is equally important that the true biological function of each new peptide is 
deduced in order to provide any potential therapeutic benefit. Furthermore, it must 
also be determined whether the effects of each peptide differ between the healthy and 
diseased states.  
 
 
The current thesis is concerned with three recently identified peptides which have had 
few or no functional studies reported. Urotensin II (UII), urotensin II-related peptide 
(URP) and proangiotensin-12 (PA12) are all of low molecular weight (~1000-1572 
kD), 8-14 amino acids in length, and exhibit wide tissue expression throughout their 
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host species, as well as within the circulation. What makes UII, URP and PA12 
unique is their differential expression between healthy and diseased states. It has been 
reported that circulating UII and URP are expressed at low picomolar concentrations 
in healthy subjects, but become significantly elevated in those suffering 
cardiovascular and renal diseases (Richards et al. 2002, Matsushita et al. 2001, 
Russell et al. 2003, Lapp et al. 2004, Gruson et al. 2005, Ng et al. 2002). PA12 has 
also been reported to be significantly elevated in the heart (and significantly reduced 
in the kidneys) of spontaneously hypertensive rats (SHRs) when compared to 
normotensives (Jessup et al. 2008). These significant elevations in peptide tissue 
expression and circulating concentrations suggest a pathological role, either 
augmenting pathogenesis or providing some form of cardiovascular protection. The 
aim of the current thesis therefore, was to elucidate the direct actions of these three 
peptides upon the heart in a healthy state, followed by observing their effects in a 
model of cardiac injury. The approach to this was to encompass the physiological 
responses down to the enzymes, receptors and intracellular proteins mediating them. 
 
While these peptides share many similarities, they are somewhat contrasting in their 
history and their purported physiological roles, as detailed below.  
 
PA12 was recently identified (first reported in late 2006) and suggested to have a role 
in the renin-angiotensin system (RAS) based on its amino acid sequence. The RAS is 
a highly researched system responsible for elevating and maintaining blood pressure 
at homeostatic levels through activation of a cascade of specific enzymes and 
peptides, stimulating both mechanical and humoral responses. The discovery of a new 
‘functional’ peptide within the RAS has come as a surprise as the RAS was believed 
to be relatively well-defined. The maiden report indicated PA12 was a potent 
vasoconstrictor in the rat (Nagata et al. 2006), revealing it to be a functional peptide, 
potentially aiding RAS-induced increases in blood pressure, and hence potentially 
involved with RAS-induced progression of cardiovascular disease.  
 
Accordingly, the initial aim of the current thesis was to ascertain whether PA12 has 
direct effects on the isolated rat heart. Furthermore, based on its high homology with 
angiotensin I, can PA12 provide an alternate substrate for AngII (or other angiotensin 
peptide) generation? It is also unknown whether PA12 influences recovery from 
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cardiac ischemic injury, nor whether the current therapeutic agents administered to 
patients with hypertension and/or an overstimulated RAS influence PA12-induced 
cardiac activity. The underlying mechanisms of PA12-induced activity also require 
defining, isolating the cytokines mediating the physiological response to PA12. 
Completion of these aims will provide a solid foundation into the cardiac functions of 
PA12 including the mechanisms regulating its activity, and in doing so, suggesting a 
therapeutic course of action.  
 
UII was initially discovered in fish 40 years ago and first isolated from teleost fish in 
1980 (Pearson et al. 1980), before eventually being identified in human tissue in 1998 
(Coulouarn et al. 1998). Research into the cardiovascular effects of UII were 
stimulated by a report in Nature establishing UII as one of the most potent 
mammalian vasoconstrictors identified (Ames et al. 1999). Moreover, reports indicate 
UII levels are elevated in the circulation of patients suffering congestive heart failure 
(CHF) (Richards et al. 2000, Russell F.D. 2003). The evolutionary and genetic history 
of UII are now becoming well established highlighting its highly conserved amino 
acid sequence, however its physiological effects and the intracellular signalling 
pathways mediating them are inconsistent in the literature, while its role in disease 
remains unclear. Initial publications reported UII as a potent vasoconstrictor in 
mammals (Ames et al. 1999, Douglass et al. 2000, Gray et al. 2001), whilst other 
reports indicated UII could also stimulate vasodilation (Gibson A. 1987, Katano et al. 
2000, Prosser et al. 2006) and stimulate both positive (Russell et al. 2001) and 
negative (Ames et al. 1999) inotropism in mammalian hearts. Unlike PA12, UII does 
not appear to be part of a larger system activating or deactivating further peptides, nor 
has it been consistently shown to have clear synergistic activity with other peptides.  
 
Urotensin II-Related Peptide (URP) was discovered in 2003 by Sugo et al. when 
probing for UII-like peptides in the rat brain. URP shares the same highly conserved 6 
amino acid ring structure common to all known species of UII, but comprises a 
shortened N-terminus of a single amino acid. Due to its sequential homology with UII 
it is assumed URP elicits the same physiological effects as UII and stimulates the 
same intracellular pathways. However, direct comparisons of the two peptides’ effects 
upon the heart have not been reported, nor has a UII receptor blocker been employed 
to observe if the receptor blocker inhibits both peptides with equal efficacy.  
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With regard to UII and URP the species-specificity of the peptides needs to be 
directly and succinctly addressed providing a base for future studies when observing 
the response to UII or URP. Once achieved, the pathophysiological effects of UII and 
URP requires attention, herein we will employ a model of cardiac ischemia-
reperfusion injury. This model is designed to simulate patients experiencing elevated 
circulating UII levels prior to an ischemic event, or can also be used to simulate those 
experiencing significantly elevated UII concentration immediately following an 
ischemic event. The mechanisms underlying UII- and URP-induced physiological 
cardiovascular activity also need to be determined, reporting the effects of UII and 
URP from the observed physiological response to the underlying mechanisms 
mediating them. 
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2. Introduction to urotensin II (UII) and 
urotensin II-related peptide (URP) 
 
Abstract 
 
Since its initial isolation from the urophyses of Goby fish, urotensin II (UII) and its 
cognate receptor (GPR14) have now been identified in many species from fish to 
amphibians to mammals, including humans. The bioactive, mature form of UII 
contains a cyclic heptapeptide preserved across all known species, spanning millions 
of years of evolution. UII has now been researched in a wide range of settings with 
initial demonstration of potent vasoconstrictor activity and cardiac depression. 
However, further reports indicate UII to be a vasoactive peptide with highly variable 
effects, dependent upon species, tissue bad and cell type, suggesting a regulatory role 
maintaining vascular tone. Cardiovascular expression of UII and its receptor are 
elevated in the diseased state, indicating a potential pathological role. Current reports 
are conflicting, suggesting UII augments atherosclerosis and coronary artery disease 
through its pro-mitogenic effects, while others suggest elevated circulating levels of 
UII afford a level of cardioprotection, and minimise injury following a cardiac event.  
Urotensin II-related peptide (URP) shares the conserved cyclic heptapeptide of UII, 
however was not identified until recent times. Due to its high homology with UII it is 
assumed URP will stimulate the same physiological effects as UII, however this is yet 
to be explored. Here we review the literature to date, from the initial identification and 
description of UII as a “somatostatin-like” peptide due to its shared tri-amino acid 
motif, to the recent identification of URP including discussing the physiological role 
of UII as a regulator of vascular tone and cardiac function, including the receptors, 
enzymes and intracellular mechanisms underlying the response. 
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2.1.  Discovery of the ‘somatostatin-like’ peptide urotensin II 
 
Within the caudal region of the teleost spinal cord large neurons form linear columns 
with their axons projecting into a highly vascularised organ called the urophysis (Bern 
2008). This gland-like organ is suggested to have a key role in osmoregulation as 
conformational alterations were observed in response to changes in salinity of the 
surrounding medium (Kriebel R.M. 1980; Arnold-Reed and Belmont 1989). Analysis 
of extracts from the urophyses found it to contain a large array of neurohormonal 
substances that were broadly categorised into four groups, urotensin I-IV (Bern and 
Lederis 1969). Bern and Lederis (1969) suggested urotensin I and II (UI and UII 
respectively) influence blood pressure and smooth muscle activity, while urotensins 
III and IV (UIII and UIV) have potential roles in osmoregulation within the kidney 
and bladder (Bern and Lederis 1969). Of note, the urophysis was later found to 
contain very high concentrations of acetylcholine (Ach), which may have contributed 
to the observed smooth muscle contractions whenever extracts of the urophysis were 
administered directly to the tissue (Conlon et al. 1996). Over the following 3 decades 
since the initial identification of the urotensin family, research has confirmed the 
initial report of Bern and Lederis (1969) to be correct, indicating urotensin peptides 
are vasoactive agents capable of exerting a range of hemodynamic effects in fish, 
tetrapods and mammals including humans. UII was reported to be approximately 10 
fold more potent than UI in elevating arterial blood pressure in the eel (Chan D.K. 
1975), stimulating interest into its potent vascular effects. 
 
Urotensin II was first isolated from the urophysis of the Goby fish Gillichthys 
mirabilis and found to be synthesised in large neurosecretory cells (Dahlgren cells) 
within the spinal cord (Pearson et al. 1980). The mature, biologically active sequence 
of Goby UII was identified as 12 amino acids in length, comprising a 6 amino acid 
ring at the C-terminus held by disulphide bonds between 2 cysteines, with an 
extended N-terminus (Table 2.1) (Pearson et al. 1980).  
Interest was stimulated into the role of UII after it was reported that UII isolated from 
Goby fish constricted trout hindgut segments and major rat vessels through 
stimulation of smooth muscle cells, as well as altering cardiovascular activity and 
inducing hypertension in rats (Bern and Lederis 1969; Gibson et al. 1986; Gibson A. 
1987; Itoh et al. 1987). These early studies indicated UII stimulated haemodynamic 
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effects in both fish and mammals, suggesting the existence of mammalian UII 
orthologs as well as an endogenous receptor(s). The cloning of carp UII cDNA in 
1986 (Ohsako et al. 1986) enabled the first non-piscine UII isoform to be identified in 
the European green frog (Rana radibunda) (Conlon et al. 1992). UII has since been 
identified and purified from many species of fish including lamprey (Waugh et al. 
1995), elasmobranchs and teleosts (Waugh and Conlon 1993); amphibians (Conlon et 
al. 1992), and many species of mammals including humans (Coulouarn et al. 1998; 
Ames et al. 1999; Coulouarn et al. 1999; Mori et al. 1999). The amino acid sequence 
of all species of UII identified to date possess an identical 6 amino acid ring at the C-
terminal end (-Cys-Phe-Trp-Lys-Tyr-Cys-). Across fish species the length of UII does 
not vary, all being 12 amino acids long and possessing the conserved cyclic ring. 
However there is large sequential variation within the N-terminus (Table 2.1). The 
sequence and length of UII becomes more varied from tetrapods to higher order 
species further up the evolutionary tree, with frog UII consisting of 13, mouse and rat 
14, pig 12 and human 11 amino acids respectively. There is also large inter-species 
variation within the N-terminus, however the heptapeptide cyclic region remains 
conserved. The C-terminus is also preserved across all species with the exception of 
the mouse and rat where ‘Val’ is exchanged for ‘Ile’ (Table 2.1).  
 
Two variants of prepro-human UII have been identified with 124 (Coulouarn et al. 
1998) and 139 (Ames et al. 1999) amino acid residues respectively. These proteins 
differ only at the N-terminus, while the resultant mature UII peptide remains identical. 
This difference in the prepro-UII sequence is suggested to be the result of alternative 
splicing (Ames et al. 1999). Observing the direct activity of prepro-UII and the mature 
UII forms, it is clear that prepro-UII requires cleavage into the mature 11 amino acid 
peptide, displaying considerably higher potency than its precursor (Ong et al. 2005; 
Tölle and van der Giet 2008). The proteolytic enzyme responsible for the cleavage of 
prepro-UII is currently unknown, however Russell and co-workers reported that furin 
and trypsin cleaved the pro-hormone into mature UII in human epicardial mesothelial 
cells in vitro (Russell et al. 2004). Administering furin antagonists abolished the 
presence of the mature UII peptide, suggesting that the urotensin converting enzyme 
(UCE) responsible for the generation of biologically active UII possesses furin-like 
activity (discussed in more detail below) (Russell et al. 2004). 
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2.1 
Following identification of the AA sequence of UII in fish species, similarities were 
apparent with another recently identified peptide, somatostatin (SS) (Bern et al. 1985). 
Somatostatin was first discovered in sheep hypothalamus in 1973 in two forms – 
SS14 and SS28, expressed throughout the CNS and peripheral tissue of many 
vertebrates and is suggested to suppress growth hormone release (Brazeau et al. 
1973). Distribution of the SS receptors are spread in an overlapping pattern 
throughout the brain, CNS and peripheral tissues, enabling release of somatostatin to 
be tissue dependent (Lin and Peter 2001). Urotensin II was initially believed to be an 
isoform of the peptide SS14 due to the similarities in their peptide sequence, 27% 
receptor homology, and their similar distributive expression through the CNS and 
peripheral tissue of fish species (Bern et al. 1985; Lin and Peter 2001). Of note, SS14 
contains the tri-peptide motif -Phe-Trp-Lys-, reported to be the biologically important 
Table 2.1. The amino acid sequence of UII and URP from different species indicating 
the high level of homology within the C-terminus, while the N-terminus is variable. 
The tissue from which the sequence was identified is indicated under the ‘origin’. FW 
and SW represent ‘fresh water’ and ‘salt water’ respectively. From Chatenet et al. 
2004 
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component of SS14 for receptor activation (Conlon et al. 1997), which overlaps the 
biologically important tri-peptide motif –Trp-Lys-Tyr- of UII (Flohr et al. 2002; 
Kinney et al. 2002; Qi et al. 2005) (Figure 2.1). Because of these similarities, and the 
fact that UII had no known receptor, UII was dubbed a ‘somatostatin-like peptide’ and 
believed UII may act through the SS receptors (Conlon et al. 1996). Early genetic 
studies suggested UII and somatostatin, although similar in their mature form, showed 
little similarity when comparing their precursors, and therefore most likely did not 
derive from a common ancestral precursor (Ohsako et al. 1986; Conlon et al. 1997; 
Coulouarn et al. 1998; Tostivint et al. 2006). With the recent discovery of a second 
urotensin II-like peptide dubbed urotensin II-related peptide (URP), described in more 
detail below, interest into the ancestral genetic relationship between UII/URP and 
somatostatin was reignited. Tostivint et al. (2006) suggests that UII and somatostatin 
belong to the same genetic superfamily, proposing the theory that over evolution two 
ancestral genes (SS and UII) were physically linked and underwent tandem 
duplication into UII and SS. They then were subjected to segmental duplication, 
splitting the two genes again, with UII closely linked to the gene encoding 
SS2/cortistatin (CST), and URP located in the same chromosomal region as the SS1 
gene (Tostivint et al. 2006) (Figure 2.2).  
 
Figure 2.1 Comparing UII, URP, 
Somatostatin (SS) and cortistatin (CST) 
mature peptide sequences indicating 
the shared tri-amino acid motif in bold. 
From Tostivint et al. 2006. 
Figure 2.2 Diagram of the proposed 
evolutionary history of UII, URP and SS 
suggesting the genes resulted from an 
initial tandem duplication followed by 
segmental duplication. From Tostivint et 
al. 2006.
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Structure-activity studies have indicated that the tri-AA motif (Trp-Lys-Tyr) sequence 
in the ring structure of UII, URP, SS and CST mature peptides is of high functional 
importance in receptor binding and activation (Flohr et al. 2002; Brkovic et al. 2003); 
and the UII receptor, G-protein coupled receptor-14 (GPR14) or ‘UT’ for the purpose 
of the current thesis, also shares high sequence similarity with somatostatin receptors 
(Marchese et al. 1995). Furthermore, the UT receptor is located in the same 
chromosomal region as the SST3 receptor suggesting that the receptors, like their 
correlate peptides, arose by tandem duplication (Tostivint et al. 2006). It has therefore 
been proposed that the two peptides may be capable of binding and activating the 
same receptor (Tostivint et al. 2006). Examining this hypothesis, somatostatin and 
cortistatin have been shown to cause minor stimulation of the UII receptor (UT) (Liu 
et al. 1999; Rossowski et al. 2002) indicating partial agonistic activity. Recently, with 
the development of better UT antagonists it was revealed that both UII and URP are 
able to activate the somatostatin receptors SST2 and SST5 in transfected CHO-K1 
cells (Malagon et al. 2008); and Rossowski et al. (2002) reported that SST antagonists 
inhibited human UII-induced calcium transients in rat thoracic aortic rings 
(Rossowski et al. 2002). In sum, the high level of homology between the two peptides 
and their correlate receptors appears at this stage to enable minor cross activation of 
one another. Whether this cross activation provides a specific function, such as 
providing a feedback mechanism, synergism or an alternate route if one system was to 
fail; or whether it is simply co-incidental and the evolutionary branching from the 
original gene has not diversified sufficiently remains to be defined. 
 
 
2.2  Discovery and distribution of the UII receptor (UT) 
 
The UII receptor was not identified until 1995 when a G-protein coupled receptor was 
identified and cloned from rat brain extracts (Marchese et al. 1995). This G-protein 
coupled receptor was labelled GPR14 and at the time of discovery showed no specific 
binding to any common ligands, thus was dubbed an ‘orphan’ receptor (Marchese et 
al. 1995). It was not until 4 years later that a study identified the orphan GPR14 
receptor as the endogenous receptor for UII in rats and humans (Ames et al. 1999) and 
several studies have now established that UII specifically binds and activates GPR14 
in several species (Ames et al. 1999; Liu et al. 1999; Mori et al. 1999; Nothacker et al. 
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1999). The development of a GPR14 knockout model (UT-/-) in mice confirmed it as 
the as endogenous receptor for UII, as administration of human UII to arteries from 
UT-/- mice in vitro showed a significant loss of potency compared with wild type mice 
(Behm et al. 2003).  
 
The distribution of GPR14, otherwise known as UT, displays greatest within the CNS 
but is also expressed throughout the peripheral tissue including the heart, (localised in 
cardiomyocytes, endothelium and vascular smooth muscle cells (Gong et al. 2004)), 
kidney, liver, pancreas, thyroid, adrenal gland, vascular endothelial cells, and pituitary 
(Matsushita et al. 2001; Sugo et al. 2003; Richards and Charles 2004; Silvestre et al. 
2004; Charles et al. 2005; Albertin et al. 2006; Jégou et al. 2006). UII and UT mRNA 
are expressed in comparatively high amounts within the heart (Liu et al. 1999; 
Douglas et al. 2002), peripheral vasculature (Maguire et al. 2000) and kidneys 
(Shenouda et al. 2002), with UT mRNA expression greatest in skeletal muscle 
(Douglas et al. 2004). This suggests UII is a potential regulatory peptide controlling 
cardiac homeostasis, peripheral vascular activity, kidney function, and thus blood 
pressure. Because UII is also present in the circulation at low levels, the distribution 
and density of the UT receptor in peripheral tissues may provide a regulatory 
mechanism in itself (Itoh et al. 1988). UT displays greatest expression within the brain 
and CNS, specifically within the endothelial cells (Spinazzi et al. 2006) and axonal 
terminals while UT mRNA expression is greatest in skeletal muscle (Douglas et al. 
2004). This suggests UT may act as both a presynaptic receptor with UII or URP 
being the ligand (Clark et al. 2001), as well as modulating vascular tone and having 
other physiological effects. The direct influence of UII in the brain has been observed 
in both fish and mammals where intracerebroventricular (ICV) administration of UII 
significantly altered blood pressure, heart rate, and ventilation in the trout, indicating 
UII may have a specific role within the brain (Watson et al. 2003; Lancien et al. 2004; 
Watson and May 2004). Interestingly, an early study suggests UII function in the 
earliest vertebrates was as a neurotransmitter or modulator in the CNS rather than a 
hormone within the caudal neurosecretory system, as early fish species lacked a 
caudal neurosecretory system and the structure of UII is better conserved in 
phylogenetically ancient fish when compared with teleosts (Waugh et al. 1995). This 
would suggest that over time with the development of the caudal neurosecretory 
system UII (and potentially URP) became capable of exerting effects throughout the 
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animal dependent upon its cognate receptor distribution and explains why UII and 
URP exhibit strong expression within the CNS and are able to exert effects in the 
CNS as well as the peripheral tissue. Several studies have indicated stimulation of UII 
receptors within the brain and CNS produce many physiological and behavioural 
effects (Le Mével et al. 1996; de Lecea and Bourgin 2008; do Rego et al. 2008; Ono 
et al. 2008; Watson et al. 2008) indicating the neurotransmitter function of UII to be 
preserved in higher order species. Interestingly, UII administered via ICV has been 
repeatedly shown to produce different effects compared with IV application. This 
effect is maintained from fish to mammals. Le Mevel (1996) and colleagues reported 
ICV administration of UII to conscious trout caused an elevation in blood pressure 
with a slight increase in HR while intravenously administered UII increased blood 
pressure but reduced HR (Le Mével et al. 1996). In sheep ICV administration 
produced tachycardia, elevated cardiac output, reduced peripheral resistance and 
stimulated greater adrenocorticotropic hormone (ACTH) release while IV 
administration only caused tachycardia with no change in cardiac output or ACTH 
levels (Watson et al. 2003; Hood et al. 2005). Furthermore, ICV injection of UII 
increased arterial pressure and heart rate in conscious rats while IV injection elicited a 
depressor response (Lin et al. 2003). The historical evidence that UII was primarily a 
neurotransmitter in ancient fish species (Waugh et al. 1995) combined with the fact 
that UII and UT are expressed at their greatest amounts within the CNS, illustrates 
that the neurotransmitter function of UII/UT is conserved and elicits potent activity in 
the brain and CNS of mammals as well as producing haemodynamic effects directly 
on the vasculature. These studies indicate the potential for UII to produce disparate 
effects dependent upon the location of the receptor, providing a level of receptor 
control in regulating cardiovascular haemodynamics. UT is localised to the 
sarcolemma of rat skeletal muscle cells, where it is suggested that UII stimulates 
hindquarter vasodilation mediated by co-localised nitric oxide synthase (NOS) in the 
skeletal muscle (Maguire et al. 2008).  
 
Inter-species distribution of UT and UII are reported to be relatively consistent, with 
the notable exception that rat vascular endothelial expression of UT-immunoreactivity 
was significantly less than compared with the same cells in humans (Liu et al. 1999; 
Maguire et al. 2000; Maguire et al. 2008). UT sequential homology is 92% between 
rat and mouse, 95% between human and monkey and 74% between rodent and 
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monkey (Proulx et al. 2008). Differences in receptor homology between species may 
influence ligand binding and may help explain the different haemodynamic responses 
when different species-forms of UII are administered (Douglas et al. 2000; Prosser et 
al. 2006). Structure-activity studies report little difference in UT receptor binding and 
activation between UII isoforms, revealing the WKY motif within the conserved 6 
amino acid ring as vital for receptor binding and activity with alterations in the N- and 
C-terminus having little effect (Coy et al. 2002; Flohr et al. 2002; Brkovic et al. 2003; 
Labarrère et al. 2003; Guerrini et al. 2005). Extracellular loops 2 and 3 have been 
recognised as important in binding UII and URP, with loop 1 having no influence. As 
UII is known to produce a broad range of effects, not surprisingly binding of UII to 
UT activates intracellular pathways capable of eliciting vasoconstriction, vasodilation, 
cell proliferation and growth. UII is reported to act through the 
Gq/11/PLC/IP3/PKC/RhoA/Rho pathway causing an influx of intracellular Ca+2 
eliciting constriction (Russell and Molenaar 2004; Yoshimoto et al. 2004; Brailoiu et 
al. 2008), whilst also capable of causing vasodilation through stimulating eNOS 
(Katano et al. 2000; Gray et al. 2001; Prosser et al. 2006), as well as promoting 
VSMC proliferation mediated by extracellular signal-regulated kinase (ERK1/2) 
(Watanabe et al. 2001a; Watanabe et al. 2001b; Tamura et al. 2003). Furthermore, UII 
is known to elevate cyclooxygenase activity, initiating prostaglandin production, 
capable of exerting dilative, constrictive and hypertrophic effects dependent upon the 
isoforms produced (Gardiner et al. 2004; Horie et al. 2005; Gardiner et al. 2006; Deeb 
et al. 2008).  
 
Recent reports suggest the possibility of a second UII receptor as Gendron et al. 
(2005) and Prosser et al. (2008) reported unusual responses when administering UT 
antagonists to rat hearts suggesting the presence of further receptor activity (Gendron 
et al. 2005; Prosser et al. 2008). Behm et al. 2004 also reported contrasting effects in 
response to the UT antagonist SB-710411 where it significantly attenuated UII-
induced inositol phosphate formation at the rat UT receptor, but functioned as an 
agonist at the monkey UT receptor (Behm et al. 2004). Furthermore, the UT 
antagonists urantide and palosuran functioned as a partial agonists in the rat 
cardiovasculature, while antagonising UII-induced activity (Song et al. 2006; Prosser 
et al. 2008). These studies illustrate the complex nature of UII/UT binding and 
activity, and suggest development of a UT antagonist may have to be species-specific. 
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2.3   Source and stimulus of UII 
 
 
Trans-organ sampling indicated UII is secreted from the heart, liver and kidney in 
sheep (Heller et al. 2002; Charles et al. 2005). Expression of UII mRNA has been 
identified in human coronary artery and endothelial cells (Totsune et al. 2004), human 
VSMCs, endocardial endothelial cells (Douglas et al. 2002), and cardiac fibroblasts 
(Tzanidis et al. 2001). It is expressed at high levels in inflammatory cells including 
lymphocytes, monocytes, macrophages and foam cells (Bousette et al. 2004), as well 
as the CNS in the brain stem and spinal motorneurons (Coulouarn et al. 1998; 
Dubessy et al. 2008). Stimulation of UII production and secretion is yet to be 
concretely defined, however UII levels have been repeatedly shown to be elevated in 
many cardiac diseases and with increased pressure load (Cheung et al. 2004). The 
conversion of prepro-UII to its bioactive, mature form has had little research focus 
and it is yet to be fully established which urotensin-II-converting enzyme(s) (UCE) 
contribute to proteolytic cleavage, including whether cleavage is localised within the 
cell or at the cell surface. Russell et al. (2004) investigated UCE activity in cultured 
human epicardial mesothelial cells and in blood and reported an intracellular enzyme 
capable of converting pro-hUII to hUII with minimal conversion at the cell surface 
(Russell et al. 2004). This intracellular UCE exhibited furin-like characteristics while 
it was suggested that a serine protease such as trypsin also contributed in converting 
pro-hUII to hUII in the blood assuming the prohormone was secreted into the 
circulation (Russell et al. 2004). Assuming the elevations in UII concentration 
reported are in fact augmenting cardiovascular disease, it would of great benefit to 
define the proteolytic enzyme(s) involved in generating the mature UII peptide. This 
would enable the development of antagonists to inhibit UCE activity as a means of 
attenuating any potential pathological effects stimulated by UII, as current UT 
receptor blockers are reported to have variable efficacy in blocking UII activity, some 
of which behaving as partial agonists (Song et al. 2006; Behm et al. 2008). 
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2.4  Effect of UII on hemodynamics 
 
 
Initial studies identified UII as a potent spasmogen, constricting isolated trout rectum 
and intestine rings in vitro (Bern and Lederis 1969). Further studies confirmed UII as 
a vasoactive agent altering arterial tone, constricting isolated arteries and stimulating 
hypertension and altering heart rate (HR) in live trout (Conlon et al. 1996). In 
elasmobranchs UII altered cardiovascular function, but had little influence on isolated 
rings of dogfish intestine or rectum, indicating a more defined role for UII in 
elasmobranchs as a regulator of cardiovascular function (Conlon et al. 1992; Hazon et 
al. 1993; Conlon et al. 1996). With reports indicating fish UII could alter isolated rat 
vessel tone (Gibson et al. 1986; Gibson 1987; Itoh et al. 1987; Gibson et al. 1988) it 
was hypothesised that UII and its cognate receptor UT were present in rats, and 
potentially all mammalian species including humans. UII is now synonymous with 
being named the most potent vasoconstrictor identified to date with a potency many 
times that of endothlelin-1, serotonin or norepinephrine (Russell et al. 2001; 
Watanabe et al. 2001a; Zhu et al. 2004). UII-induced vasoconstriction has now been 
demonstrated in isolated vessels of many different species including the rat, mouse, 
dog, pig, cynomolgus monkey and human (Bottrill et al. 2000; Douglas et al. 2000; 
Maguire et al. 2000). The vasoconstrictive effect of UII is attributed to an influx of 
intracellular calcium mediated by binding to the UT receptor, activating PLC and IP3 
(Opgaard et al. 2000; Brailoiu et al. 2008). However, the vascular response to UII is 
inconsistent, as Gibson et al. (1987), Katano et al. (2000) and Li et al. (2004) all 
reported UII induced vasodilation in rat coronary arteries (Gibson 1987; Katano et al. 
2000; Li et al. 2004). UII-induced vasodilation can be attenuated by reducing the 
presence of endothelial nitric oxide (eNOS), and inhibiting cyclooxygenase (COX) 
activity (Katano et al. 2000; MacLean et al. 2000; Gray et al. 2001; Prosser et al. 
2006), indicating UII-induced vasodilation is the result of elevating nitric oxide (NO) 
and activating prostaglandins, specifically PGE2, prostacyclin as well as endothelium-
derived hyperpolarizing factor (EDHF) (MacLean et al. 2000; Ishihata et al. 2005a; b; 
Lacza and Busija 2006). NO is a known vasodilative agent, well established in 
mammals (Gamboa et al. 2007) and reported to provide regulatory control of coronary 
flow in teleosts, including salmon, modulating appropriate blood supply to the 
ventricle under basal and stressed conditions (Agnisola 2005). Furthermore, it has 
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been displayed that UII-induced vasoconstriction is elevated when in the presence of 
L-NAME and indomethacin (MacLean et al. 2000; Gray et al. 2001; Deuchar et al. 
2006). The dilative effects of UII have also been reported in in vivo studies in rats and 
cynomolgus monkeys where UII elicited hypotension and a depressor response, 
constricting some arteries while severely reducing peripheral resistance ((Gibson et al. 
1986; Gibson 1987; Ames et al. 1999; Gardiner et al. 2004; Zhu et al. 2004). This 
hypotensive response in cynomolgus monkeys was accompanied by a severe 
reduction in cardiac output resulting in death (Ames et al. 1999; Zhu et al. 2004), 
suggesting UII also directly influences cardiac contractility and other physiological 
effects (Table 2.2). 
 
Indeed like the vascular response, the effect of UII on contractility is varied with 
studies suggesting UII acts as a positive (Russell et al. 2001; Watson et al. 2003; 
Gong et al. 2004; Gardiner et al. 2006) or negative inotrope (Hassan et al. 2003; Zhu 
et al. 2004; Fontes-Sousa et al. 2008). The method of application of UII to the subject 
animal appears to heavily influence the contractile response to UII, as IV injection 
produces opposing effects compared with ICV infusion. This is best illustrated by two 
studies in sheep where UII administered IV elevated HR and produced negative 
inotropic activity, while ICV application elevated HR and caused positive inotropic 
effects (Watson et al. 2003; Hood et al. 2005). The reason why UII elicits opposing 
responses in the same subject animal is suggested to be due to the different pathways 
activated. ICV infusion of UII reportedly stimulates cardiac sympathetic nerve 
activity, epinephrine release, and is dependent upon beta-adrenoreceptor stimulation, 
whereas UII administered IV does not stimulate beta-adrenoreceptors and is 
dependent upon activating its own intracellular pathways (Watson et al. 2003; Hood et 
al. 2005) (Table 2.2). The intracellular pathway mediating the UII-induced positive 
inotropic response is reported to be PKC- and myosin light chain 2-dependent 
(Russell and Molenaar 2004). 
 
 
 
 
 
 
 17
UII Systemic Administration ICV Administration 
Heart Constricts / dilates the 
coronary arteries 
Negative Inotrope 
↑ or ↓ Heart Rate 
Positive Inotrope 
↑ Heart Rate 
 
Peripheral Vasoconstrictor - ↑ MAP 
Vasodilator - ↓ MAP 
↑ Blood pressure 
CNS Behavioural effects altering 
ventilation, REM 
↑ Sympathetic activity 
↑ epinephrine release 
Kidney Epithelial cell proliferation 
Decreased renal blood flow 
Altered Na+ excretion 
 
 
 
2.5   The role of UII in the kidney and its influence in renal disease 
 
 
The kidneys play a vital role in the regulation of cardiovascular homeostasis as they 
control cardiac preload through regulating plasma volume, and are a major influence 
on peripheral resistance through release and clearance of vasoactive agents. The 
physiological effects of UII were initially witnessed in their regulation of blood 
pressure in the fish when the osmolarity of the media was altered indicating UII may 
regulate salt and water balance (Bern et al. 1985; Bond et al. 2002). UII, UII mRNA 
and UT have since been identified in the kidney of mammals, with expression there 
higher than other tissues (Nothacker et al. 1999; Shenouda et al. 2002). UII is capable 
of stimulating intracellular extracellular signal-regulated kinase 1/2 (ERK1/2) in pig 
renal tubular epithelial cells (Matsushita et al. 2003) indicating a potential for cell 
proliferation. The renal role of UII is yet to be fully determined, however UII has been 
suggested to alter Na+ excretion and decrease renal blood flow (Douglas et al. 2004). 
However, it has been established that UII levels are elevated in the plasma and urine 
Table 2.2. Physiological and behavioural responses to UII in healthy subjects 
revealing a wide range of effects, suggested to be dependent upon the method of 
drug administration.  
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of patients with renal dysfunction and disease (Matsushita et al. 2001; Totsune et al. 
2001), and the kidney has been identified as a source of UII in the circulation (Charles 
et al. 2005). Interestingly, the majority of studies observing circulating UII levels in 
renal disease indicate UII provides cardiorenal protection and is inversely correlated 
with cardiovascular events (Mallamaci et al. 2006; Ravani et al. 2008; Zoccali et al. 
2008), when compared with pure cardiovascular diseases which heavily portray UII as 
pathogenic (Bousette et al. 2006a; Bousette et al. 2006b; Watanabe et al. 2006). 
 
 
2.6  UII is species-, tissue- and cell type-dependent 
 
2.6.1  Dependence on species-specific form of UII 
The general assumption has been that the N-terminus of UII has little or no influence 
on receptor activation, and thus little effect on the intracellular signalling pathways 
activated. Reasons underlying this are: a) all species of UII retain the highly 
conserved ring structure (Douglas and Ohlstein 2000; Onan et al. 2004), b) several 
reports showed fish UII was capable of producing a hypotensive response in rats and 
rabbits (Gibson et al. 1986; Itoh et al. 1988; Conlon et al. 1996) whilst fish UII 
administered at low doses caused vasodilation in rat vascular smooth muscle and 
vasoconstriction at high doses (Gibson 1987). Furthermore, non-native UII was 
capable of elevating intracellular calcium concentrations in cultured cells containing 
transfected human UT receptors (Ames et al. 1999; Liu et al. 1999; Mori et al. 1999; 
Nothacker et al. 1999). Structure-activity studies have reported that binding of UII to 
its cognate receptor UT is highly dependent upon the conserved Trp-Lys-Tyr amino 
acid motif within the conserved ring, with modification of the N-terminus having little 
or no influence on binding affinity or potency (Flohr et al. 2002; Kinney et al. 2002; 
Greco et al. 2003; Labarrère et al. 2003; Qi et al. 2005). However, initial studies 
reported UII may have species-specific actions; for example frog UII caused 
significant vasoconstriction in the frog, a response that could not be repeated when rat 
UII was given to rats (Yano et al. 1994; Conlon et al. 1996). Thus, analysis of 
publications to date suggest that the species-dependent N-terminus of UII may 
substantially influence receptor binding, activation and the resultant physiological 
response(s) (Table 2.3). This hypothesis was supported by a study observing the effect 
of UII in different species and different tissue types, indicating human UII could elicit 
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vasoconstriction or have no effect in the same vessel of different species (Douglas et 
al. 2000). Figure 2.3 displays the percentage of receptor sequential homology between 
species indicating the homology between fish and mammals can vary up to 44% (Lu 
et al. 2008). Whether the difference in response to different species-forms of UII 
administered is due to the sequential differences in the UII ligand or the slight 
differences in receptor homology between species is yet to be determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3 displays the different responses to UII in many species. Some vessels such 
as the thoracic aorta respond to UII solely with vasoconstriction, independent of the 
species of UII administered; however, other vessels such as the coronary, mesenteric, 
pulmonary and abdominal resistance arteries exhibit variable responses producing 
either vasodilation, vasoconstriction or no effect dependent upon the species of UII 
administered (Table 2.3). Since research began recording the cardiovascular effects of 
UII, studies have generally administered the non-native form of UII to the subject 
animal, and in doing so have potentially reported false physiological responses that 
would not occur under the natural setting. Only recently has it become increasingly 
Figure 2.3 Evolutionary tree 
comparing the % UT receptor sequence 
homology between species. From Lu et 
al. 2008. 
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apparent that UII is highly species-specific, a factor potentially responsible for the 
large variation in results currently reported (Douglas et al. 2000; Prosser et al. 2006).  
 
 
2.6.2  Dependence on Cell and Tissue Type 
 
The physiological effects of UII also appear to be dependent upon the cell type 
expressing UT. UT is expressed on both VSMCs and endothelial cells affording the 
ligand direct binding and activation of either cell type (Maguire et al. 2008). 
Activation of receptors located on VSMCs display consistent vasoconstriction, while 
activation of receptors located on the endothelium stimulated vasodilation (Gendron 
et al. 2005). The role of the endothelium in mediating the response to UII remains to 
be concretely defined, however currently it appears UII activity becomes altered upon 
removal of the endothelium. Some studies reported UII activity to be independent of 
endothelial cells with human UII and fish UII, constricting rat thoracic aorta 
independently of endothelium removal (Itoh et al. 1987; Bottrill et al. 2000), a finding 
repeated in rabbit thoracic aorta (Opgaard et al. 2000). Studies indicating UII-induced 
vasoconstriction is endothelium-dependent, found removal of the endothelium 
augmented UII-induced vasoconstriction in rat thoracic aorta (Wang et al. 2007), and 
rat & human main pulmonary arteries (MacLean et al. 2000).  
 
Not surprisingly, UII-induced vasodilation is shown to be strongly endothelium-
dependent, for example hUII-induced vasorelaxation of rat coronary arteries could be 
converted to vasoconstriction when the endothelium was removed (Bottrill et al. 
2000). This UII-induced vasoconstriction or loss of UII-induced vasodilation in 
endothelial denuded/damaged vessels has also been displayed in human coronary 
(Russell et al. 2001), pulmonary and abdominal resistance arteries (Stirrat et al. 2001). 
Gendron et al’s (2005) suggestion that UII causes differential effects dependent upon 
the cellular level (i.e. smooth muscle cells respond differently to UII compared to 
endothelial cells) is now appearing highly likely (Gendron et al. 2005). 
 
Interestingly, the studies suggesting UII activity to be endothelium-independent were 
observed only in the thoracic aorta. The thoracic aorta appears to differ somewhat 
from other vessels in response to UII in that it shows no dilative response and is 
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seemingly independent of the species form of UII administered. This indicates UII 
may also be tissue-dependent, whereby producing different effects on different tissue 
beds. This suggests that the differential responses to UII observed in different vessels 
throughout the body may lie within the receptor as opposed to the ligand, and/or the 
intracellular signalling pathways activated. As previously indicated: a) UII may 
trigger 1 receptor with several alternate intracellular pathways whereby the dominant 
(alpha) pathway produces the observed effect and the alpha pathway may change in 
order to maintain homeostasis; or b) UII may activate greater than one receptor, 
(Gendron et al. 2005). 
 
Further possible explanations for the inconsistencies reported between research 
groups include the concentration of calcium used within the buffer solution when 
observing the vessel or organ ex vivo. The concentration of calcium used is highly 
important when measuring the response to UII as UII-induced vasoconstriction is 
calcium-dependent (Brailoiu et al. 2008), and therefore it is vital that the 
concentration of calcium within the buffer is at a homeostatic level for that animal.  
 
In sum, analysis of reports observing the physiological response to UII, indicates UII-
induced activity is dependent upon the species form of UII administered, the cell type 
exposed, the tissue type and the method of administration (Table 2.3).  
 
 
2.7  Urotensin II-related peptide (URP) 
 
Urotensin II-related peptide (URP) was isolated from rat brain in 2003 by Sugo and 
his team when searching for products displaying immunoreactivity to anti-UII 
antibody (Sugo et al. 2003). Structure analysis determined the sequence of URP to be 
8 amino acids in length, comprising Ala-Cys-Phe-Trp-Lys-Tyr-Cys-Val with Cys-Cys 
bound by disulphide bonds producing the cyclic ring common to all known species of 
UII. Human, rat and mouse prepro-URP were found to comprise 119, 118 and 113 
amino acids respectively, displaying sequence homology of 54.2% for human and rat, 
47.5% for human and mouse, and 73.6% for rat and mouse (Sugo et al. 2003). Like 
UII, the mature URP peptide is located at the C-terminus and the proposed site of 
proteolytic cleavage is at the Lys-Arg residues immediately preceding the mature 
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URP peptide (Mori and Fujino 2004). Little similarity is shown in the sequence 
homology between prepro-URP and prepro–UII, suggesting they are not derived from 
a common ancestor and indeed the two precursor peptides are located on separate 
chromosomes (UII on 1p36 and URP on 3q29) (Sugo et al. 2003; Mori and Fujino 
2004). The genetic history of UII and URP was explored in more detail recently by 
Tostinivt et al. (2006). As mentioned above, Tostivint and colleagues suggest the URP 
gene was originally part of a UII/somatostatin/cortistatin genetic ‘superfamily’ which 
then underwent evolutionary pressures resulting in the URP gene to become located in 
the same chromosomal region as the SS1 gene, however separated from UII (Tostivint 
et al. 2006). 
 
In rodents, prepro-URP gene expression was greatly elevated in the testis, spleen and 
thymus, but displayed equal expression in the spinal cord when compared with 
prepro-UII (Figure 2.4). The distribution of prepro-URP gene expression differs 
between species, for example, human prepro-URP is expressed in its highest amount 
within the ovary whilst it is non-existent in the rat ovary; in contrast, the rat spinal 
cord expresses more prepro-URP (Sugo et al. 2003). Of note, the greatest expression 
of prepro-URP in the human was located within the ovary and testis; while it was the 
testis and spleen in the rat (Figure 2.4) (Sugo et al. 2003). The reason for the high 
expression of URP within the reproductive organs of both human sexes and the testis 
but not ovary of rats is yet to be explored. It is not uncommon for the testis and/or 
ovaries to express high levels of circulating peptides with little known reproductive 
function, for example CNP is primarily known for its role in bone growth and 
natriuretic effects throughout the body (Potter et al. 2009), but its expression is 
greatest within the testis, and has since been shown to regulate the blood-testis barrier 
in rats (Xia et al. 2007). 
 
Immunohistochemistry studies observing URP in the CNS revealed URP-
immunoreactive axon terminals were located within specific regions of the mouse 
brain; these regions are known to control gonadotropic cells of the anterior pituitary 
(Egginger and Calas 2005). Furthermore, neurons expressing URP are located within 
the mouse hypothalamus and thoracic spinal cord, and found to contain both URP-
mRNA and URP peptide indicating URP can be synthesized and released from these 
cells (Egginger and Calas 2005; Pelletier et al. 2005). This supports the theory that 
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URP is a potential neuroendocrine peptide in mammals, a theory also suggested for 
UII as the cardiovascular effects following ICV administration of UII have been 
shown to significantly alter cardiac haemodynamics (Lin et al. 2003; Watson et al. 
2003; Hood et al. 2005). It is yet to be tested whether URP shows variable responses 
dependent upon IV or ICV administration as observed with UII. The wide peripheral 
distribution of URP indicates that it potentially has a role outside of the CNS, 
however without an assay currently capable of differentiating URP from UII it is 
difficult to define the role of each peptide in the CNS and peripheral tissue. 
 
UT was confirmed as the endogenous receptor for URP, the same receptor believed to 
be endogenous for UII based on reports observing URP-induced physiological 
changes and binding-activity studies (Sugo et al. 2003; Chatenet et al. 2004; Sugo and 
Mori 2009). Administration of URP to Chinese hamster ovary (CHO) cells expressing 
human or rat UT caused an increase in intracellular calcium mobilization with high 
binding affinity for both receptors (Sugo et al. 2003). The binding affinity of URP for 
human UT-transfected cells has been shown by two reports to be slightly higher than 
human UII, indicating UT is likely to be the functional receptor for URP (Sugo et al. 
2003; Chatenet et al. 2004).  
 
In vivo, URP caused sustained hypotension when administered intravenously into the 
anaesthetised rat, the same effect observed with rat UII (Sugo et al. 2003), while in 
vitro URP constricted rat aortic rings, exhibiting slightly reduced potency, but slightly 
higher binding affinity for UT when compared with human UII (Chatenet et al. 2004).  
 
Taken together, these initial reports indicate URP binds and activates GPR14, 
stimulating the same physiological effects as UII with reduced potency (Chatenet et 
al. 2004). Furthermore, like UII, structure-activity studies indicate the Phe-Trp-Lys 
motif (particularly Tyr) within the cyclic domain of URP is pivotal for receptor 
binding and activation, whilst altering in the N- or C-terminus had little influence on 
receptor binding (Chatenet et al. 2004). 
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2.8  Summary of the UII/URP system 
 
From rather humble beginnings as a simple neurosecretory peptide from the urophysis 
of fish, UII has now been identified as a potent endocrine agent present in all species 
tested from fish to mammals, including humans. UII is manufactured throughout the 
body including the CNS, heart, liver & kidneys and has a wide receptor distribution 
affording UII a wide range of effects throughout the body, from influencing 
ventilation and rapid eye movement (de Lecea and Bourgin 2008), to vascular 
constriction and dilation, to having a potential role in synaptic nerve activity within 
the CNS (Nothacker and Clark 2005) (Table 2.2). Urotensin II has become 
synonymous with being the most potent vasoconstrictor identified to date.  However 
with increasing numbers of studies observing the effects of UII both in vivo and in 
vitro, it is apparent UII can also stimulate sustained vasodilation as well as VSMC 
proliferation and augment the development of atherosclerosis. The true biological 
function of UII has become increasingly difficult to define due to its dependence on 
cell type, tissue bed, species, method of administration, and development of receptor 
antagonists now reported to display species-specificity. Thus, there is a clear need for 
basic species-specific studies, identifying the effects of UII and URP directly upon the 
heart and cardiac vasculature. Furthermore, whether UII and/or URP provide 
beneficial or detrimental effects in the context of cardiac injury and cardiovascular 
pathology must be addressed. 
 
Salmon and rats were chosen as experimental subjects to provide a foundation for 
observing the comparative physiological effects in response to direct infusion of UII. 
This method provided a clear view of the endogenous effects of UII from teleost fish 
to mammals, observing whether the response to UII was conserved with its highly 
conserved structure over evolutionary time, as well as determining the species-
specificity of UII, as an early study indicated that fish UII could elicit a response in rat 
vessels (Itoh et al. 1987). Coronary arteries were chosen as the experimental vessel as 
the effect of UII on this vessel could be accurately measured in both the rat and 
salmon, enabling direct comparative analysis.  
 
The doses of rUII and URP administered were based upon preliminary dose-response 
studies (Figure 3.1A). These doses were based upon calculated dilutions of the 
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original peptide with subsequent RIA analysis revealing the viable concentration of 
UII reaching the heart to be approximately one third of that calculated (Chapter 3). 
Subsequent studies report the effects of administering 1 nM rUII and 10 nM URP 
based upon calculated dilutions alone, however this may be a gross overestimation 
based on the previous analysis. This must be taken into account when addressing the 
physiological versus pathophysiological doses administered in the following 
experiments.  
 
Previous studies determining the concentrations of UII from plasma of healthy 
subjects and patients suffering cardiac disease have reported concentrations ranging 
from 0.6 pmol/L to 29 nmol/L, respectively (Totsune et al. 2001; Dschietzig et al. 
2002; Heller et al. 2002; Richards et al. 2002; Gruson et al. 2005; Zoccali et al. 2006; 
Dai et al. 2007). Our own study found the circulating concentration of UII in healthy 
rats to be 3 pmol/L (Prosser et al 2006). The chosen dose of 1 nM rUII and 10 nM 
URP were based upon our own dose-response studies and are consistent with previous 
reports both in vivo, ex vivo and in vitro (Douglass et al. 2000; Itoh et al; 1987; 
Ishihata et al. 2005 and 2006; Gray et al. 2001; Johns et al. 2004; Tzanidis et al. 
20003; Russell and Molenaar 2004). The EC50 of UII across monkey and dog 
coronary arteries and rat aorta is reported to be just below 1 nM (Douglass et al. 2000; 
Itoh et al. 1987). Experiments to date have elicited responses following administration 
of low picomolar doses to fish, while other studies require higher doses to observe any 
effect, commonly 1-100 nM in explanted organs or vessels (Douglass et al. 2000; Itoh 
et al; 1987; Ishihata et al. 2005 and 2006; Gray et al. 2001; Johns et al. 2004; Tzanidis 
et al. 20003; Russell and Molenaar 2004), however higher doses (up to 1 µM) have 
also been employed (Gray et al. 2001; Douglas et al. 2000). The use of 1 nM UII in 
the following studies could, therefore be considered pathophysiological, providing a 
good measure of UII-induced cardiac effects both in healthy and ischemic hearts. As 
UII is chronically elevated in diseased patients as opposed to acute release, the 
following studies administered UII and URP over 30 min to better simulate the natural 
setting of elevated UII during cardiac disease, and provide a more accurate analysis 
into the role of elevated UII/URP in the healthy and ischemic heart. The concentration 
of URP administered (10 nM) is consistent with a previous study (Sugo et al. 2003), 
with preliminary dose-response studies indicating URP to have reduced vasoactive 
potency when compared with rUII (Figures 3.1 and 3.2).
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Figure 2.4 Distributive expression of genes encoding the preproproteins: human UII (A) and URP (B), rat UII (C) and URP 
(D) displaying interspecial differences, and comparing the gene expression encoding prepro-UII and prepro-URP throughout 
the rat and human. Gene expression was determined using TaqMan PCR with the value obtained for each tissue normalised to 
that of GAPDH (the value for the human spinal cord in (A) is out of range). From Sugo et al. 2003.
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Table 2.3 Vascular response to UII throuout many species 
Vessel Animal UII Response Reference(s) 
Thoracic Aorta 
Rat HUII Constricted 
(Ames et al. 1999; Bottrill et al. 
2000; Douglas et al. 2000; Maguire 
et al. 2000; Hillier et al. 2001; 
Rossowski et al. 2002) 
 
 URP Constricted 
(Brkovic et al. 2003; Sugo et al. 
2003; Chatenet et al. 2004) 
  Goby Constricted (Itoh et al. 1987) 
 Mouse HUII N/C (Douglas et al. 2000) 
 Rabbit HUII Constricted (Opgaard et al. 2000) 
 Dog HUII N/C (Douglas et al. 2000) 
 Pig HUII Constricted (Douglas et al. 2000) 
 Marmoset HUII Constricted (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII Constricted (Douglas et al. 2000) 
Coronary arteries Rat RUII Dilation (Li et al. 2004) 
  HUII N/C (Douglas et al. 2000) 
 
 HUII Constricted 
(Bottrill et al. 2000; Gray et al. 
2001) 
  HUII Dilation* (Bottrill et al. 2000) 
  HUII Dilation (Katano et al. 2000) 
 Mouse HUII N/C (Douglas et al. 2000) 
 Dog HUII Constricted (Douglas et al. 2000) 
 Pig HUII N/C (Douglas et al. 2000) 
 Marmoset HUII N/C (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII Constricted 
(Ames et al. 1999; Douglas et al. 
2000; Zhu et al. 2004) 
 
Human HUII Constricted 
(Maguire et al. 2000; Russell et al. 
2001; Maguire et al. 2004) 
Renal artery Rat HUII N/C (Douglas et al. 2000) 
 Mouse HUII N/C (Douglas et al. 2000) 
 
Dog HUII 
Variable 
constriction (Douglas et al. 2000) 
 
Pig HUII 
Variable 
constriction (Douglas et al. 2000) 
 Marmoset HUII N/C (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII Constricted (Douglas et al. 2000) 
Femoral artery Rat HUII N/C (Douglas et al. 2000) 
  Goby N/C (Itoh et al. 1987) 
 Mouse HUII N/C (Douglas et al. 2000) 
 
Dog HUII 
Variable 
constriction (Douglas et al. 2000) 
 Pig HUII Constricted (Douglas et al. 2000) 
 
Marmoset HUII 
Variable 
constriction (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII Constricted (Douglas et al. 2000) 
Mesenteric artery 
Rat HUII N/C 
(Bottrill et al. 2000; Douglas et al. 
2000) 
  RUII Dilation (Gardiner et al. 2001) 
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Table 2.3 Vascular response to UII throuout many species 
Vessel Animal UII Response Reference(s) 
 
 Goby 
variable 
constriction (Itoh et al. 1987) 
  HUII Dilation (Gardiner et al. 2001) 
  HUII Dilation** (Bottrill et al. 2000) 
 Mouse HUII N/C (Douglas et al. 2000) 
 
Dog HUII 
Variable 
constriction (Douglas et al. 2000) 
 Pig HUII Constricted (Douglas et al. 2000) 
 Marmoset HUII Constricted (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII Constricte (Douglas et al. 2000) 
Abdominal aorta Rat HUII Constricted (Douglas et al. 2000) 
  
Goby 
Variable 
constriction (Itoh et al. 1987) 
 Mouse HUII N/C (Douglas et al. 2000) 
 Dog HUII N/C (Douglas et al. 2000) 
 Pig HUII Constricted (Douglas et al. 2000) 
 Marmoset HUII Constricted (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII Constricted (Douglas et al. 2000) 
Pulmonary artery Rat HUII N/C (Douglas et al. 2000) 
  HUII Constricted (MacLean et al. 2000) 
 Mouse HUII N/C (Douglas et al. 2000) 
 Dog HUII N/C (Douglas et al. 2000) 
 Pig HUII Constricted (Douglas et al. 2000) 
 Marmoset HUII N/C (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII Constricted 
(Douglas et al. 2000; Zhu et al. 
2004) 
 
Human HUII 
Variable 
constriction (MacLean et al. 2000) 
  HUII Dilation (Stirrat et al. 2001) 
Mammary artery Rat HUII N/C (Douglas et al. 2000) 
 Mouse HUII N/C (Douglas et al. 2000) 
 
Dog HUII 
Variable 
constriction (Douglas et al. 2000) 
 
Pig HUII 
Variable 
constriction (Douglas et al. 2000) 
 Marmoset HUII N/C (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII Constricted (Douglas et al. 2000) 
 Human HUII N/C (Hillier et al. 2001) 
Carotid artery Rat HUII Constricted (Douglas et al. 2000) 
  Goby Constricted (Itoh et al. 1987) 
 Mouse HUII N/C (Douglas et al. 2000) 
 
Dog HUII 
Variable 
constriction (Douglas et al. 2000) 
 
Pig HUII 
Variable 
constriction (Douglas et al. 2000) 
 Marmoset HUII Constricted (Douglas et al. 2000) 
 Cynomolgu HUII Constricted (Douglas et al. 2000) 
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Table 2.3 Vascular response to UII throuout many species 
Vessel Animal UII Response Reference(s) 
s Monkey 
 
 HUII 
Constricted 
(in vivo) (Zhu et al. 2004) 
Pulmonary Vein Rat HUII N/C (Douglas et al. 2000) 
 Mouse HUII N/C (Douglas et al. 2000) 
 Dog HUII Constricted (Douglas et al. 2000) 
 Pig HUII N/C (Douglas et al. 2000) 
 Marmoset HUII N/C (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII Constricted (Douglas et al. 2000) 
Jugular vein 
Rat HUII 
Variable 
constriction (Douglas et al. 2000) 
 Mouse HUII N/C (Douglas et al. 2000) 
 
Dog HUII 
Variable 
constriction (Douglas et al. 2000) 
 Pig HUII N/C (Douglas et al. 2000) 
 Marmoset HUII N/C (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII 
Variable 
constriction (Douglas et al. 2000) 
Saphenous vein Rat HUII N/C (Douglas et al. 2000) 
 Mouse HUII N/C (Douglas et al. 2000) 
 
Dog HUII 
Variable 
constriction (Douglas et al. 2000) 
 
Pig HUII 
Variable 
constriction (Douglas et al. 2000) 
 Marmoset HUII N/C (Douglas et al. 2000) 
 Cynomolgu
s Monkey HUII 
Variable 
constriction (Douglas et al. 2000) 
 Human HUII N/C (Hillier et al. 2001) 
Abdominal 
resistence artery Human HUII Dilation (Stirrat et al. 2001) 
Small 
subcutaneous 
resistence artery Human HUII N/C (Hillier et al. 2001) 
Forearm blood 
flow Human HUII Constricted (Böhm and Pernow 2002) 
 
 
 
 
Table 2.3 The vascular response to UII in vessels throughout the arterial and venous 
system. The response to UII is shown to be highly species-specific in some vessels, while 
showing little species-dependence in others. *Response only when preconstricted with 5HT. 
**Response only when preconstricted with methoxamine. N/C represents no change. 
 30
3.  Cardiovascular effects of native vs non-
native urotensin II and urotensin II-
related peptide on rat and salmon hearts 
 
(The following chapter is a copy of the published article Prosser et al. Peptides, 2006 
Dec;27(12):3261-8) 
 
Abstract 
Urotensin II (UII) was first discovered in the urophyses of goby fish and later 
identified in mammals, while urotensin II-related peptide (URP) was recently isolated 
from rat brain. We studied the effects of UII on isolated heart preparations of Chinook 
salmon and Sprague Dawley rats. Native rat UII caused potent and sustained, dose-
dependent dilation of the coronary arteries in the rat, whereas non-native UII (human 
and trout UII) showed attenuated vasodilation. Rat URP dilated rat coronary arteries, 
with 10-fold less potency compared with rUII. In salmon, native trout UII caused 
sustained dilation of the coronary arteries, while human UII and URP caused 
significant constriction. L-NAME and indomethacin significantly attenuated the URP 
and rat UII-induced vasodilation in the rat heart. We conclude that UII is a coronary 
vasodilator, an action that is species form specific. We also provide the first evidence 
for cardiac actions of URP, possibly via mechanisms common with UII 
 
3.1   Introduction 
 
Urotensin II (UII) was first identified as a neurosecretory hormone thought to be 
present only in fish (Pearson et al. 1980). UII is now known to be present in most 
animal species and has been isolated from the brain of frogs, mice, rats, pigs and 
humans (Coulouarn et al. 1998; Coulouarn et al. 1999; Mori et al. 1999). 
Measurement of plasma concentrations of UII has been purported to hold clinical 
significance, being elevated in patients with congestive heart disease (Richards et al. 
2002; Russell et al. 2003) cardiac dysfunction (Heringlake et al. 2004), renal 
dysfunction (Totsune et al. 2001), cirrhosis (Heller et al. 2002), and diabetes 
(Langham et al. 2004; Totsune et al. 2004). Recently, urotensin II-related peptide 
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(URP) was isolated and cloned from rat brains by Sugo et al. (Sugo et al. 2003). URP 
has been shown to bind to the same receptor as UII (Mori and Fujino 2004) and have 
approximately the same binding affinity, but less potency than UII in contracting rat 
aortic strips in vitro (Chatenet et al. 2004). In vivo, a single study has suggested that 
URP (like UII) is hypotensive (Sugo et al. 2003), however no studies have yet 
investigated potential direct cardiac effects of URP. A prominent feature of UII is its 
structural and sequence preservation across species (Chatenet et al. 2004) which 
appears to flow onto its biological actions as studies have shown that fish UII is 
capable of exerting in vitro contractile effects on the rat vasculature (Itoh et al. 1987). 
Because of the apparent structural conservation of the disulphide bonded bioactive 6 
amino acid ring that binds to the UII receptor (Coy et al. 2002), it has been assumed 
that this plays the major role in defining the biological actions of UII/URP. However, 
it is becoming more apparent that UII has opposing actions in vessels isolated from 
different vascular beds (Douglas et al. 2000). Furthermore, the amino terminal 
sequence of UII, upstream from the 6 amino acid ring structure differs in length and 
composition across species (Lihrmann et al. 2006). Accordingly, we sought to 
determine if direct administration of native (species-specific form) versus non-native 
UII has any influence on observable bioactivity. Furthermore, we provide the first 
evidence of direct cardiac actions of URP and report circulating plasma levels of UII 
& URP. Finally, previous studies highlighted NO and prostanoids as possible 
mediators of the response to UII in the heart (Katano et al. 2000; Abdelrahman and 
Pang 2002; Gardiner et al. 2004; Lin et al. 2004; Ishihata et al. 2005a; b). 
Accordingly, we investigated whether URP can activate these same mechanisms. 
 
3.2   Materials and methods 
 
3.2.1.   Materials 
Male Sprague-Dawley (SD) rats weighing ~300 g (60-75 days old) were housed under 
controlled temperature (21ºC), humidity (~40%) and natural day length, with free 
access to standard rat food and water. 
 
Rat UII (rUII), human UII (hUII), URP, Nω-Nitro-L-arginine methyl (L-NAME) and 
indomethacin were obtained from Pharmac (Belmont, CA) and Sigma (St. Louis, MI). 
Trout UII (tUII) was synthesized by the solid phase methodology on a Fmoc-Val-
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PEG-PS, using a Pioneer PerSeptive Biosystems peptide synthesizer (Applera-France, 
Courtaboeuf, France) and the standard Fmoc procedure as previously described 
(Labarrere et al. 2003, Lancien et al. 2004). The synthetic peptide was purified by 
reversed-phase HPLC (purity was >99.5%) and characterized by MALDI-TOF mass 
spectrometry on a Voyager DE PRO spectrometer (Applera-France). All peptides and 
L-NAME were diluted in distilled water, aliquoted and stored at –20ºC prior to use. 
Indomethacin was diluted in 100% ethanol, aliquoted and stored at –80ºC prior to use. 
(The percentage of ethanol infused into the heart containing indomethacin was 
0.0025-0.0063%. Control infusions of 0.01% ethanol had no influence on cardiac 
function when compared with infusion of vehicle alone). 
 
3.2.2.   Isolated rat heart perfusion 
In vitro perfusion of rat hearts was performed as previously described (Pemberton et 
al. 2005). Briefly, rats were anesthetized by i.p. injection of 50 mg/kg sodium 
pentobarbital. The heart was then rapidly excised, rinsed in ice-cold buffer, mounted 
in the Langendorff apparatus and perfused at 12 ml/min (constant retrograde flow) 
with perfusion buffer comprising (mM); 123 NaCl, 22.0 NaHCO3, 4.7 KCl, 1.2 
KH2PO4, 1.1 MgSO4.7H2O, 1.5 CaCl2.2H2O, and 11.0 glucose (final pH 7.40). 
Buffer was maintained at 37°C, and gassed with 95%O2/5%CO2. The left atrium was 
removed allowing an ethanol-filled balloon attached to a pressure transducer to be 
inserted into the left ventricle, enabling measurement of hemodynamic contractile 
parameters. A side-arm cannula was inserted into the rubber aortic cannula to measure 
vascular reactivity. Hearts were paced at 350 bpm (Digitimer DS2A – Mk. II). Hearts 
were allowed to settle for a further 30 minutes before administration of drugs or 
control vehicle. Data was recorded and analyzed using a Powerlab Chart 5 system 
(AD Instruments). Rats were chosen at random for each dose of UII/URP or control. 
The control vehicle or drugs were infused over 30 minutes at 0.5 ml/min using a 
syringe pump feeding into the perfusion line. See Appendix B.1 for supplementary 
information and Langendorff methodology. 
 
3.2.3.   Antagonist studies 
Hearts were prepared as described above. Antagonist agents were diluted in buffer 
enabling infusion of 0.5 ml/min for 30 minutes. The effect of the antagonists on rUII / 
URP was observed by co-infusion of L-NAME (an inhibitor of nitric oxide synthase) 
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or indomethacin (a non-selective inhibitor of cyclooxygenase) mixed with either 300 
pmol rUII or 10 nM URP and infused into the heart as described above. Experiments 
were run in pairs: one heart infused with both the antagonist and peptide; the other 
simultaneously infused with the peptide only from the same stock solution and same 
buffer reservoir providing a parallel control for all antagonist experiments. The heart 
given the antagonist was chosen at random. 
 
3.2.4.   Myography of salmon coronary arteries 
Salmon (mean weight 1918 ± 533g) were obtained from Isaacs Salmon Farm 
(Christchurch, NZ). Salmon were removed from raceways and held in 20,000 L flow 
through tanks with no less than 3 fish per tank at any time. Water was provided from 
an underground bore directly below the salmon farm with temperature maintained at 
10°C in the tanks. Salmon were fed every 3 days with standard salmon chow. 
Coronary arteries running along the dorsal or ventral side of the bulbous arteriosus 
were isolated and refrigerated in salmon Ringer comprising (mM): NaCl 120, KCl 4, 
MgSO4 1.2, CaCl2 1.53, Glucose 5.5, HEPES 3, NaHEPES 7 (values in mM, final 
pH 7.8) overnight allowing them to relax and metabolize agents released during the 
capturing process. Vessels were cut to 2 mm lengths and mounted on wires in the 
jaws of a Mulvany myograph (model 410A, JP Trading, Århus, Denmark); see 
Appendix B.2 for supplimentry methods. The vessels were then pretensioned in 12ºC 
Ringer bath and allowed 2 hours to settle and reach their resting tension. One 
‘control’ vessel was untouched throughout the experiment to measure any 
spontaneous change in tension. Changes in tension were recorded using Chart 4 (AD 
Instruments). Aliquots of UII were administered directly into the bath. The effects of 
1 nM and 100 nM concentrations were measured, 40 minutes apart. A full 
concentration-response curve was not attempted as tachyphylaxis was discovered in 
preliminary experiments. At the end of the experiment 0.12 M KCl was administered 
as to obtain each vessel’s maximum potential contraction and ensure viability. 
 
3.2.5.   RIA measurement of rat plasma URP and rUII 
An RIA kit specific for rUII was supplied by Phoenix Pharmaceuticals Inc. in order to 
measure the concentration of rUII circulating in plasma from 13 healthy rats and in 
the perfusing solution. Blood was collected into tubes containing EDTA, placed on 
ice and centrifuged at 5000 rpm for 10 min at 4 °C before being stored at -80 °C until 
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required. The RIA kit is 100% cross-reactive with URP, thus the result reveals the 
potential combined concentration of both rUII and URP in rat plasma. In order to 
overcome this RP-HPLC was employed (run at 0-60% CH3CN over 60 min) and RIA 
repeated on the subsequent aliquots collected at 1 min intervals. 
 
3.2.6.   Statistical analysis 
All data are presented as mean ± SEM. Analysis of time-point changes in perfusion 
pressure was performed using a two-way ANOVA with repeated measurements. 
Comparisons of peptide responses were analyzed for significance using one-way 
ANOVA with Bonferroni’s multiple comparison test, post-hoc. The significance of all 
data concerning salmon coronary vessels was analyzed using a one way repeated 
measures ANOVA with Newman-Keuls multiple comparison test, post-hoc. In all 
statistical tests a value of P<0.05 was considered significant. 
 
3.3.  Results 
3.3.1.   Effect of rat UII upon isolated, perfused rat hearts  
30 minute infusion of rat UII effected a dose-dependent reduction in perfusion 
pressure (PP) at 3, 30 and 300 pmol/L of 10% (P=0.08), 17% (P<0.001) and 33% 
(P<0.001), respectively, compared with control (Figure 3.1A). The influence of rUII 
on PP was immediate and sustained over the 30 min infusion, with all concentrations 
stimulating maximum vasodilation by 20-30 min. 
 
3.3.2.   Effect of non-native UII in isolated perfused rat hearts  
Both human and trout UII reduced PP in the perfused rat heart, but the changes were 
not significantly different from those observed in control perfusions at 30 minutes 
(P>0.05) (Figure 3.1B). Neither native nor non-native UII had significant effects on 
cardiac contractility in rat hearts (Appendix C, Figure C.1). 
 
3.3.3.  Effect of URP on PP in rat hearts 
URP significantly reduced PP in the rat heart at both 1 nM (P<0.001) and 10 nM 
(P<0.001) (Figure 3.2), but with a reduced potency compared with rUII. 1 nM URP 
caused a maximal reduction in PP of 23% at 20 min and 10 nM 30% at 10 min during 
infusion, when compared with control. The response of rat hearts to URP compared 
with rUII, was less potent, requiring 10-fold more URP to elicit a comparable 
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reduction in PP. Like UII, URP had no direct contractile effects on isolated, perfused 
rat heart preparations (Appendix C, Figure C.1). 
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Figure 3.1 (A) Dose-dependent response of perfusion pressure to rUII in the rat heart. 3, 30 
and 300 pmol/L rUII all significantly reduced PP compared with control infusion using a one-
way ANOVA (*P=0.08, **P<0.001 and ***P<0.001, respectively) indicating potent, 
sustained dilation of the coronary arteries. (B) Observing 300 pmol/L native (rUII) and non-
native species of UII (tUII and hUII) on perfusion pressure in the isolated, perfused rat heart. 
RUII significantly reduced PP compared with vehicle (***P<0.001 analysed by one-way 
ANOVA) and significantly differs from both non-native hUII and tUII (two-way ANOVA 
found both #P<0.002). The effects of both non-native hUII and tUII do not significantly differ 
from control at 30 min post infusion (P>0.05). Gray bar indicates infusion period. 
# 
# 
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3.3.4.  Effect of antagonists on rUII and URP in the isolated rat heart 
To determine whether NO was involved in the observed vasodilation in response to 
rUII and URP, L-NAME was co-infused with each factor. 0.59 μM L-NAME alone 
raised PP above control vehicle levels, consistent with blockade of nitric oxide 
synthase (Figure 3.3A) and had no effect on contractile parameters. L-NAME 
significantly inhibited the vasodilatory effect of 300 pmol rUII throughout the 
infusion period (P<0.05), maintaining PP at a level not significantly different from 
control vehicle (P>0.05) (Figure 3.3A). L-NAME was less effective at inhibiting 10 
nM URP-induced dilation (Figure 3.3B). L-NAME co-infused with URP significantly 
increased PP above URP alone at 5 and 10 minutes post-infusion (P<0.05), but 
remained significantly different from control vehicle until after 10 minutes of infusion 
(P<0.05). By 20 minutes of co-infusion, PP became insignificant from both control 
vehicle and URP alone (P>0.05). Infusion of 3 μM indomethacin significantly 
reduced PP (P<0.05). 3 μM indomethacin significantly inhibited rUII-induced 
reductions in PP (P<0.05, Figure 3.4A). Likewise, 3 μM indomethacin also 
significantly inhibited the URP-induced reduction in PP up to 10 minutes post-
infusion (P<0.05, Figure 3.4B). Indomethacin had no significant influence on altering 
DP when co-infused with either rUII or URP.  
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Figure 3.2 Dose-dependent response to URP observing perfusion pressure (1 and 10 nM) 
in the isolated, perfused rat heart. Both 1 nM and 10 nM URP significantly reduced PP 
compared to control. ***P<0.001 following two-way ANOVA; gray bar indicates infusion 
period. 
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Figure 3.3. (A) The effect of 0.59 μM L-NAME on 300 pmol/L rUII-induced vasodilation 
in isolated, perfused rat hearts. 0.59 μM L-NAME alone significantly raised PP, consistent 
with blockade of NOS activity. L-NAME significantly attenuated the dilatory response to 
rUII throughout the infusion period compared with 300 pmol/L rUII alone (individual 
time-point comparison using student’s t-test: *P=0.014, **P=0.004, ***P=0.001). (B) The 
effect of 0.59 μM L-NAME on 10 nM URP-induced vasodilation in isolated, perfused rat 
hearts. URP alone significantly reduced PP when compared with control infusion 
(P<0.001). L-NAME significantly attenuated the drop in PP caused by URP at 5 and 10 
minutes post infusion using Student’s t-test analysis (*P<0.05). The gray bar indicates 
infusion period. 
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Figure 3.4. (A) The effect of indomethacin on 300 pmol/L rUII-induced vasodilation of 
the coronary arteries in isolated, perfused rat hearts. Indomethacin significantly prevented 
all rUII-induced reduction in PP at each time point (*P<0.05, **P<0.005). When combined 
with indomethacin, rUII could not reduce PP below that of 3 μM indomethacin infusion 
alone. (B) The effect of indomethacin on 10 nM URP-induced vasodilation of the coronary 
arteries in isolated, perfused rat hearts. Indomethacin significantly inhibited the URP-
induced reduction in PP at 5 and 10 min post-infusion (*P<0.05 comparing individual time 
points). Gray bar indicates infusion period. 
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3.3.5.   Plasma concentration of UII/URP in healthy rats 
Mean circulating concentrations of rUII/URP in plasma from 13 SD rats were 2.9 ± 
0.3 pmol/L. 
 
3.3.6.   Effect of native and non-native UII on salmon coronary arteries 
Salmon coronary vessels responded to tUII in a biphasic fashion. Native tUII dilated 
salmon coronary arteries, although this did not achieve significance below 100 nM 
(Figure 3.5). In contrast, non-native rUII caused a significant constriction of salmon 
coronary arteries at both 1 nM (P=0.032) and 100 nM (P=0.033), with constriction 
being immediate upon addition of rUII at both doses. This contraction peaked at 2 
minutes then reduced gradually to 31.53% of its maximum contraction by 40 minutes 
post administration. 
 
3.3.7.  Effect of URP on salmon coronary arteries 
URP constricted salmon coronary arteries significantly at 100 nM (P<0.01) (Figure 
3.5), with maximum constriction of the vessel occurring within 1 min of drug 
administration. Constriction was not sustained, falling rapidly to just 20.95% of initial 
maximum contraction by 10 min; and by 40 min the tension was back to resting 
levels. 
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Figure 3.5. The effect of URP and native and non-native species of UII 
on Chinook salmon coronary arteries. Non-native rUII and URP 
significantly constricted coronary vessels (P<0.01 using a one-way 
ANOVA), while native tUII significantly dilated the vessels at 10 min 
(*P<0.05 when comparing individual time points using student’s t-test). 
Arrow indicates addition of the peptide or vehicle at 0 min. 
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3.4   Discussion 
 
In coronary artery preparations, UII has been shown to be a vasoconstrictor (Bottrill et 
al. 2000; Gray et al. 2001), vasodilator (Katano et al. 2000; Li et al. 2004), or have no 
effect (Douglas et al. 2000). Interestingly, in nearly all of these studies, hUII was used 
instead of the appropriate native rat UII. We build on prior knowledge to show: 
1) UII has consistent vasodilatory activity in the coronary vasculature when 
the species appropriate form is used in both rat and fish species. 
2) This dilation is severely attenuated or reversed (i.e. constriction) when 
nonnative forms are used. 
3) URP has dilatory actions in the rat but at approximately 10-fold lower 
potency than UII. 
4) Nitric oxide and prostanoids have a significant role in both rUII and URP-
induced vasodilation of rat coronary arteries 
5) UII/URP circulates in the plasma of healthy SD rats at ~3 pmol/L  
As our results show, the use of non-native UII markedly attenuated or reversed the 
vasodilator effect of native UII on coronary vasculature. Our results found rUII to be 
a potent, dose-dependent vasodilator of the coronary arteries in the perfused rat heart, 
dilating the coronary arteries up to 33% after 30 min, indicating native UII causes not 
only a rapid response, but can maintain dilation of the coronary vasculature. 
Consistent with previous reports (Bottrill et al. 2000; Douglas et al. 2000; Gray et al. 
2001) non-native UII had little influence on PP in rat hearts when compared to 
control, with both tUII and hUII not significantly different from control at 20-30 
minutes post infusion. 
 
We found both native and non-native UII to have no significant influence on left 
ventricular contractility. Published in vivo studies across rats and sheep have shown 
UII to be both a positive (Watson et al. 2003; Hood et al. 2005) and negative inotrope 
(Ames et al. 1999; Hassan et al. 2003; Zhu et al. 2004), however the response appears 
to be dependent upon the method of infusion with intracerebroventricular infuse on 
increasing (Watson et al. 2003; Hood et al. 2005), and intravenous infusion either 
having no effect or reducing left ventricular contractility (Ames et al. 1999; Heller et 
al. 2002; Watson et al. 2003; Zhu et al. 2004). Ours is the first report to document the 
direct effects of URP in the mammalian heart and fish coronary arteries. Because the 
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URP sequence comprises the “active region” of UII, it has been hypothesized that, 
compared with UII, URP might have approximately equal or greater binding affinity 
with GPR14, provoking an equally rapid response, and being equally potent (Sugo et 
al. 2003). In our hands, URP rapidly reduced PP in the rat heart in a concentration-
dependent manner. However, URP was noticeably less potent than rUII in dilating the 
coronary arteries, and it was unable to maintain the dilation over the 30 minute 
infusion period. In agreement with our findings, Chatenet et al. report that URP has a 
slightly higher binding affinity for GPR14, but is less potent than hUII on rat thoracic 
aorta in vitro, but it must be noted that the species of URP used in salmon and rat tests 
was rat URP (Chatenet et al. 2004). Thus far, URP has been identified in rats, mice 
and humans and all retain the same amino acid (AA) sequence. It remains unknown 
whether URP exists in fish retaining the same AA sequence, a different sequence or 
whether URP is specific only to mammals.  
 
In salmon, native tUII, elicited a biphasic response on coronary arteries with initial 
minor contraction, followed by sustained dilation. In contrast, the non-native rUII 
caused pronounced constriction of the coronary arteries. Although the 6 amino acid 
‘active’ ring structure is conserved throughout all known UII species (Lihrmann et al. 
2006), there is great variation in the N-terminal sequence and length. For example, 
hUII is only 67% identical to rUII (Coulouarn et al. 1999). Structure-activity 
relationship studies have suggested that shortening the N-terminus of hUII has no 
significant effect on binding affinity to rat or human UII receptors (Brkovic et al. 
2003), or in constricting rat aortic strips compared with hUII itself (Coy et al. 2002; 
Kinney et al. 2002; Brkovic et al. 2003). However, removal or substitution of hUII’s 
C-terminus caused a substantial loss in potency and binding affinity to the rat and 
human UII receptors (Coy et al. 2002; Brkovic et al. 2003). The C-terminus of rUII 
differs from both hUII and tUII, and this may be partially responsible for our 
observed differences between rat and salmon coronary artery responses. 
 
The biphasic response provoked by tUII in salmon coronary arteries could suggest 
that more than one receptor may be activated by UII in this species. This is not 
uncommon in biological systems; for example catecholamines activate alpha and beta 
receptors which have opposing effects on one another (Forster 1981; Agnisola et al. 
1996). Alternatively, tUII may bind to the only known UII receptor, GPR14 (Ames et 
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al. 1999; Liu et al. 1999; Mori et al. 1999; Behm et al. 2003), but activate more than 
one intracellular pathway, causing initial contraction, prior to the secondary pathway 
overriding the first resulting in a biphasic response. Gendron et al. showed UII 
constricted rat thoracic aorta in vitro, but reduced mean arterial pressure (MAP) in 
vivo. They suggest UII may use the “same or similar metabolic pathways, but be 
localized in different cells with opposite functions” (Gendron et al. 2005), as GPR14 
is present in both aortic smooth muscle and the endothelium of tissues (Onan et al. 
2004). Thus, UII has the potential to constrict smooth muscle directly by increasing 
[Ca2+]i activating PKC, calmodulin and phospholipase C (Ames et al. 1999; 
Rossowski et al. 2002; Russell and Molenaar 2004), and/or dilate vessels via 
stimulating NOS and prostanoid expression in the endothelium and adventitia (Behm 
et al. 2003; Lin et al. 2004; Horie et al. 2005). These opposing responses produced by 
UII may explain the biphasic effect observed with tUII in salmon coronary arteries. 
Our results suggest both rUII and URP stimulate the release of NO in rat coronary 
arteries as L-NAME significantly attenuated the vasodilatory actions of rUII and URP 
in the isolated rat heart. These findings agree with previous reports observing the 
relationship between NO and UII (Katano et al. 2000; Li et al. 2004; Ishihata et al. 
2005a; Ishihata et al. 2006). 
 
In rat hearts, L-NAME significantly attenuated URP-induced vasodilation at 5 and 10 
minutes post-infusion, with PP climbing towards control levels after 5-10 minutes 
post-infusion. Interestingly, the inhibitory potency of L-NAME upon URP was less 
than for rUII suggesting rUII is more dependent upon NO than URP to dilate coronary 
arteries. However, L-NAME could not totally inhibit vasodilation induced by rUII / 
URP indicating other intracellular pathways may be utilized by both factors. 
Prostanoids (specifically PGE2, PGD2, PGI2) have been previously shown to dilate 
coronary arteries of isolated, perfused rat hearts (Bouchard et al. 1994) and may be a 
mechanism utilized by UII in the rat heart (Ishihata et al. 2005b). Our results agree 
with this hypothesis as indomethacin significantly inhibited rUII-induced dilatory 
activity in our preparations. Intriguingly indomethacin alone had vasodilatory actions 
in rat heart preparations. Prostanoids encompass a large family of molecules, some of 
which previously shown to vasodilate and others vasoconstrict coronary arteries 
(Cornish et al. 1983). The dilation may suggest that the balance of constrictive PGs 
versus dilatory PGs occurring in the coronaries at the time of infusion was slightly in 
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favour of constriction, and thus removal of all PG activity by indomethacin resulted in 
a slight dilation. Co-infusion of indomethacin with rUII or URP did not result in 
synergistic decreases in perfusion pressures. Why indomethacin-induced dilation 
should inhibit UII / URP dilation is unclear, but it may relate to the constant 
biological control, balancing activated and suppressed peptides and molecules to 
maintain homeostasis. This hypothesis agrees with our results observing the 
antagonism of rUII with indomethacin suggesting UII activates vasodilatory PGs and 
may inhibit vasoconstrictive PGs. 
 
This is the first study to reveal the effects of inhibiting prostanoids on URP bioactivity 
in the isolated, perfused rat heart. Indomethacin significantly inhibited URP-induced 
vasodilation but lost significance past 10 minutes post-infusion. This was the same 
pattern of response observed with L-NAME above, due to URP naturally losing 
potency and rising towards control levels. Co-infusion of URP and indomethacin 
caused PP to remain at levels equal to infusion of indomethacin alone, revealing: a) 
URP influences prostanoid activity in the isolated, perfused rat heart; and b) 
prostanoids possess greater potency than NO in dilating the coronary arteries when 
stimulated by URP. Circulating levels of rUII/URP in the rat were ~3 pmol/L. We 
attempted to discriminate the molecular forms of UII/URP in the rat circulation 
through coupling RP-HPLC with a specific commercially available URP RIA but we 
could not achieve consistent results. Discrimination of URP/UII forms in the 
circulation thus remains a logical target for future study. 
 
In conclusion, UII has consistent vasodilatory activity in the coronary vasculature 
when the species appropriate form is used in both rat and fish, but this dilation is 
severely attenuated or reversed (i.e. constriction) when non-native forms are used. 
URP has dilatory actions in the rat but at approximately 10-fold lower potency than 
UII. Nitric oxide and prostanoids have a significant role in both rUII and URP-
induced vasodilation of rat coronary arteries. These findings reveal the level of 
species-specificity of UII and the possible importance the C- or N-terminals for 
correct receptor activation. 
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4.  Urotensin II and Disease 
 
 
Abstract 
 
At the commencement of this thesis the American Heart Association (AHA) reported 
cardiovascular disease (CVD) to be prevalent in 80 million Americans and 
responsible for the death of 864,500 Americans in 2005, recognising it as the greatest 
cause of death in America and the Western world (American Heart Association 2009). 
Understanding the pathogenesis of CVD is vital in order to design means of reducing 
its pathological effects and reduce mortality. This includes identifying the peptides, 
enzymes, receptors and intracellular agents underlying the progression of CVD, 
including both cardioprotective and pathogenic.  UII has been suggested to have a 
significant role in the pathology of CVD in mammals as circulating UII is elevated in 
patients suffering congestive heart failure (CHF), and other cardiovascular diseases. 
UII is also reported to be correlated with elevated left ventricular end-diastolic 
dysfunction, and severity of disease, suggesting circulating UII concentration may 
provide a potential marker of disease and predictor of future complications and patient 
survival. This review will look specifically at the role of UII in two major types of 
cardiovascular disease, congestive heart failure (CHF) and atherosclerosis, examining 
UII-induced pathogenic and protective properties, as well as its potential as a marker 
of cardiac disease.  
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4.1.   Congestive Heart Failure (CHF) 
 
Many studies have now reported the UII/UT system (including UT mRNA and 
prepro-UII mRNA) to be upregulated in cardiovascular disease and CHF (Maguire et 
al. 2000; Douglas et al. 2002; Zhang et al. 2002). UII/UT expression within the 
myocardium itself is shown to be altered with disease; for example Zhang et al. 
(2002) reported rats that with CHF displayed elevated cardiac UT expression, which 
was greatest in the right ventricle, suggesting UT expression is related to pulmonary 
hypertension (Zhang et al. 2002). Douglas et al. (2002) reported prepro-UII mRNA 
and UII expression to be greater in the left ventricle of patients with ischemic heart 
disease, while patients with dilated cardiomyopathy showed similarly elevated 
expression across both ventricles and atria (Douglas et al. 2002). Furthermore, UT 
density was reported to be elevated in the myocardium of CHF hearts, specifically 
localised to the cardiomyocytes, VSMCs and endothelial cells (Douglas et al. 2002), 
while another study reported no significant difference in UT density in coronary 
artery medial smooth muscle cells between CHF patients and healthy volunteers 
(Maguire et al. 2000; Maguire et al. 2004). Experimental animal models inducing 
CHF in rats recorded elevations in plasma UII levels compared to their controls 
(Bousette et al. 2004; Bousette and Giaid 2006), while spontaneously hypertensive 
rats (SHRs) also exhibited elevated UII levels (Song et al. 2006; Watanabe et al. 
2006). These studies reveal UII is produced throughout the heart and indicate UII 
production is elevated in cardiovascular disease suggesting a potential pathological 
role in CHF. However, it is yet to be confirmed whether UII and its mRNA are 
elevated in response to the disease in order to provide a level of protection, or whether 
the elevation augments the progression of the disease. This is the key finding 
currently eluding researchers and in doing so hindering the development of using UII 
as a potential therapeutic tool.  
 
Studies have provided evidence for UII as both a cardioprotective and pathogenic 
agent. For example, patients expressing low UII levels exhibited poorer outcomes 
with increased likelihood of a cardiovascular event occurring (Khan et al. 2006; 
Mallamaci et al. 2006; Ravani et al. 2008); while maintaining an elevated UII 
concentration in a rat model of volume overload preserved myocardial contractility 
(Harris et al. 2007) indicating UII possesses protective properties. In contrast, reports 
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have also indicated blockade of the UII receptor aided recovery from ischemia, 
significantly lowered collagen I:III ratio and attenuated cardiac fibrosis in live rats 
(Bousette et al. 2006a; Bousette et al. 2006b). Further in vitro studies have shown UII 
to promote collagen gene expression and synthesis in cardiac fibroblasts (Tzanidis et 
al. 2001; Tzanidis et al. 2003; Bousette and Giaid 2006) and stimulate VSMC 
proliferation, causing vessel wall thickening and contributing to CHF (Sauzeau et al. 
2001; Watanabe et al. 2001a; Tamura et al. 2003).  
 
Observing the effect of UII on the pulmonary artery in mammalian species, UII has 
been shown to stimulate vasoconstriction, or have no effect (Douglas et al. 2000; Zhu 
et al. 2004), while in human arteries hUII is reported to cause variable 
vasoconstriction (MacLean et al. 2000) and vasodilation (when preconstricted with 
endothelin) (Stirrat et al. 2001), suggesting UII may regulate pulmonary arterial tone. 
Dschietzig et al. reported that increasing pressure over isolated pulmonary artery 
endothelial cells within a flow chamber caused a reduction in prepro-UII mRNA and 
UII peptide expression (Dschietzig et al. 2001). Their results suggest that if viewing 
UII as a potent vasoconstrictor, the observed reduction in UII in response to increased 
pressure suggests UII does not contribute in the pathophysiology of pulmonary 
hypertension. However, if UII naturally dilates the pulmonary artery in the healthy 
setting, the reduction in response to elevated pressure may contribute to the 
pathophysiology of pulmonary hypertension by reducing UII-induced vasodilative 
effects (Dschietzig et al. 2001). This again illustrates the complexity of the UII system 
and calls for analysis on a vessel-by vessel, species-by-species basis. 
 
 
4.2   Atherosclerosis and Coronary Artery Disease (CAD) 
 
The endothelium lining the lumen of all vessels is of vital importance in the regulation 
of blood pressure and vascular health as it produces and secretes vasoactive agents 
regulating vascular tone. Hypertension, smoking, hyperlipidemia, 
hypercholesterolemia, diabetes, all increase the likelihood of endothelial dysfunction 
(ED), which in turn, can result in the development of coronary artery disease (CAD) 
and atherosclerosis (Katz 1997; Meigs et al. 2002; Hadi et al. 2005; Haluska et al. 
2008). UII levels are reported to be elevated in hypertensive subjects (Cheung et al. 
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2004; Suguro et al. 2007) and ICV application of UII to normotensive and SHRs 
significantly elevated blood pressure (Lin et al. 2003). UII-induced rises in blood 
pressure were more pronounced in SHR animals, suggesting existing hypertension 
may increase sensitivity of the vasculature to UII/UT activity. 
 
Hypertension-induced vascular stress and stretch results in ED, the symptoms of 
which include loss of endothelial integrity resulting in increased endothelial 
permeability, reduced ability to produce vasodilative agents, monocyte migration, 
platelet activation and increased vascular reactivity, which combined, lead to CAD 
and atherosclerosis (Schiffrin 2008a; b). The development and progression of 
atherosclerosis and hypertension can be divided into two hypertension-induced 
pathways: one leading to the development of atherosclerotic plaques, while the other 
simultaneously stimulates maladaptive vascular remodelling (Watanabe et al. 2006) 
(Figure 4.1).  
 
UII and UT expression are elevated in patients with hypertension and positively 
correlated with atherosclerotic plaque score and severity of CAD (Heringlake et al. 
2004; Suguro et al. 2007), suggesting that UII may have a significant pathological 
role on the development of CAD and atherosclerosis. No difference in UT density was 
observed in human medial VSMCs when comparing normal and atherosclerotic 
coronary arteries (Katugampola et al. 2002), however UT expression is elevated in the 
atherosclerotic plaque and regulated by inflammatory mediators, produced in 
abundance within and around the sight of atherosclerotic plaque (Papadopoulos et al. 
2008). UII is now reported to significantly influence both plaque formation and 
vascular remodelling (Figure 4.1), discussed below. 
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It is now well established that UII stimulates NO production, causing vasodilation, 
and potentially a level of vascular protection to alleviate pressure, stretch and shear 
stress (Gray et al. 2001; Zhang et al. 2003; Lin et al. 2004; Ishihata et al. 2006; Lacza 
and Busija 2006). However, in dysfunctional endothelial cells the production of nitric 
oxide (NO) is known to become uncoupled, and ironically, eNOS produces reactive 
oxygen species (ROS) instead of NO (Otani 2009). NO is also scavenged by excess 
ROS, and thus in the diseased state NO availability is quenched, limiting 
endothelium-dependent vasodilation (Lavi et al. 2008). This has been observed in the 
human left anterior descending coronary artery where patients suffering ED expressed 
significantly reduced NO bioavailability due to increased oxidative stress, whilst NO 
production remained the same as vessels from healthy patients (Lavi et al. 2008). The 
Figure 4.1. Flow diagram illustrating the pathways stimulated in response to hypertension 
leading to the development and progression of atherosclerosis and hypertension. ROS - 
reactive oxygen species; LDL - low-density lipoprotein; VSMC - vascular smooth muscle 
cell. From Watanabe et al. 2006. 
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elevation in oxidative stress observed is primarily due to activation of vascular 
nicotinamide adenine dinucleotide (NADPH) oxidase, forming ROS. To our 
knowledge, only one study has observed the direct effects of UII on NADPH activity. 
Djordjevic et al. administered UII to human pulmonary artery smooth muscle cells in 
vitro and concluded that UII elevated ROS activity via increased NADPH oxidase. 
ROS then initiated cellular proliferation and pulmonary arterial remodelling through 
the activation of cytokines, as well as reducing NO bioavailability, suggesting UII 
augments pulmonary hypertension (Djordjevic et al. 2005). NADPH oxidase can also 
convert LDL to oxidised LDL in the arterial wall. Oxidised LDL has been found to 
interact with other agents including angiotensin II and serotonin, and recently it has 
been suggested that UII can act synergistically with mildly oxidised LDL to further 
increase VSMC proliferation, reducing the diameter of the lumen, elevating 
hypertension (Watanabe et al. 2001a). Hypertension-induced ED also stimulates the 
release of growth factors from endothelial cells and macrophages in the intimal layer 
that induce cellular proliferation and migration of VSMCs to the intima (Hadi et al. 
2005). Atherosclerotic plaques occur when the dysfunctional endothelium enables 
lipid and leukocyte deposition in the arterial wall, producing a fatty streak which over 
time accumulates foam cells, lipids, myointimal cells and extracellular matrix proteins 
to form a plaque (Watanabe et al. 2006). UII has been suggested to progress 
atherogenesis by upregulating ACAT-1 levels, an enzyme responsible for converting 
intracellular free cholesterol to cholesterol ester capable of then being stored in lipid 
droplets accelerating foam cell formation, eventually leading to the formation of fatty 
streaks (Watanabe et al. 2005; Papadopoulos et al. 2008; Shiraishi et al. 2008). UII 
has also been reported to increase endothelial cell permeability (Gendron et al. 2005), 
promote VSMC proliferation and inhibit apoptosis through ERK1/2 and RhoA/Rho 
kinase activity (Matsushita et al. 2001; Watanabe et al. 2001a; Watanabe et al. 2001b; 
Zou et al. 2001; Tamura et al. 2003; Tzanidis et al. 2003; Shi et al. 2006; Chen et al. 
2008). Further proatherogenic effects of UII currently reported include UII-induced 
increases in collagen synthesis and expression (Wang et al. 2004; Zhang et al. 2008), 
promotion of cardiac fibrosis (Zhang et al. 2007), and elevating acetylcholine levels 
(Russell and Molenaar 2004) augmenting vasoconstriction. The distributive 
expression of UII also suggests a close relationship with inflammation and 
atherosclerotic lesions as UII and UT are both localised within human carotid plaque 
(Bousette et al. 2004). UII is expressed in foam cells and myointimal and medial 
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VSMCs of atherosclerotic human coronary arteries (Hassan et al. 2005), and is 
produced by macrophages and lymphocytes (Bousette et al. 2004; Maguire et al. 
2004) indicating localised production of UII within the atherosclerotic lesion. 
Furthermore, UII colocalises with macrophages in human atherosclerotic coronary 
artery lesions (Maguire et al. 2004) and expression of UII/UT is regulated by 
inflammatory mediators including interlukin-6 and 1β and interferon-γ produced by T 
lymphocytes in the atherosclerotic plaque (Papadopoulos et al. 2008). Shiraishi et al. 
(2008) recently confirmed that infusion of UII into live rats for 4-14 weeks elevates 
the presence of aortic atheromas and lesion size, while UT and UII expression were 
both elevated in ApoE knock-out mice, specifically within the endothelium, smooth 
muscle cells and atheroma. Blockade of the UT receptor effectively attenuated the 
UII-induced effects, reducing aterosclerotic lesions in the ApoE ko animal model, and 
effectively inhibiting the development of atherosclerosis (Shiraishi et al. 2008). 
 
In summary, these reports indicate UII to be a potentially potent proatherogenic, 
hypertensive agent stimulating vascular hypertrophy, and promoting the development 
of atherosclerotic plaque by accelerating foam cell formation, and increasing collagen 
expression. This suggests that inhibiting UII activity through blockade of UT may 
attenuate the progression of atherosclerosis and CAD. Rakowski and co-authors 
provide further support for this by demonstrating that blockade of the UT receptor 
reduced myointimal thickening and increased lumen size in a rat model of carotid 
artery stenosis (Rakowski et al. 2005). Currently, just one report has suggested a 
potential cardioprotective function for UII in atherosclerosis. Russell et al. (2004) 
proposed that UII-induced elevations in collagen and fibrinogen may afford a means 
of protection by maintaining the integrity of the fibrous atherosclerotic plaque cap, 
preventing the release of the lipid lesion into the vessel (Russell 2004). This theory is 
yet to be tested, however it has been reported that TGFβ1 stabilizes atherosclerotic 
plaque (Cipollone et al. 2004b) while PGE2 is associated with atherosclerotic plaque 
destabilization (Cipollone et al. 2004a); both agents reported to be produced in 
response to UII. 
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4.3  Protective and pathogenic pathways stimulated by UII 
 
Identifying the intracellular agents and pathways stimulated in response to UII may 
provide beneficial explanations to the complex, dichotomous activity of UII observed 
in studies using healthy and diseased subjects (Figure 4.3). The cardioprotective 
properties of UII are evident in that UII stimulates nitric oxide production, EDHF, 
TGFβ1, and prostanoid activity (namely PGE2 and prostacyclin), all known to provide 
cardioprotection through eliciting vasodilation and regulating cellular proliferation 
(Lamontagne et al. 1992; Yano et al. 1995; Gray et al. 2001; Horie et al. 2005; 
Gardiner et al. 2006; Jia et al. 2008). Bottrill et al. (2000) reported that while UII 
constricted rat coronary arteries, it also caused dilation when the same arteries were 
preconstricted suggesting UII may provide a means of homeostatic regulation, 
maintaining blood pressure within normal levels (Bottrill et al. 2000). This has also 
recently been reported in cultured human aortic endothelial cells where UII induced 
an increase in [Ca2+]i when the vessel was undergoing light shear stress, but UII had 
no effect on the vessel when static (Brailoiu et al. 2008). This pattern of response 
suggests UII has a protective, regulatory role in the cardiovasculature of healthy 
vessels (Figures 4.2 & 4.3). However, as discussed above, many reports implicate UII 
as a potent pathogenic factor, augmenting cardiovascular disease, including 
exacerbating atherosclerosis via the activation of ROS and accelerating foam cell 
formation (Watanabe et al. 2005; Watanabe et al. 2006), and stimulating extracellular-
regulated kinase (ERK)- and c-jun N-terminal kinase (JNK)-mediated maladaptive 
VSMC remodelling (Figures 4.2 & 4.3). While the vasoconstrictive effects of UII 
promoting hypertension are reported to be mediated via Ca2+-dependent stimulation of 
protein kinase C (PKC) and calmodulin within the VSMC (Figure 4.2). The 
contrasting effects of UII are proposed to be dependent upon endothelial dysfunction.   
 
Endothelial dysfunction (ED) is a known characteristic of CHF (Katz 1997) and 
results in severe reduction of local NO expression and endothelium-derived 
hyperpolarizing factor (Andersson et al. 2003; Triggle et al. 2003). Due to this 
reduction in available vasodilative agents, UII may have reduced potency in dilating 
the vessel. This exact phenomenon was observed in a human in vivo study by Lim et 
al. (2004), where UII administered to healthy controls caused increased blood flow 
through the skin microvasculature, but application of UII to the same vessels of CHF 
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patients elicited vasoconstriction (Lim et al. 2004). Studies observing the effects of 
UII on endothelium-denuded vessels are, in theory, observing the effect of UII on 
diseased vessels. Endothelial-dependence studies have all reported UII to stimulate 
equal or increased vasoconstriction and a loss of vasodilation upon removal of the 
endothelium (MacLean et al. 2000). The reason for the elevated vasoconstriction is 
that the UT receptors are located on both endothelial and smooth muscle cells and 
thus if the endothelium becomes damaged or degraded, UII can bind directly to the 
smooth muscle cells stimulating an influx of calcium via the PLC/IP3/PKC pathway, 
resulting in sustained vasoconstriction and possible cellular hypertrophy (Figure 4.2). 
Furthermore, dysfunctional endothelial cells still capable of binding UII can produce 
detrimental disruption of intracellular pathways that were once beneficial. For 
example, UII-induced stimulation of the NO pathway within a dysfunctional 
endothelial cell can lead to the production of reactive oxygen species (ROS) due to 
eNOS uncoupling, leading to eNOS-mediated superoxide anion production resulting 
in damage to surrounding cells and hypertrophy (Bauersachs and Fraccarollo 2008).  
 
 
Figure 4.2 Schematic illustration of the intracellular pathways stimulated by UII in 
both endothelial and vascular smooth muscle cells. UII can stimulate NO- / PGI-
induced vasodilation or PKC- / calmodulin-induced vasoconstriction dependent upon 
the cell type stimulated. UII can also promote VSMC proliferation and foam cell 
formation through stimulating ACAT-1 activity in macrophages, together developing 
and progressing atherosclerosis. From Papadopoulos et al. 2008. 
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Figure 4.3 Summarizing the urotensin II-induced cardioprotective and pathogenic 
effects on the cardiovasculature reported to date.  
 
 
 
In renal and cardiac disease the elevation in UII is significantly correlated with an 
elevation in TGFβ1 expression, and UII has since been shown to directly stimulate 
TGFβ1 expression including its mRNA (Mallamaci et al. 2006; Dai et al. 2007). In the 
healthy state TGFβ1 has been reported as vasculoprotective (Mallamaci et al. 2006) 
regulating cellular proliferation through stimulating apoptosis and growth factors 
within the cell. However, in the diseased state TGFβ1 functions can reverse becoming 
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a profibrotic cytokine, stimulating cardiac and renal hypertrophy and fibrosis (Border 
and Noble 1994; Li et al. 1998; Hein et al. 2003). In renal disease the elevation in UII 
levels was reported to provide TGFβ1-mediated vasculoprotection and be 
antiatherogenic  (Mallamaci et al. 2006), while diabetes-induced upregulation of UII 
and UT aided TGFβ1-mediated renal fibrosis and dysfunction in the kidney (Tian et al. 
2008). In healthy rat myocardial fibroblasts UII elevated TGFβ1-mediated collagen 
mRNA expression, indicating UII aids pro-fibrotic cardiac remodelling, as 
antagonism of the UT receptor and TGFβ1 both inhibited collagen synthesis (Dai et al. 
2007). These studies indicate UII-induced TGFβ1 activity can stimulate both 
protective and detrimental effects in both healthy and diseased cells revealing the 
difficulty in interpreting the UII-induced TGFβ1-mediated role in cardiovascular 
disease.  
 
UII also stimulates activation of cyclooxygenase-1 and -2 (COX-1 and -2) enzymes 
producing prostaglandins capable of both preventing and promoting vascular disease 
(Deeb et al. 2008). COX-1 is suggested to cause pathological effects through 
stimulating vasoconstriction, inflammation, and cellular proliferation, while COX-2 is 
reported to be vasoprotective eliciting PG-mediated vasodilation, and inhibiting 
platelet activation and adhesion (Deeb et al. 2008). As with TGFβ1, the variable 
effects produced by UII-induced PG activity may also depend upon the functional 
state of the cell. To date all studies observing COX activity in response to infusion of 
UII have been performed in healthy vessels or animals, providing little evidence that 
UII-induced PG production can differ in the diseased state. COX-2 expression is 
reported to be elevated in atherosclerotic lesions in animals and humans providing 
vasoprotection (Deeb et al. 2006), however the increased expression also results in 
elevated proinflammatory PGs contributing to plaque rupture (Cipollone et al. 2004a). 
Based on this it is plausible that UII-induced upregualtion of COX expression could 
potentially progress atherosclerosis, although this is yet to be tested. 
 
In summary, three of the main pathways activated by UII (NO, PGs and TGFβ1) are 
known to produce opposing effects dependent upon the functional state of the cell. 
NO is a known dilative agent, however stimulation of eNOS can produce ROS in 
dysfunctional endothelial cells, progressing atherosclerosis and CAD. Activation of 
COX enzymes stimulate PGs capable of producing vasodilative, vasoconstrictive and 
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proliferative effects depending upon which isoforms is stimulated. Lastly, TGFβ1 is 
described as a vasculoprotective agent regulating cellular growth in healthy cells; 
however, UII-induced stimulation of TGFβ1 resulted in collagen synthesis in both 
healthy and diseased myocardial fibroblasts proving it is not a simple 
vasculoprotective agents but can also induced pathogenic effects, adding to the 
complex nature of UII activity. 
 
 
4.4   UII as a novel biomarker of cardiac disease 
 
Correlation studies between plasma levels of circulating UII and other markers of 
CHF suggest a possible association between BNP and UII, as UII was found to be 
positively correlated with BNP in CHF patients (Lapp et al. 2004; Gruson et al. 2005). 
In contrast, plasma UII levels negatively correlate with BNP in chronic renal failure 
(Zoccali et al. 2006). Whether the positive and negative correlations between UII and 
BNP are dependent on the disease state is yet to be determined and warrants further 
research. Currently, UII is not used as a measure of cardiovascular disease. One report 
suggests UII may be a better marker of CHF than NT-BNP as UII is independent of 
age, sex or NYHA class (Ng et al. 2002). The potential for UII to be used as a 
measure of CHF, CAD, or other cardiovascular diseases requires further research, and 
it has been recently reported that UII may be a marker of rheumatic valve disease 
(RVD), where plasma levels of UII correlated significantly with valvular regurgitation 
and pulmonary artery pressure, indicating that plasma UII may be predictive of 
pulmonary arterial hypertension (Ozer et al. 2009). Plasma UII levels have also been 
shown to correlate significantly with the level of atherosclerotic plaque score (Suguro 
et al. 2007), with UII and UT mRNA shown to be elevated in atherosclerotic legions 
of human aorta (Bousette et al. 2004), indicating UII could potentially be used as a 
marker for these conditions.  
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4.5  Summary 
 
Taken together, it is becoming clear UII has a key role in CHF, atherosclerosis and 
CAD, heavily influencing the vasculature and myocardium. UII and UT expression 
are consistently reported to be elevated in cardiovascular and renal disease, however 
UII is yet to be established as a consistent biomarker of CVD. It is also yet to be 
concretely determined whether the elevation in UII and UT expression in response to 
cardiovascular disease provides cardioprotective effects, or whether UII augments 
CVD. Aggregating the reports to date it is evident that the number of reports 
suggesting UII augments CVD with blockade of the UT receptor providing 
antiatherogenic, antihypertensive effects outweigh the number of reports suggesting 
upregulation of UII/UT provides cardioprotective properties in the diseased state. The 
intracellular pathways stimulated by UII provide some explanation into the 
differential results reported as the vasculoprotective, vasodilative and 
antihypertrophic stimulation of NO synthesis, COX activity and TGF1 can also 
produce vasoconstrictive, atherogenic, hypertrophic effects, in the pathological, 
maladaptive state. This indicates that development of a UT blocker may provide 
therapeutic benefits to ‘at risk’ patients with CVD or CHF.  
 
As discussed in Chapter 2, UII is highly dependent upon species, tissue and cell-type 
(Chapter 2.6, page 18), while the development of specific UT antagonists are 
reportedly capable of having both agonistic and antagonistic effects, again seemingly 
dependent upon the species type (Chapter 2.2, page 10). Due to these complexities it 
is important to be aware of studies reporting pathogenic or protective effects of 
elevated UII concentration or blockade of UT where the non-native species form of 
UII has been administered, or a UT blocker with reported agonistic effects has been 
used. Until research is repeated using these guidelines the pathological effects of UII 
may remain ambiguous. Thus, the following chapters aim to provide significant 
insight into the cardioprotective or pathogenic effects of UII/URP in the setting of 
acute, global ischemia in the isolated, perfused rat heart. We determine the effects of 
both agonistic (UII/URP) activity and antagonism of UT upon recovery from 
ischemia.
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5.   Urotensin II and urotensin II-related 
peptide (URP) in cardiac ischemia-reperfusion injury 
(A) 
 
(The following chapter is a copy of the published article Prosser et al. Peptides, 2008 
May;29(5):770-7) 
 
Abstract 
 
Circulating urotensin II (UII) concentrations and the tissue expression of its cognate 
receptor (UT) are elevated in patients with cardiovascular disease (CVD). The 
functional significance of elevated plasma UII levels in CVD is unclear. Urotensin-
related peptide (URP) is a paralog of UII in that it contains the 6 amino acid ring 
structure found in UII. Although both peptides are implicated as bioactive factors 
capable of modulating cardiovascular status, the role of both UII and URP in ischemic 
injury is unknown. Accordingly, we provide here the first report describing the direct 
cardiac effects of UII and URP in ischemia-reperfusion injury. Isolated perfused rat 
hearts were subjected to no-flow global ischemia for 45 min after 30 min 
preconditioning with either 1 nM rUII or 10 nM URP. Both rUII and URP induced 
significant vasodilation of coronary arteries before (both P<0.05) and after ischemia 
(both P<0.05). Rat UII alone lowered contractility prior to ischemia (P=0.053). 
Specific assay of perfusate revealed rUII and URP both significantly inhibited 
reperfusion myocardial creatine kinase (CK) release (P=0.012 and 0.036 respectively) 
and atrial natriuretic peptide (ANP) secretion (P=0.025). Antagonism of the UT 
receptor with 1 µM palosuran caused a significant increase in perfusion pressure (PP) 
prior to and post ischemia. Furthermore, palosuran significantly inhibited reductions 
in both PP and myocardial damage marker release induced by both rUII and URP. In 
conclusion, our data suggests rUII and URP reduce cardiac ischemia-reperfusion 
injury by increasing flow through the coronary circulation, reducing contractility and 
therefore myocardial energy demand, and inhibiting reperfusion myocardial damage. 
Thus, UII and URP present as novel peptides with potential cardioprotective actions.  
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5.1.   Introduction 
 
Urotensin II (UII) is a cardiovascular peptide with an array of biological effects that 
are species and tissue specific (Douglas et al. 2000; Prosser et al. 2006). Thus, UII has 
been shown to constrict and dilate vascular tissue (Bottrill et al. 2000; Katano et al. 
2000; Opgaard et al. 2000), increase and decrease blood pressure and contractility in 
vivo (Ames et al. 1999; Hassan et al. 2003; Watson et al. 2003; Zhu et al. 2004), 
stimulate vascular smooth muscle cell proliferation (Watanabe et al. 2001a; Watanabe 
et al. 2001b), and promote cardiomyocyte hypertrophy (Tzanidis et al. 2003; Zoccali 
et al. 2006). Blood levels of UII and the tissue expression of its cognate G protein-
coupled receptor (UT) are both elevated in patients with congestive heart failure 
(CHF) and other cardiovascular diseases (Douglas et al. 2002; Richards et al. 2002; 
Russell et al. 2003; Heringlake et al. 2004; Lapp et al. 2004).   
 
Recently a precursor cDNA peptide encoding the same conserved 6 amino acid ring 
as UII was isolated from rat, mouse and human tissues. This UII paralog has been 
named urotensin-related peptide (URP) and is a second endogenous ligand for the UT 
receptor (Sugo et al. 2003; Chatenet et al. 2004), with studies administering URP both 
in vitro and in vivo reporting biological actions similar to UII (Sugo et al. 2003; 
Chatenet et al. 2004). The distribution of prepro-URP in human and rat tissue is 
widespread, including brain, and the cardiovascular system (Sugo et al. 2003). 
However, its biological effects in these systems are unclear. 
 
Despite a number of reports documenting cardiovascular actions of UII (Ames et al. 
1999; Douglas et al. 2004; Richards and Charles 2004; Zhu et al. 2004) its role in 
cardiac ischemia-reperfusion injury is unclear. Experimental animal models of heart 
failure suggest UII may have a pathological role, as antagonism of UT results in 
reduced mortality and improved recovery of heart function in rats (Watanabe et al. 
2001a; Bousette et al. 2006a; Bousette et al. 2006b). In contrast, patients with 
significantly elevated plasma UII levels have improved outcomes post myocardial 
infarction, suggesting UII may play a cardioprotective role (Khan et al. 2006; Zoccali 
et al. 2006). Furthermore, any role for URP in cardiac ischemia-reperfusion injury is 
unreported. Accordingly, we provide here the first documentation of the species-
 60
specific actions of rUII and URP in cardiac ischemia-reperfusion injury and their 
comparative effects upon contractile and cardioendocrine function.  
 
 
5.2  Methods 
 
5.2.1  Materials 
All animals used in this study were male Sprague-Dawley rats (250-400 g, 60-75 days 
old) obtained from the Christchurch School of Medicine, Christchurch, New Zealand. 
Rats had free access to standard rat chow and water and were housed under controlled 
temperature (21ºC), humidity (~40%) and natural day length. 
 
Rat urotensin II (rUII) and URP were obtained from Phoenix Pharmaceuticals 
(Belmont, USA). UII receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-
hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt) was a 
generous gift from Dr M Iglarz, Actelion Pharmaceuticals Ltd (Switzerland) (Clozel 
et al. 2004). All peptides and palosuran were diluted in distilled water, aliquoted and 
stored at -20ºC prior to use.  
 
5.2.2  Langendorff isolated heart preparation 
Isolated heart perfusion was carried out as previously described (Pemberton et al. 
2005; Prosser et al. 2006). Briefly, rats were anesthetized with sodium-pentobarbitol 
(50mg/kg, i.p.). The heart was exposed and cannulated above the aortic valve with 
oxygenated (95% O2/5% CO2) buffer comprising (mM): 123 NaCl, 22.0 NaHCO3, 4.7 
KCl, 1.2 KH2PO4, 1.1 MgSO4.7H2O, 1.5 CaCl2.H2O and 11.0 glucose (final pH 7.40). 
Buffer was maintained at 37ºC. The heart was rapidly excised and attached to the 
Langendorff apparatus perfused retrograde at 12 ml/min. The left atrium was removed 
allowing an ethanol-filled balloon (attached to a pressure transducer) to be inserted 
into the left ventricle, enabling the measurement of left ventricular developed pressure 
(DP) and rate of change in pressure (±dP/dt). A side-arm cannula attached to a 
pressure transducer was inserted into the rubber aortic cannula measuring perfusion 
pressure (PP), a direct measure of coronary artery resistance. All data were recorded 
using a Powerlab Chart 5 System (ADInstruments). All hearts were paced at 330 bpm 
using a Digitimer DS2A-Mk. II stimulator placed on the right atrium. In all studies 
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hearts were allowed to equilibrate for 30 minutes before any experimental procedure 
was started (see Appendix B.1 for supplementary information and methodology). All 
experiments in the current study were approved by the University of Otago Animal 
Ethics Committee. 
 
5.2.3  Ischemia-reperfusion protocols 
Hearts were allowed to stabilize before being infused with either 1 nM rUII, 10 nM 
URP, 1µM palosuran or vehicle continuously for 30 min (0.5 ml/min). The doses of 
rUII and URP were employed based on our previous work (Prosser et al. 2006). The 
concentration of 1 µM palosuran was based on the manufacturers’ report (Clozel et al. 
2004). Infusion of the drug/vehicle was then stopped and hearts underwent no-flow 
global ischemia for 45 min with pacing halted. Hearts were then reperfused with 
pacing for 105 min following ischemia (Figure 5.1).  
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5.2.4 Analysis of Atrial Natriuretic Peptide (ANP) secretion and myocardial 
Creatine Kinase (CK) release 
Perfusate samples were collected at specific time points after passing through the 
heart (Figure 5.1). ANP release was measured by extracting perfusate samples using 
SepPak columns and measured by radioimmunoassay (RIA) as previously described 
(Pemberton et al. 2000, refer Appendix D.2). Perfusate creatine kinase (CK) 
concentrations were determined on an Abbot Aeroset (Canterbury Health Labs, 
Christchurch, New Zealand).  
Figure 5.1. Experimental protocol of ischemia-reperfusion. Rat hearts underwent 
preconditioning infusion (30 min), followed by no-flow global ischemia (45 min), 
and a reperfusion period (105 min). Arrows indicate hemodynamic and hormonal 
sampling timepoints. 
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5.2.5  Statistical Analysis 
All data are presented as mean + S.E.M. Analysis of changes in cardiac hormones and 
hemodynamics measured were performed on SPSS using a two-way ANOVA with 
repeated measures, with Bonferroni’s multiple comparison test, post hoc. Cumulative 
data comparisons were made using a paired student’s t-test. In all statistical tests a 
value of P<0.05 was considered significant. 
 
 
5.3.   Results 
 
5.3.1  RUII and URP reduce PP prior to and following ischemia 
Both rUII and URP significantly reduced PP during preconditioning by a maximum of 
8 % at 10 min (P<0.05, Figures 5.2A and 5.2B, respectively) compared with vehicle. 
During the first 15 min of reperfusion this vasodilation was retained in both rUII and 
URP preconditioned hearts with maximum reductions of 16 and 18% respectively 
compared with vehicle (P<0.05, Figures 5.2A and 5.2B), before returning to vehicle 
levels. 
 
5.3.2  Effect of UT receptor antagonism upon PP 
Infusion of 1 µM palosuran alone caused a significant increase in PP (mean=9.5 ±1.7 
%, P<0.05) during the 30 min preconditioning phase (Figures 5.2A and 5.2B). Co-
infusion of palosuran with 1nM rUII significantly attenuated rUII-induced reductions 
in PP during preconditioning (P<0.05, Figure 5.2A). Palosuran maintained this 
attenuation of rUII during early reperfusion, entirely blocking the rUII-induced 
reduction in PP (P<0.05). 
 
Palosuran also significantly inhibited URP-induced reductions in PP during 
preconditioning (P<0.05, Figure 5.2B).  Post-ischemia, palosuran had no influence on 
URP actions upon PP.  
 
 
 
 
 63
5.3.3 The effect of rUII, URP and palosuran on left ventricular (LV) 
contractility following ischemia 
 
Compared with control, preconditioning with rUII tended to reduce DP (P=0.053, 
Figure 5.3A), both + and –dP/dt and left ventricle (LV) systolic pressure. This trend 
remained during reperfusion.  
 
Preconditioning with 1 µM palosuran alone induced a reduction in DP by 5 ±1.8 % 
(P<0.05, Figure 5.3A) and also reduced both + and –dP/dt (P=0.004 and 0.017 
respectively, Figures 5.3C and 5.3D) and LV systolic pressure, (P=0.002, Figure 
5.3E). Palosuran had no effect on LV end diastolic pressure throughout the study. 
During reperfusion, palosuran tended to increase DP above control (P=0.074), and it 
attenuated the rUII-induced reduction in DP (P=0.058, Figure 5.3A). The same 
response was repeated observing + and –dP/dt, where palosuran attenuated the rUII-
induced reduction (P=0.088 and 0.117 respectively, Figure 5.3C and 5.3D), however 
showed no attenuation of LV systolic pressure (P=0.17, Figure 5.3E). 
  
Preconditioning the heart with 10 nM URP had no significant effect on DP or ±dP/dt 
before or after ischemia when compared with control (Figure 5.3B). Co-infusion of 
palosuran with URP had no significant effect during preconditioning, however raised 
DP above control (P>0.05) during reperfusion. 
 
 
5.3.4  Myocardial CK and ANP release following ischemia 
Both rUII (Figure 5.4A) and URP (Figure 5.4B) significantly reduced perfusate CK 
levels during reperfusion, when compared with control vehicle (P=0.012, and 0.036 
respectively). Preconditioning the heart with 1 µM palosuran alone also significantly 
reduced CK release below that of control vehicle (P=0.013, Figure 5.4A). Co-infusion 
of 1 µM palosuran with 1 nM rUII (Figure 5.4A) or 10 nM URP (Figure 5.4B) did not 
significantly alter CK release compared with each respective peptide alone. 
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Figure 5.2. Changes in coronary perfusion pressure (PP) in response to (A) 1 nM rUII, and 
(B) 10 nM URP with and without the UT receptor antagonist palosuran during ischemia-
reperfusion. All data represented as mean +SEM % relative to time = -10 min prior to 
infusion of drug or vehicle. ANOVA revealed significant time points of difference 
between vehicle and rUII/URP, or vehicle and 1 µM palosuran (*P<0.05, # P<0.01). 
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Figure 5.3. Left ventricular developed pressure (DP) in hearts preconditioned with 1 nM 
rUII (A) and 10 nM URP (B), with and without 1 µM palosuran. Further analysis revealed 
significant changes in left ventricular ±dP/dt (C & D) and left ventricular maximum 
systolic pressure (E), (end diastolic pressure not shown as did not differ from control). All 
data represented as mean +SEM % relative to 10 min prior to infusion of drug or vehicle. 
One-way ANOVA revealed significant points of difference between vehicle and rUII, or 
vehicle and 1 µM palosuran (*P<0.05, # P<0.01).
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Figure 5.4. Myocardial creatine kinase (CK) release during reperfusion in isolated hearts 
preconditioned with (A) 1 nM rUII or (B) 10 nM URP, with or without the presence of 1 
µM palosuran. Perfusate samples were collected after passing through the heart at specific 
time points throughout the reperfusion period (line graph) and cumulative CK release was 
calculated (inset, bar graph). One-way ANOVA revealed significant points of difference 
between vehicle and rUII, or vehicle and 1 µM palosuran (*P<0.05, # P<0.01). 
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RUII preconditioning had no significant effect upon basal ANP release. 
Preconditioning hearts with 1 nM rUII significantly attenuated the sharp increase in 
ANP secretion observed in vehicle treated hearts upon reperfusion (P=0.025, Figure 
5.5A). Hearts preconditioned with palosuran alone also showed a reduction in ANP 
secretion during reperfusion (Figure 5.5A). In contrast, co-infusion of rUII with 
palosuran resulted in a marked increase in ANP release well above control levels 
following ischemia (P<0.05, Figure 5.5A).  
 
Infusion of 10 nM URP had no significant effect on ANP release (Figure 5.5B). As 
observed with rUII, co-infusion of 1 µM palosuran with 10 nM URP resulted in 
greatly increased ANP secretion above that of control vehicle, (P<0.05, Figure 5.5B). 
 
 
 
5.4   Discussion 
 
We provide here the first documentation that: 1) rUII and URP dilate cardiac coronary 
arteries both prior to and post-ischemia. 2) RUII weakly reduces left ventricular (LV) 
contractility post-ischemia but URP does not. 3) Both rUII and URP significantly 
reduce cardiac CK release upon reperfusion, whereas post-ischemia ANP release is 
attenuated in the isolated heart when preconditioned with rUII only. 4) Palosuran has 
a constrictor action in the coronary vasculature, consistent with its blockade of a 
vasodilatory ligand such as UII. 5) Palosuran exhibits differing actions on the vascular 
activity of UII and URP in the heart. 6) Hearts preconditioned with palosuran, rUII or 
URP alone had reduced CK and ANP release post-ischemia-reperfusion, whereas co-
infusion of palosuran with rUII or URP elevated CK and ANP release post-ischemia-
reperfusion. Taken together the findings suggest that when infused alone, palosuran is 
a partial agonist of the UT receptor.  
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Figure 5.5. Atrial Natriuretic Peptide (ANP) secretion in the isolated rat 
heart undergone ischemia-reperfusion preconditioned with (A) 1 nM rUII or 
(B) 10 nM URP with or without the presence of 1 µM palosuran. Data are 
shown as mean +SEM % relative to 0 min infusion. One-way ANOVA 
analysis revealed significant points of difference between vehicle and 1 nM 
rUII or 10 nM URP, vehicle and 1 µM palosuran, or vehicle and palosuran + 
rUII/URP (*P<0.05, # P=0.01). 
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Circulating UII concentrations have been reported to range between 0.6 pmol/L to 29 
nM/L (Totsune et al. 2001; Dschietzig et al. 2002; Heller et al. 2002; Richards et al. 
2002; Gruson et al. 2005; Zoccali et al. 2006; Dai et al. 2007) and are elevated above 
normal levels in patients with coronary artery disease (Lapp et al. 2004; Hassan et al. 
2005), atherosclerotic lesions of human aorta (Bousette et al. 2004), ischemic heart 
failure (Heringlake et al. 2004), hypertension (Suguro et al. 2007) and congestive 
heart failure (Richards et al. 2002). Thus, the concentration of rUII infused in the 
current study is within the physiological range. No study has yet measured the 
circulating concentration of URP in humans. However, the pEC50 of hUII and URP in 
isolated cells have been shown to be equivalent in binding affinity (pEC50 8.55 and 
8.68 respectively) while URP showed reduced potency in constricting rat aortic rings 
(pEC50 of 8.11 for hUII and 7.75 for URP) (Chatenet et al. 2004).  
 
To our knowledge, this is the first comparative study observing the species specific 
effects of rUII and URP in a model of global ischemia-reperfusion. A single report 
studying the effect of human UII in the ischemic rat heart (Zhou et al. 2003) reported 
UII-induced reductions in coronary flow and contractile function, alongside increased 
lactate dehydrogenase release during reperfusion. In contrast, we utilized the species 
specific form of UII (rat), and consistent with our previous work (Prosser et al. 2006) 
documented vasodilatory and potential cardio-protective effects upon recovery from 
ischemia. The assumed effect of UII has been vasoconstriction with reports showing 
UII constricts multiple artery types in vitro (Douglas et al. 2000) a trend that 
continues in in vivo animal models of heart failure (Ames et al. 1999; Bousette et al. 
2006a; Bousette et al. 2006b). We have previously shown UII and URP to be potent 
vasodilators of coronary arteries when the species-specific form of UII is used 
(Prosser et al. 2006). In the present study, rUII and URP significantly reduced PP 
prior to ischemia, and we have now extended those findings to show that 
preconditioning the heart with rUII and URP for 30 minutes prior to ischemia results 
in continued vasodilation during the early stages of subsequent reperfusion.  
 
UII has been reported as both a negative and positive inotrope (Ames et al. 1999; 
Hassan et al. 2003; Gong et al. 2004; Russell and Molenaar 2004), or to have no 
effect (Li et al. 2004). In our hands, infusion of rUII caused a minor reduction in DP 
during the pre-conditioning phase and further maintained DP below control levels 
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during the initial 5-30 min of reperfusion. RUII weakly reduced +dP/dt and –dP/dt 
and left ventricular maximum systolic pressure, with no effect on LV end diastolic 
pressure. The observed reductions in ±dP/dt are consistent with other in vivo reports 
observing the effect of UII on contractility in the monkey (Ames et al. 1999) and rat 
(Hassan et al. 2003). In contrast, URP had no influence on DP or ±dP/dt, nor did these 
parameters significantly differ from control during the reperfusion phase following 
ischemia. This points to differential contractile activities of UII and URP upon the 
heart. Interestingly, in our hands rUII activity appears to mimic beta-blocker effects 
including dilation of the coronary arteries and negative inotropism. Reports observing 
the dependence of UII on β-adrenoreceptors for bioactivity have been performed, but 
results vary depending upon the method of administration (intravenous or 
intracerebroventricular) (Watson et al. 2003; Hood et al. 2005). In keeping with our 
previous work (Prosser et al. 2006), we suggest N- or C-terminus differences in 
sequence are responsible for the observed contrasting effects of rUII and URP on LV 
contractility. This minor, although significant reduction in LV contractility in 
response to rUII was not observed in our previous study (Prosser et al 2006, Chapter 
3) where rUII and URP were found to have no significant effect on LV contractility. 
However, analysis of the earlier study reveals a trend for rUII and URP to reduce LV 
contractility, although not significantly differing from vehicle levels (Appendix C, 
Figure C.1). The reason for this discrepancy is suggested to be due to the inconsistent 
effects produced by UII (as mentioned above), and the reduced variability of the latter 
study resulting in statictically significant results, despite the changes being very 
minor. 
 
We measured perfusate CK release from the heart as an index of myocardial damage. 
We found rUII and URP both significantly reduced CK release, with rUII possibly 
being more potent. This suggests rUII and URP possess similar cardio-protective 
qualities, reducing myocardial damage following ischemia.  
 
Differences between the two peptides were revealed when the UT receptor was 
blocked with palosuran. Hearts infused with palosuran alone had significantly 
increased PP prior to ischemia, consistent with blockade of a receptor that induces 
vasodilation. The elevation in PP suggests palosuran blocks endogenous UII/URP 
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produced by the heart. No reports have yet investigated direct cardiac production of 
UII/URP in the rat, however many reports have shown UII/URP is produced by the 
sheep (Charles et al. 2005) and human heart, with UII mRNA and cDNA expressed in 
many cell types of the human heart (Sugo et al. 2003; Liu et al. 1999; Douglas et al. 
2002; Totsune et al. 2004; Tzanidid et al. 2001). Furthermore, co-infusion of 
palosuran with either rUII or URP abolished reductions in PP induced by rUII and 
URP during the 30 min infusion period, and significantly inhibited rUII-induced 
reductions in PP during the initial reperfusion period. In contrast, palosuran had no 
influence on reductions in PP induced by URP. The reason(s) underlying the observed 
comparative and disparate hemodynamic effects in response to rUII and URP in the 
rat heart undergone ischemia-reperfusion may lie in the sequential differences 
between the two peptides. Both peptides retain the highly conserved 6 amino acid ring 
structure common to all known species of UII. However, rUII differs from URP 
having an extra 6 amino acids at the N-terminus, and the C-terminus of URP is 
Valine, while it is Isoleucine for rUII (Chatenet et al. 2004). The longer N-terminus of 
rUII may afford it greater time bound to the receptor and in doing so, enable 
activation of a greater number of intracellular pathways for an extended period of 
time. The antagonistic potency of palosuran against URP has not previously been 
tested, in fact, no UT receptor antagonist has yet been directly tested on URP activity, 
this report being the first study to do so. The effects caused by blockade of the UT-
receptor suggests a more complex system with potentially separate pathways being 
switched on or off in response to inhibition or activation of the UT receptor, and the 
possibility of more than one receptor capable of binding UII/URP or palosuran. 
 
Hearts preconditioned with rUII, URP or palosuran alone had reduced CK and ANP 
release, suggesting reduced myocardial damage and stress and enhanced recovery 
from ischemia. However, the ability of palosuran to also induce cardio-protection was 
surprising, given its ability to inhibit UII and URP induced vasodilation. The finding 
that palosuran alone acts weakly in a similar direction to UII/URP for some actions 
strongly suggests palosuran itself may be a partial agonist of the UT receptor. A 
similar finding has been reported for the UT receptor antagonist, SB-710411, where it 
potently antagonized UII-induced inositol phosphate formation at the rat UT receptor, 
however functioned as an agonist at the monkey UT receptor (Behm et al. 2004). This 
pattern of activity has been reported for other peptides such as the renin-angiotensin 
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system where the angiotensin-II receptor antagonist Saralasin caused partial agonistic 
activity, in a system now found to contain greater than one receptor (Case et al. 1976). 
 
Furthermore, when palosuran was co-infused with rUII or URP, CK and ANP 
secretion were elevated, suggesting blockade of the UT receptor combined with the 
elevated presence of rUII/URP results in greater myocardial damage and increased 
cardiac stress. These findings support the hypothesis that over-expression of UII in 
diseased cardiac tissue may cause further deleterious effects and inhibit recovery as 
seen in in vivo rat models of ischemia (Bousette et al. 2006a; Bousette et al. 2006b). 
However, our results serve to highlight the complicated nature of UII and URP 
signaling in the heart, and suggest that multiple receptors, of distinct types, may be 
present in the cardiac vascular beds. UT receptor sequence homology differs between 
species producing differential effects in response to the same species of UII 
administered (Douglas et al. 2000), while UII can produce vasoconstriction or 
vasodilation when activating receptors located in smooth muscle cells or endothelial 
cells respectively (Gendron et al. 2005). Many peptides involved in cardiac 
homeostasis, such as angiotensin II, endothelin and the family of natriuretic peptides 
ANP, BNP and CNP have multiple receptors. We therefore suggest UII/URP may 
activate greater than one receptor triggering multiple signaling pathways (analogous 
to RAMPS identified for adrenomedullin and CGRP peptides (Conner et al. 2004)) 
present in cardiac tissue.  
 
Taken together, our data demonstrates that rUII dilates the coronary arteries, induces 
mild negative inotropic effects and reduces post-ischemia CK and ANP release. In 
contrast, URP displayed dilation of the coronary arteries and reduced CK release with 
reduced potency compared to rUII, but had no other significant effects comparable 
with rUII. These effects were reduced by palosuran. This suggests these peptides have 
a cardioprotective role, minimizing damage to the myocardium by reducing energy 
requirements following ischemia. 
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6.  Urotensin II and urotensin II-related 
peptide (URP) in cardiac ischemia-
reperfusion injury 
 
 
Abstract 
 
Urotensin II (UII) expression is elevated in cardiovascular disease, both within tissue 
and the circulation. However, the pathological role of UII in mammalian 
cardiovascular disease is currently undefined. Studies have reported disparate 
responses to UII, suggesting inhibition of the UII receptor aids recovery from 
ischemia and attenuates maladaptive myocardial remodelling, while other studies 
have reported UII can stimulate cardioprotective effects, with elevated circulating UII 
levels correlated with an overall better outcome and reduced cardiac risk. The current 
report builds on a previous publication observing the effect of preconditioning hearts 
with UII or its paralog, urotensin II-Related peptide (URP), on recovery from 
ischemic injury. However, reports have identified that UII-induced vasodilative 
activity may be dependent upon the endothelial state. Herein, we explore the effect of 
administering rat UII and URP upon reperfusion in a Langendorff, isolated rat heart 
model of ischemia-reperfusion. This provided insight into whether the response to UII 
and URP is altered following endothelial and myocardial ischemic damage. UII and 
URP caused significant, sustained dilation of the coronary arteries during reperfusion 
(both P<0.001), and both peptides attenuated myocardial injury, indicated by a 
significant reduction in creatine kinase (CK) release (both P<0.005). UII and URP 
displayed no significant influence on left ventricular contractile parameters, and did 
not significantly alter atrial natriuretic peptide (ANP) secretion (both P>0.05). In sum, 
infusion of the native form of UII or URP upon reperfusion stimulated sustained 
vasodilation, and significantly attenuated ischemic injury. 
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6.1.   Introduction 
 
Prosser et al. recently reported that hearts infused with rat UII (rUII) or urotensin II-
related peptide (URP) for 30 min prior to global ischemia displayed significantly less 
myocardial damage and had greater coronary flow when compared to hearts infused 
with vehicle (Prosser et al. 2008). Their study effectively mimicked patients with 
chronically elevated plasma UII concentrations prior to experiencing myocardial 
ischemia, however a known characteristic of ischemia and cardiovascular disease is 
endothelial dysfunction (ED). Vascular hypoxia can cause ED, inducing the 
production of reactive oxygen species (ROS) and stimulating inflammatory agents 
causing significant damage to the endothelium, negatively altering its intracellular 
pathways (Schiffrin 2008a). ED is reported to uncouple the production of nitric oxide 
(NO), converting the process to produce ROS, and in so doing severely reducing the 
vasodilative potential, as well as promoting ROS-induced cellular damage (Lavi et al. 
2008; Schiffrin 2008a). UII has been repeatedly shown to stimulate NO (Katano et al. 
2000; Gray et al. 2001; Li et al. 2004; Prosser et al. 2006), dilating coronary arteries 
in the rat, while experimental removal of the endothelium or infusion of L-NAME 
caused a loss or reduction in UII-induced vasodilation respectively (Bottrill et al. 
2000; Russell et al. 2001; Stirrat et al. 2001).  
 
Here, we provide further research into the effect of rat UII (rUII) and URP on 
recovery from cardiac ischemia. The Langendorff isolated rat heart model was 
employed to observe the influence of rUII and URP on recovery from ischemia, when 
administered following ischemia. In theory, infusion of rUII or URP at the time of 
reperfusion provides a model to test whether the previously reported vasodilative and 
cardioprotective effects of rUII/URP in healthy hearts are conserved when 
administered immediately following ischemia, or whether their protective 
physiological effects are lost with ischemic injury sustained. 
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6.2.   Methods 
 
6.2.1  Materials  
All animals used in this study were male Sprague-Dawley rats (250-400 g, 60-75 days 
old) obtained from the Christchurch School of Medicine, Christchurch, New Zealand. 
Rats had free access to standard rat chow and water and were housed under controlled 
temperature (21ºC), humidity (~40%) and natural day length. 
 
Rat urotensin II (rUII) and URP were obtained from Phoenix Pharmaceuticals 
(Belmont, USA). Both peptides were diluted in distilled water, aliquoted and stored at 
-20ºC prior to use. 
 
6.2.2  Langendorff isolated heart preparation 
Refer Chapter 5.2.2 (page 59) of the current thesis. 
 
6.2.3   Ischemia-reperfusion protocol 
Once attached to the Langendorff apparatus hearts were allowed to stabilize for 30 
min before being paced at 330 bpm for a further 30 min. Following this period 
perfusion was stopped and hearts underwent 45 min of no-flow global ischemia with 
pacing halted. At reperfusion, hearts were infused continuously for 30 min (0.5 
ml/min) with either 1 nM rUII (n=5), 10 nM URP (n=5) or vehicle (n=10) with pacing 
recommenced. After the 30 min infusion hearts underwent a further 75 min perfused 
with buffer alone (Figure 6.1). 
 
10 20 30 75 90 120 180
Buffer only Ischemia Reperfusion buffer alone
Time (min)
0 105
Reperfusion 
   + Agent  
 
 
 
 
 
Figure 6.1. Ischemia-reperfusion protocol performed on isolated rat 
hearts. Arrows indicate times of data/samples taken.  
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6.2.4 Analysis and Measurement of Atrial Natriuretic Peptide (ANP) 
secretion and myocardial Creatine Kinase (CK) release  
Refer Chapter 5.2.4 (page 60) of the current thesis 
 
6.2.5  Statistical analysis  
Refer Chapter 5.2.5 (page 61) of the current thesis 
 
 
 
 
6.3   Results 
 
6.3.1   Effects of rUII and URP on PP and LV contractility following ischemia 
Infusion of both 1 nM rUII or 10 nM URP at reperfusion caused a potent and 
sustained reduction in PP of 24.43 ± 2.03 and 16.46 ± 1.46 % below vehicle levels 
throughout the reperfusion period respectively (both P<0.01, Figure 6.2).  
 
 
Left ventricular contractile parameters (DP, ±dP/dt, systolic and end diastolic 
pressures) were not significantly influenced by rUII or URP when infused upon 
reperfusion compared with control (Figures 6.3A-E). However, rUII and URP 
maintained systolic pressure slightly above vehicle levels throughout reperfusion 
(Figure 6.3D). 
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Figure 6.2. Infusion of 1 nM rUII or 10 nM URP significantly reduced perfusion 
pressure (PP) throughout the reperfusion period maintaining levels significantly 
below that of vehicle. Bar indicates reperfusion period and the infusion of agent; 
two-way ANOVA indicated significant differences between control and treatment 
groups **P<0.005. 
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Figure 6.3. Observing the effect 
of rUII and URP on left 
ventricular (LV) contractile 
parameters. 1 nM RUII or 10 nM 
URP infused upon reperfusion did 
not significantly alter: A) 
developed pressure (DP), B & C) 
±dP/dt, D) systolic pressure (SP), 
or E) end diastolic pressure 
(EDP). Bar indicates reperfusion 
and infusion of agent, (all P>0.05 
vs vehicle). 
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6.3.2  Myocardial CK and ANP release during post-conditioning reperfusion 
Both rUII and URP reduced perfusate CK levels significantly below that of vehicle 
during reperfusion (both P<0.05, Figure 6.4) indicating a significant reduction in 
myocardial damage. 
 
Post-ischaemia, ANP concentrations increased in the perfusate of all three treatments, 
by a comparable amount. There is a suggestion that rUII might have stimulated a 
prolonged secretion of ANP in the following period of perfusion with buffer alone, 
but the variability in ANP titres, coupled with the relatively small sample size 
precludes any firm conclusions (Figure 6.5). 
 
 
 
 
Figure 6.4. Creatine kinase (CK) release was measured from the 
perfusate at specific time points throughout reperfusion. Analysing 
cumulative CK release displays hearts infused with 1 nM rUII or 10 nM 
URP released significantly less CK compared to vehicle, indicating 
reduced myocardial damage. Bar indicates infusion/reperfusion period, 
**P<0.005 using student’s t-test. 
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6.4   Discussion 
 
UII levels are known to be elevated in patients with cardiac or renal diseases 
(Matsushita et al. 2001; Ng et al. 2002; Richards et al. 2002; Russell et al. 2003; Lapp 
et al. 2004; Gruson et al. 2005), however it is unclear whether the elevation in UII 
expression progresses or alleviates disease. Many studies have now reported on the 
role of UII in cardiac disease, with some indicating UII augments pathogenesis 
(Watanabe et al. 2001a; Bousette et al. 2006a; Bousette et al. 2006b), while other 
reports suggest UII possesses cardioprotective properties (Mallamaci et al. 2006; 
Harris et al. 2007; Prosser et al. 2008); thus the true role of UII and URP in 
cardiovascular disease remains to be determined.  
 
Figure 6.5. Atrial Natriuretic peptide (ANP) secretion during reperfusion in 
hearts treated with vehicle, 1 nM rUII or 10 nM URP. Data is displayed as % 
of ANP levels 10 minutes prior to ischemia. Neither rUII nor URP 
significantly differed from vehicle levels (P>0.05). 
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In our previous paper we reported that infusion of rUII and URP immediately prior to 
global ischemia significantly reduced cardiac injury during reperfusion through 
reducing PP, inhibiting CK release and rUII reduced LV ±dP/dt and systolic pressure 
(Prosser et al. 2008). It was concluded that hearts preconditioned with rUII and URP 
displayed cardioprotective properties, aiding recovery from ischemia through 
increased coronary flow allowing greater oxygen supply to the myocardium, reducing 
myocardial damage, and rUII-induced negative inotropy, together alleviating cardiac 
energy requirements and aiding recovery (Prosser et al. 2008). This finding was 
supported by several reports  indicating patients with elevated UII levels correlated 
with a better outcome following a cardiac event compared to those exhibiting lower 
UII expression (Khan et al. 2006; Mallamaci et al. 2006; Ravani et al. 2008). The 
cardioprotective, vasodilative actions of UII/URP have been shown to be mediated by 
NO and prostaglandins released from endothelial cells (Katano et al. 2000; MacLean 
et al. 2000; Gray et al. 2001; Gardiner et al. 2004; Ishihata et al. 2005a; b). Both NO 
and cyclooxygenase, the enzyme responsible for prostaglandin production, have been 
reported to reduce mitochondrial oxygen consumption and provide cardioprotection 
during early reperfusion in the isolated rat heart (Bolli et al. 2002; Dawn and Bolli 
2002). However, it is well documented that during cardiovascular disease where 
vascular shear stress or ischemia occurs, such as in hypertension, CHF, CAD, 
atherosclerosis and myocardial infarction the endothelium becomes damaged and 
dysfunctional. ED causes increased endothelial permeability, due to loss of cellular 
membrane integrity, as well as significant detrimental alterations in endothelial 
intracellular functioning (Schiffrin 2008a). This is most evident when observing 
endothelial production of nitric oxide (NO). In diseased endothelial cells, the 
intracellular pathway to produce NO becomes uncoupled and results in the production 
of reactive oxygen species (ROS) (Otani 2009). Ironically, ROS activity directly 
opposes that of NO, quenching NO availability and thus inhibiting vessel dilative 
potential, as well as stimulating vasoconstriction, cellular proliferation and further 
cellular damage, which if unregulated, can progress to the development of 
atherosclerosis (Bauersachs and Fraccarollo 2008; Lavi et al. 2008). Because UII-
induced vasodilation is known to be mediated by NO and stimulation of COX 
activity, it could be hypothesized that the response to rUII or URP may beome altered 
in the diseased state. This phenomenom has been observed in human skin in vivo 
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where UII caused dilation of the microvasculature in healthy subjects, but elicited 
vasoconstriction when infused into CHF patients (Lim et al. 2004).   
 
We found infusion of rUII and URP following ischemia caused potent dilation of the 
coronary arteries, maintaining PP significantly below vehicle levels throughout 
reperfusion, including 75 minutes after the infusion of rUII or URP had been halted. 
Both rUII and URP had no significant effect on DP or ±dP/dT but significantly 
reduced CK release during reperfusion. These results indicate rUII and URP 
attenuated myocardial injury and increased coronary arterial flow when infused 
following ischemia. These results are consistent with our previous report revealing the 
vasodilative, cardioprotective effects of rUII and URP are conserved when infused 
either prior to, or following ischemia (Prosser et al. 2008).   
 
The main discrepancy observed between pre- and post-ischemic infusion of rUII/URP 
in the isolated rat heart was that pre-ischemic infusion caused a reduction in ANP 
levels (Prosser et al. 2008), while post-ischemic infusion had no effect. This contrast 
may indicate one example where the response to rUII/URP was influenced by healthy 
versus damaged cells. Infusing rUII upon reperfusion caused a slight, although non-
signficant, elevation in ANP secretion, potentially revealing an association between 
UII and ANP at the myocardium. UII has been previously shown to stimulate ANP 
and BNP genes in cardiac myocytes (Zou et al. 2001). This may afford additional 
cardioprotection as ANP can stimulate vasodilation and possesses antihypertrophic, 
antifibrotic characteristics (Nishikimi et al. 2006).  
 
Furthermore, DP, ±dP/dT, systolic and end diastolic pressures were not found to 
significantly differ from vehicle levels, although rUII and URP visibly elevated 
systolic pressure above vehicle levels throughout reperfusion. This may indicate 
rUII/URP stimulated a minor increase in LV contractility, potentially explaining the 
slight elevation in ANP secretion. Infusing rUII into a healthy heart preparation prior 
to ischemia caused a significant negative inotropic effect, and this was continued 
following ischemia, although not significantly below vehicle levels (Prosser et al. 
2008). Infusion of rUII post-ischemia had no significant influence on DP, ±dP/dT, 
systolic or ED pressures, but saw a minor, non-significant increase in systolic 
pressure. This suggests that UII-induced cardiac contractility may be dependent upon 
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the functional state of the cell. 
 
1 nM rUII was visibly more potent compared with 10 nM URP in lowering PP, 
despite the 10 fold difference in concentration. Both peptides retain the highly 
conserved 6 amino acid ring structure, however rUII possesses an extended N-
terminus and different C-terminus compared to URP. This sequential difference may 
be responsible for the difference in potency observed, perhaps affording rUII greater 
receptor binding time providing extended activation, and/or resisting proteolysis. 
Receptor-activity and binding studies found URP to have slightly higher binding 
affinity for the native receptor GPR14 but exhibiting lower potency when compared 
with hUII (Chatenet et al. 2004), supporting the current findings. 
 
In summary, the sustained reduction in PP in response to rUII or URP following 
ischemia was comparable to that of infusing either peptide prior to ischemia (Prosser 
et al. 2008). However, rUII-induced negative inotropy was lost when infused post-
ischemia. This indicates that administering UII/URP immediately following the 
cardiac event was effective in dilating the coronary vasculature and reducing cardiac 
damage, alleviating injury and aiding cardiac recovery, whilst not influencing left 
ventricular contractility. Subjecting the heart to no-flow global ischemia for 45 min 
with zero oxygen supply to the vasculature was assumed to cause substantial vascular 
and myocardial damage as illustrated by the significant rise in CK release and PP 
levels exhibited during reperfusion in control hearts. Our results illustrate that rUII 
and URP protect the cardiovasculature in spite of the vascular damage sustained 
through stimulating vasodilation and attenuating myocardial damage. Therefore, we 
advocate UII and URP as potential therapeutic agents providing cardioprotection 
through both preconditioning the heart prior to a cardiac event, as well as attenuating 
injury sustained. Although rUII and URP were observed to aid recovery from 
ischemia, the preventative qualities of UII or URP are yet to be reported.  
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7.  The Renin-Angiotensin-System (RAS) 
 
 
Abstract 
 
The arterial and venous system is under constant regulatory control, influenced by the 
production and secretion of constrictive and dilative agents balancing vessel tone, 
which, in turn, maintains flow and influences blood pressure. Angiotensin II is the 
main potent, effector product of the renin-angiotensin system (RAS), responsible for 
elevating blood pressure when it falls below homeostatic levels through activating 
humoral and mechanical mechanisms. The generation of AngII is seemingly linear, 
with the primary enzyme renin produced and released from the kidneys in response to 
a drop pressure cleaving circulating angiotensinogen. To form angiotensin I (AngI). 
Ang I is then cleaved to angiotensin II (AngII) by the carboxypeptidases angiotensin-
converting enzyme 1 (ACE1) and chymase (and other less potent enzymes). 
Overstimulation of the RAS is well known to develop and promote cardiovascular 
disease, producing hypertension and progressing atherosclerosis, with many human 
trials reporting the significant benefits of inhibiting RAS activity and attenuating 
AngII-induced effects, specifically with regard to cardiovascular disease. Recently, a 
peptide sharing high sequence homology with angiotensin I (AngI) was identified. 
Proangiotensin-12 (PA12) was identified and isolated from rat small intestine, and 
was suggested to be a new component of the RAS. Preliminary studies suggest PA12 
may directly stimulate vascular constriction and have other physiological effects 
within the heart. Little is currently established concerning the physiological effects of 
PA12, its mechanisms of function, or the receptors and enzymes potentially mediating 
its activity. The current review provides a general introduction to the RAS, observing 
the peptides and enzymes responsible for regulating its activity, as well as introducing 
PA12 as a novel RAS peptide, and reviewing the pathological effects of the RAS.
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7.1   Introduction to the RAS 
 
Maintenance of blood pressure at the homeostatic level to provide sufficient perfusion 
to all tissue throughout the body, whilst not exerting unnecessary work on the heart, is 
regulated by both mechanical and humoral mechanisms. One key system controlling 
these mechanisms is the renin-angiotensin system (RAS), which elevates blood 
pressure via: stimulating arteriolar vasoconstriction, increasing sympathetic activity, 
secreting aldosterone from the adrenal gland, increasing tubular reabsorption of Na+ 
and Cl- while excreting K+ to increase water retention, stimulating the release of 
antidiuretic hormone (ADH) from the pituitary, and reducing glomular filtration rate 
(Robertson and Nicholls 1993). The RAS is also involved in the central nervous 
system where it can stimulate thirst (Serova et al. 2004). The RAS is initially 
stimulated at the kidneys where juxtaglomerular cells produce renin in response to a 
drop in pressure. Renin is the initial enzyme responsible for triggering the hormonal 
cascade converting hepatically secreted angiotensinogen to the effector peptide, AngII 
(Figure 7.1). Angiotensinogen (Ang) circulates as a 452 amino acid precursor 
molecule, which is cleaved by renin to form angiotensin I (AngI), comprising 10 
amino acids of Ang’s N-terminal end. Secondary enzymes are then responsible for 
converting AngI into biologically active AngII including angiotensin converting 
enzyme 1 (ACE1), chymase, and other less common carboxypeptidases. AngII 
circulates throughout the body causing potent pressor effects listed above. Once 
homeostatic blood pressure at the kidney is restored, the juxtaglomerular cells halt the 
secretion of renin preventing further stimulation of the RAS, providing a negative 
feedback system.  
Further enzyme activity can produce shorter AngII-derived peptides including Ang1-
7, AngIII (Ang 2-8) and AngIV (3-8). AngIII and AngIV elicit a similar, although 
weakened response compared with AngII, whereas Ang1-7 has been suggested to 
stimulate vasodilation and inhibit cardiac remodelling, opposing the effects of AngII 
and potentially providing some regulatory control of the RAS (Dias-Peixoto et al. 
2008; Mercure et al. 2008). More recently, a peptide has been identified in the rat with 
the same amino acid sequence as AngI plus an additional -Leu11-Tyr12 at its C-
terminus, comprising a 12 amino acid peptide dubbed proangiotensin-12 (PA12) 
(Figure 7.2) (Nagata et al. 2006). Currently, PA12 has only been isolated from the rat 
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and it is yet to be determined whether PA12 is also present in other mammals, 
including humans, or what role it has within the RAS.  
 
 
 
g 
 
 
 
 
 
 
 
 
 
Figure 7.1. Schematic diagram of the Renin-Angiotensin System (RAS) displaying 
the generation of the effector peptide, Angiotensin II, and its wide range of 
hypertensive effects throughout the body. Figure from Rad A. 2006 
Figure 7.2. Amino acid sequence of proAngiotensin-12 (PA12) 
compared with Angiotensin II (Ang II) and Angiotensin I (Ang I). 
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7.2.   Angiotensin II-generating enzymes 
 
7.2.1   Angiotensin-converting enzyme I (ACE1) 
ACE1 is a carboxypeptidase with 2 catalytic domains enabling the cleavage of 2 
amino acids from the C-terminus of AngI to produce AngII. ACE1 not only cleaves 
off the C-terminus of AngI to produce AngII, but it also inactivates bradykinin via 
cleavage of similarly placed residues contained within bradykinin’s C-terminus. The 
physiological result is that ACE1 effectively augments the pressor effect via 
activation of the vasoconstrictor AngII, combined with simultaneous inactivation of 
the vasodilator bradykinin (Robertson and Nicholls 1993).  
 
ACE1 is currently believed to be the primary enzyme in converting AngI to AngII and 
is bound to the plasma membrane of endothelial cells present throughout many tissue 
beds, including arteries and veins. The kidneys and lungs express the greatest levels 
of ACE1 and ACE1 mRNA (Uchide et al. 2006), indicating the greatest production at 
these sights, however ACE1 is also known to be present in the brain (Whiting et al. 
1991), reproductive organs (Strittmatter et al. 1985; Vivet et al. 1987) and 
cardiovasculature (Danser and Schalekamp 1996; Borland et al. 2005).  
 
The function of ACE1 makes it an ideal target for treating hypertension and 
chronically elevated high blood pressure due to overactivation of the RAS. The use of 
ACE1 inhibitors for treating hypertension is touched on below in section 7.3 (page 
92). 
 
7.2.2   Angiotensin-converting enzyme II (ACE2) 
Recently, a second angiotensin-converting enzyme has been identified in the RAS, 
angiotensin-converting enzyme 2 (ACE2). ACE2 is an 805 amino acid protein 
exhibiting 60% homology with ACE1 with its gene located on the sex chromosome X 
as opposed to the ACE1 gene, located on chromosome 17 (Hubert et al. 1991; Palmer 
et al. 2008). Like ACE1, ACE2 is an endothelium-bound carboxypeptidase, but 
differs in that it only possesses one cleavage site, and is thus capable of cleaving only 
1 amino acid from its target peptide (Oudit et al. 2003). Furthermore, compared to the 
wide tissue distribution of ACE1, ACE2 is expressed primarily within the 
endothelium and VSMCs of arteries, arterioles and venules of the heart and kidney 
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(Donoghue et al. 2000), consistent with its suggested proteolytic role in cleaving 
vasoactive, pressure-regulating peptides. 
 
ACE2 has been shown to cleave AngI into inactive Ang1-9 (Dales et al. 2002), which 
can then be cleaved by ACE1 into Ang1-7 (Donoghue et al. 2000). ACE2 can also 
directly convert AngII into Ang1-7 (Vickers et al. 2002). The generation of Ang1-7 
suggests ACE2 may mediate vasodilation, directly opposing the effects of ACE1 
providing a check on AngII activity. Interestingly, ACE2 mRNA levels are shown to 
be significantly reduced in hypertensive rats compared with normotensive animals 
(Crackower et al. 2002), and ACE2 expression is not elevated in the failing human 
myocardium (Donoghue et al. 2000), together suggesting ACE2 production may be 
independent of blood pressure. In ACE2 knock-out mice, circulating AngII levels 
were double that of normal mice and the animals exhibited reductions in cardiac 
contractility, and reduced ±dP/dt compared with wild types (Crackower et al. 2002). 
Further studies have reported ACE2 stimulates cardioprotective effects by producing 
Ang1-7 and attenuating AngII-induced endothelial ROS production, attenuating the 
development of atherosclerosis, aiding endothelial-dependent vasorelaxation, and 
protecting the heart from ischemia-induced pathophysiology (Der Sarkissian et al. 
2008; Katovich et al. 2008; Lovren et al. 2008). However, one study reported 
overexpression of ACE2 reduced systolic blood pressure in SHRs, but also lead to 
severe cardiac fibrosis in the same animals (Masson et al. 2009).  
 
In summary, ACE2 presents an important enzyme within the RAS providing a 
counterbalance to ACE1, negatively modulating AngII activity, providing 
cardioprotection during ischemia, and maintaining endothelial homeostasis. The 
removal of the ACE2 gene severely diminishes heart function. Therefore, 
manipulation of ACE2 enzymatic activity to promote its beneficial effects provides 
another potential avenue of therapy for those requiring the downregulation of RAS-
generated AngII.  
 
7.2.3   Chymase 
Boucher et al. were the first to suggest enzymes other than ACE may be capable of 
forming AngII from its precursor (Boucher et al. 1974). Since their report other 
proteases (angiotensinases) have been identified that can cleave angiotensinogen into 
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AngI and AngII (Akasu et al. 1998) including chymase and other les abundant 
carboxypeptidases. Many studies observing AngII formation both in vivo and in vitro 
have reported ACE1 inhibitors failed to completely block AngII production in the rat, 
hamster, dog, baboon and human (Gondo et al. 1989; Hoit et al. 1995; Shiota et al. 
1997; Guo et al. 2001; Borland et al. 2005), while in human left ventricle tissue one 
report suggested ACE1 is responsible for only 10-20% of AngII formation (Urata et 
al. 1990a; Urata et al. 1990b). Whilst carboxypeptidases have been shown to form 
AngII from AngI (Robertson and Nicholls 1993), proteases contained in cytoplasmic 
granules of mast cells have also been shown to have significant proteolytic effects on 
angiotensin peptides. These proteases belong to either the chymase or tryptase family 
and are suggested to be responsible for converting remaining AngI to AngII or 
biologically inactive peptides. Okunishi et al. (1984) reported that chymostatin (a 
chymase inhibitor) combined with an ACE inhibitor completely abolished AngII 
formation in the spontaneously hypertensive rat and thus the tissue must contain 
chymostatin-sensitive AngII generating enzymes dubbed CAGE (Okunishi et al. 
1984). Later, CAGE was identified as a vascular chymase (Takai et al. 1997b) and 
was distinguished from other proteases due to its complete inhibition by chymostatin 
and its high specificity for AngI (Urata et al. 1990b; Akasu et al. 1998). Using a 
specific chymase antibody, human chymase was shown to be present in the 
interstitium, aorta and coronary arteries of the heart, and synthesized and stored 
within the granules of mast cells, mesenchymal cells and endothelial cells (Urata et al. 
1993; Guo et al. 2001). 
 
 Interestingly, ACE1 expression in the human heart is greatest in the atrium, while 
chymase expression is greatest within the ventricles, suggesting AngII-generating 
pathways may vary between chambers (Urata et al. 1993), potentially providing a 
further level of regulatory control within the heart itself. Human chymase expression 
has also been located in tissues outside of the heart including the lung, liver, kidney 
and skin (Urata et al. 1994). Chymase has been shown to be a potent enzyme with 
high efficacy in converting AngI to AngII, as well as catalysing the degradation of 
AngII in mammalian hearts. However, chymase is highly species-specific displaying 
differential effects between species (Kunori et al. 2005). In studies to date, human, 
hamster, dog and baboon chymases show high catalytic efficacy of cleaving AngI at 
Phe8 to produce AngII with little or no further cleavage of the AngII peptide in both 
 90
isolated vessels or within the human heart (Wintroub et al. 1984; Urata et al. 1990b; 
Okunishi et al. 1993; Hoit et al. 1995; Takai et al. 1996; Balcells et al. 1997; Sanker et 
al. 1997; Takai et al. 1998; Caughey et al. 2000). In contrast, rat chymase is shown to 
primarily degrade AngI into Ang1-4 and Ang5-10, both biologically inactive 
fragments, through cleavage at the Tyr4-Ile5 bond (Wintroub et al. 1984; Sanker et al. 
1997; Takai et al. 2001). Although, rat chymase does display the ability to convert 
AngI to AngII but at 20-fold less efficacy compared to the cleavage at Tyr4 (Okunishi 
et al. 1984; Wintroub et al. 1984; Sanker et al. 1997). Based on their structure and 
specificity in converting AngI, the chymase isoforms from different mammalian 
species have been classified into two groups – α and β (Chandrasekharan et al. 1996). 
Human, monkey, hamster and dog chymases all convert AngI to AngII with little or 
no further degradation and are classified as α-chymases, while β-chymases comprise 
rat mast cell protease I and II (RMCP I and II), gerbil and mouse chymase, all of 
which cleave AngII at Tyr4 with little or no AngII production (Chandrasekharan et al. 
1996). The reasons for the difference in activity is suggested to be due to subtle 
differences in binding sites at the C-terminus of AngI between species where the 
amino acid sequence differs (Yamamoto et al. 1998).  
 
With regards to the rat, it was originally believed that two isoforms of rat mast cell 
chymases exist, RMCP I and RMCP II, both shown to be biologically active serine 
proteases (Karlson et al. 2002; Kishi et al. 2006). However, Guo et al. explored the 
presence of chymase in rat vascular smooth muscle cells (VSMC) and identified and 
cloned a new third rat chymase dubbed rat vascular chymase (RVCH) (Guo et al. 
2001). The same group showed that the cDNA of RVCH exhibits 74% and 79% 
sequence homology with RMCP I and II respectively, and 56% compared to human 
heart chymase (Guo et al. 2001). Structurally, RVCH is most similar to RMCP (I and 
II) which would suggest it is a β-chymase, however its effect on AngI differs 
markedly. Purified RVCH only cleaves AngI at Phe8 to produce AngII with no 
cleavage at Tyr4 and thus exhibits α-chymase activity (Guo et al. 2001). RVCH also 
shows increased expression in isolated aortic smooth muscle cells from spontaneously 
hypertensive rats, compared with normotensive rats, suggesting a potential 
pathological role for RVCH as is suggested with chymases from other mammals 
(Urata 2000; Guo et al. 2001). It must be noted that all experiments observing the role 
of RVCH were performed in vitro on cells isolated from the rat aorta and pulmonary 
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artery and the actions of RVCH have not yet been tested in vivo where, like other 
mammalian chymases, it may have reduced or altered effects. However, the 
underlying difference between the RMCPs and RVCH is that the latter clearly forms 
AngII with no further peptide degradation, indicating the rat also contains chymase-
induced AngII-generation.  
 
Caution must be given when studying the potency of chymase in in vitro settings due 
to the localisation of chymase within mast cells. Experiments documenting chymase 
activity in human blood vessels and tissue homogenates have shown it to be 
responsible for up to 90% of AngII production from AngI (Urata et al. 1990b; 
Borland et al. 1998; Maassen Van Den Brink et al. 1999). However, in vivo and ex 
vivo studies report chymase to have reduced efficacy, with ACE1 primarily 
responsible for generating AngII (Shiota et al. 1993; de Lannoy et al. 2001; Kirimura 
et al. 2005). The differences between these studies may be due to their cellular states, 
in which in vitro studies using homogenised tissue releases maximal amounts of 
chymase stored within the mast cells, and provides an optimal pH for chymase 
activity, stimulating maximal AngII formation. In vivo, chymase is retained within the 
mast cells with its release dependent upon mast cell degranulation, usually the result 
of stress or disease stimulating oxidative agents and cytokine activity such as protein 
kinase C (Singh et al. 1999; Peng and Beaven 2005; Palaniyandi et al. 2008). Because 
of this, chymase-dependent AngII formation may be more localised to specific tissues 
undergoing stress or damage, as opposed to ACE1-induced AngII production 
occurring throughout the circulation on the vessel walls. This further harmonises with 
the differential localisation of chymase and ACE1, primarily confined to the 
interstitial tissue and circulation respectively (Miyazaki and Takai 2006).  
 
In some local events of cardiovascular damage, such as coronary bypass grafts of the 
saphenous vein (Nishimoto et al. 2001), percutaneous coronary intervention 
(Miyazaki et al. 1999) and angioplasty (MERCATOR 1992), chymase-induced AngII 
generation is elevated above that of ACE1-induced AngII generation. Increased mas 
cell and chymase expression, including chymase mRNA has been reported in 
atherosclerosis (Kaartinen et al. 1994; Takai et al. 1997a), coronary bypass grafts 
(Nishimoto et al. 2001), neointimal hyperplasia (Jin et al. 2005), abdominal aortic 
aneurysm (Nishimoto et al. 2002; Tsunemi et al. 2002), myocardial infarction (Jin et 
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al. 2001), and cardiac fibrosis (Takai et al. 2003). In all of these studies inhibition of 
chymase reduced further damage and aided recovery, strongly suggesting chymase to 
possess a pathogenic function. RVCH has also been shown to stimulate hypertension 
in rats (Guo et al. 2001) and hypertensive arteriopathy in chymase-overexpressing 
mice (Ju et al. 2001). Inhibition of chymase activity prevented cardiac fibrosis and 
dysfunction in rats following myocardial infarction and lowered collagen mRNA 
levels (Kanemitsu et al. 2005), a finding repeated in dogs with tachycardia-induce 
heart failure (Matsumoto et al. 2003) indicating the therapeutic benefits of 
suppressing chymase activity in cardiac disease. Thus, chymase inhibition represents 
a novel target for therapeutic attenuation alongside or combined with ACE1 and/or 
ARB inhibitors. Mast cell degranulation can also be inhibited through antagonising 
εPKC, reducing the release of chymase and other pro-inflammatory, pro-hypertopic, 
profibrotic and vasoactive agents, significantly attenuating pathological cardiac 
remodelling and aiding myocardial function in a rat model of hypertension-induced 
heart failure (Palaniyandi et al. 2008). AngII is known to activate intracellular PKC 
(Mehta and Griendling 2007), suggesting a potential feed-forward mechanism 
stimulating further mast cell degranulation and the release of these proinflammatory, 
pro-hypertrophic, and profibrotic mediators, including chymase stimulating further 
AngII production, exacerbating pathological cardiac remodelling (Palaniyandi et al. 
2008). However, the fact that some forms of chymase also cleave AngI into inactive 
fragments suggests a regulatory mechanism in reducing AngII generation.  
 
7.2.4   Summary of angiotensin II-generating enzymes 
Taken together, it appears ACE1 is primarily responsible for AngII-formation within 
the circulation and vessel walls, whilst chymase potently forms AngII in localised 
tissue dependent on local conditions. The identification of a new rat chymase, RVCH, 
provides a novel endogenous AngII-forming enzyme in this species, independent of 
ACE activity, extending our knowledge of the RAS and providing evidence that the 
RAS is not a simple linear system as originally thought. Several reports have now 
shown chymase expression to be elevated in many cardiac diseases and injury, with 
inhibition of chymase activity significantly reducing AngII production and AngII-
mediated pathogenic effects, attenuating hypertension and profibrotic activity 
including collagen synthesis. Inhibition of chymase may therefore be an additional 
supplement for the treatment of hypertension and alleviation of heart failure.  
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7.3   The RAS and Cardiovascular Disease 
 
It is now well established that the RAS plays an integral role in mediating and 
augmenting cardiovascular disease and dysfunction. Not only does the RAS cause 
global arteriolar constriction but it also has profound direct effects on cardiac tissue 
progressing cardiovascular disease, developing hypertension and promoting 
atherosclerosis and CAD. Overstimulation of the RAS results in chronically elevated 
levels of AngII, causing hypertension, which promotes endothelial dysfunction, 
oxidative cellular stress, progressing atherosclerosis and CAD. AngII also directly 
stimulates cardiac hypertrophy and fibrosis through altering collagen levels and 
influencing fibroblasts within the myocardial interstitium (Brilla et al. 1993; Cai and 
Harrison 2000; Higashi et al. 2002; Nickenig and Harrison 2002; Sowers 2002). 
These effects are mediated through the angiotensin II Type 1 receptor (AT1R), 
displayed in Figure 7.3. 
 
 
Figure 7.3 The pathogenic effects of AngII in the cardiovascular system. AngII 
stimulates many pathogenic effects in several different cell types, all converging to 
induce and progress vascular disease and ultimately lead to severe cardiovascular 
diseases. Figure from Mehta and Griendling 2007 
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AngII-induced stimulation of ROS, mediated by vascular NADPH oxidase 
(Griendling et al. 1994), activates pro-inflammatory cytokines including NFκB, 
promoting the development of atherosclerosis (Ferrario 2006). The RAS has also been 
reported to cross-talk with oxidised low-density lipoprotein (ox-LDL) in coronary 
artery disease resulting in synergistic elevations in oxidative stress, foam cell 
formation and the inflammatory cascade (Chen and Mehta 2006), all augmenting 
atherosclerosis.  
 
AngII phosphorylates many intracellular proteins (Figure 7.4), activating pathogenic 
pathways stimulating vasoconstriction, cellular growth and differentiation, 
hypertrophy, inflammation and apoptosis (Wollert and Drexler 1999; Lassègue et al. 
2001; Ruiz-Ortega et al. 2001). In healthy subjects these pathways are tightly 
regulated, however if AngII levels are chronically elevated, these pathways can 
become overstimulated, resulting in hypertension and maladaptive vascular 
remodelling due to unregulated cellular growth, differentiation, ROS production and 
hypertrophy. 
 
 
Figure 7.4 AngII binding to AT1R triggers the activation of many intracellular 
pathways. The downstream effector agents of these pathways stimulate cellular 
survival, growth, hypertrophy and contraction. Figure modified from Mehta 
and Griendling 2007. 
 95
The use of ACE1 inhibitors and AT1R blockers confirms that inhibition of AngII and 
blockade of its receptor provides therapeutic benefits including lowering blood 
pressure, attenuating the development of atherosclerosis, alleviating hypertension and 
minimising cellular hypertrophy and cardiac remodelling (Giles 1992; Lee et al. 1993; 
Nicholls et al. 1994; Hollenberg 2000). Many human trials have now been performed 
using ACE inhibitors and AngII receptor blockers, all indicating ACE inhibition 
attenuates hypertension and lowers the risk of stroke, atherosclerosis and myocardial 
infarction (Yusuf et al. 2000; Yusuf et al. 2003; Ferrario et al. 2004; Ferrario 2006; Al 
Khalaf et al. 2009). However, treatment of hypertension using ACE1 inhibitors does 
not always lower blood pressure to desired levels and has not been shown to prevent 
restenosis following coronary angioplasty in a human trial (1992). ACE inhibition 
also produces some undesirable side effects including a dry cough due to its influence 
in the lungs (Al Khalaf et al. 2009). Furthermore, patients using ACE1 inhibitors over 
a prolonged period may require higher doses in order to sustain blood pressure within 
the desired level (Personal correspondence with Prof. Mark Richards), with higher 
doses exacerbating undesirable side effects, indicating the need for an alternate line of 
anti-hypertensive treatment. The development of AT1R blockers (ARBs) have helped 
partially resolve this issue as ARBs do not produce coughing or detrimental effects 
within the lungs. However, they are not as favourable as ACE1 inhibitors as they do 
not minimise stroke or MI risk to the same degree (Al Khalaf et al. 2009). Renin 
inhibitors have also been recently developed, effectively halting the initial step in the 
RAS cascade and proving effective in treating mild to moderate hypertension either 
alone or in conjunction with another antihypertensive agent such as an ARB (Musini 
et al. 2009; Sanoski 2009). 
 
A ‘perfect’ therapy is yet to be established in sufficiently inhibiting the RAS whilst 
avoiding side effects. Organ damage has been shown to occur in response to high 
doses of ACE inhibitors suggesting that antihypertensive agents may need to target 
vasoconstrictive agents outside of the RAS, such as chymase.  
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7.4   PA12 and the local, tissue-based RAS 
 
 
It was initially believed that the RAS was a purely endocrine system comprising of 
renin from the kidney, angiotensinogen from the liver, and ACE from the pulmonary 
system to produce the final effector peptide AngII within the circulation. It is now 
evident that a local RAS also exists in many tissues including the vascular wall, heart, 
kidney and brain capable of producing AngII independent of the circulation (Bader 
2002; Bader and Ganten 2008). Cardiac tissue possesses all the necessary agents 
required for a functional RAS as angiotensinogen and ACE1 their mRNA have been 
detected, along with minimal expression of renin which is currently debated (Bader 
2002; Varagic and Frohlich 2002). Renin mRNA has been detected in minute 
amounts in the atria, ventricles and cardiomyocytes, while mast cells are also shown 
to store renin (Mackins et al. 2006). Overall, it appears the heart is capable of local 
AngII production independent of circulatory-derived agents. PA12 represents a 
potentially important component of any local AngII-generating system as cardiac 
immunoreactive staining for PA12 suggests it is localised to different cellular areas 
compared with Ang (Jessup et al. 2008). PA12 is primarily localised to ventricular 
myocytes but also displayed some staining of the medial layer and surrounding 
adventitia of some coronary arteries, and predominantly concentrated in the 
cytoplasm of cardiac myocytes (Jessup et al. 2008), whereas Ang was barely 
detectable in the ventricle and displayed staining patterns different to PA12 where it 
was most prominent. Furthermore, Jessup et al. report PA12 expression within the left 
ventricle of rats was higher than that of AngI and AngII further supporting PA12 as a 
potential precursor peptide. It is yet to be determined whether renin is responsible for 
producing PA12 or another enzyme more readily expressed within the tissue.  
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7.5   RAS and UII crosstalk 
 
 
Few studies have reported UII to work in combination with other peptides or 
regulatory systems. In 2001 Watanabe and colleagues reported UII acts with serotonin 
(5-HT) and mildly oxidised LDL to synergistically promote VSMC proliferation 
(Watanabe et al. 2001a; Watanabe et al. 2001b), while a recent study employed a 
mathematical formula combined with hemodynamic data and estimated that UII 
works synergistically with angiotensin II in constricting rat aortic rings (Lamarre and 
Tallarida 2008)). The synergistic activity of UII with serotonin and angiotensin II are 
both suggested to be mediated by PKC activity (Watanabe et al. 2001a; Watanabe et 
al. 2001b; Wang et al. 2007). These studies highlight the potential for UII to work 
synergistically with other known vasoconstrictive agents to produce greater 
vasoconstriction, and potentially progress CVD. No study has yet explored the 
potential of UII to work synergistically with vasorelaxant agents in vessels known to 
relax in response to UII such as the coronary arteries (Katano et al. 2000; Li et al. 
2004; Prosser et al. 2006), mesenteric and other peripheral vessels (Gardiner et al. 
2001; Stirrat et al. 2001; Gardiner et al. 2004; Hood et al. 2005). 
 
Although no synergistic effect has yet been directly observed between UII and PA12 
or the RAS, they have both been reported to stimulate similar effects and indeed 
similar pathways in augmenting atherosclerosis and cardiovascular disease. Both UII 
and AngII have been shown to interact with, and elevate oxidised low-density 
lipoproteins, enhancing the development of foam cells and atherosclerosis (Watanabe 
et al. 2005; Chen and Mehta 2006; Watanabe et al. 2006). UII activity and AngII-
induced activation of the AT1R both stimulate cellular growth and hypertrophy 
through ERK1/2, elevate ROS production through NAPH oxidase activation, and 
cause fibrosis of the intistitial tissue through elevating collagen synthesis and fibrosis. 
The apparent difference between the two peptides is that UII also possesses 
cardioprotective properties, while RAS stimulation of the AT1R does not.  
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8. Cardiac chymase converts rat 
Proangiotensin-12 (PA12) to angiotensin 
II: effects of PA12 upon cardiac 
hemodynamics 
 
(The following chapter is a copy of the published article Prosser et al. Journal of 
Cardiovascular Research, 2009 Apr;82(1):40-50) 
 
Abstract 
 
Aims: The aim of this study was to observe the direct physiological and biochemical 
cardiac effects in response to a newly identified putative component of the renin–
angiotensin system, proangiotensin-12 (PA12); and investigate whether PA12 can 
serve as a substrate for angiotensin II (AngII) generation. Methods and results: The 
direct cardiac actions of PA12 and its role as a substrate for chymase-dependent AngII 
generation were investigated in Sprague–Dawley rats using an isolated heart model of 
cardiac ischaemia–reperfusion injury. PA12 potently constricted coronary arteries 
with no significant effect on left-ventricular contractility. PA12 impaired recovery 
from global ischaemia, maintaining coronary constriction and markedly increasing 
release of creatine kinase and troponin I (TnI), indicating greater myocardial injury. 
Analysis of perfusate collected after transcardiac passage revealed a marked increase 
in AngII production from hearts infused with PA12. Cardiac AngII production was 
not blocked by angiotensin-converting enzyme inhibitors, whereas inhibition of 
chymase with chymostatin significantly reduced AngII production and attenuated 
PA12-induced vasoconstriction and myocardial damage following ischaemia. 
Furthermore, angiotensin II type 1 receptor (AT1R) blockade abolished PA12 activity. 
In vitro, PA12 was efficiently and precisely converted to AngII as assessed on reverse 
phase-high performance liquid chromatography coupled to tandem mass spectrometry. 
This conversion was blocked by chymostatin. Conclusion: PA12 may act as a 
circulating substrate for cardiac chymase-mediated AngII production, in contrast to 
ACE-mediated AngII production from AngI. 
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8.1  Introduction 
 
Knowledge of the renin-angiotensin system (RAS) began with the initial discovery of 
renin in 1898, an enzyme shown to significantly alter blood pressure (Inagami 1998). 
Since then exploration into the RAS has found it to be one of the most important 
homeostatic systems in pressure-volume homeostasis. Renin released from the kidney 
in response to reductions in renal perfusion, acts on the angiotensin-precursor peptide 
angiotensinogen, cleaving it to release the biologically inactive decapeptide 
angiotensin1-10 (AngI). Angiotensin-converting-enzyme 1 (ACE1) cleaves a further 
2 amino acids from the C-terminus of AngI to produce angiotensin1-8 (AngII), a 
potent biologically active peptide triggering a broad range of effects throughout the 
body including aldosterone secretion, salt and water retention, and potent arteriolar 
vasoconstriction (Robertson and Nicholls 1993). Biologically active AngII-derived 
peptides have been isolated, including AngIII (Ang2-8) and AngIV (Ang3-8), 
suggesting angiotensinogen is a precursor to many functional peptides (Robertson and 
Nicholls 1993). AngII (and its active derivative peptides) bind to two known G-
protein coupled receptors, AngII receptor Type 1 and 2 (AT1 and AT2). AT1 is 
expressed abundantly by most cell types throughout the body and is the primary 
receptor mediating the pressor response to AngII (Higuchi et al. 2007). AT2 is far less 
abundant in the adult and has been suggested to stimulate vasodilation, counteracting 
the pressor and other effects of AT1 (Higuchi et al. 2007; Yayama and Okamoto 
2008).  
 
Proangiotensin-12 (PA12) is a newly discovered peptide believed to be an immediate 
proteolytic fragment of angiotensinogen. PA12 was isolated from the rat small 
intestine where it was most abundant, but it is also present in the circulation and 
throughout many tissues and organs of the rat (Nagata et al. 2006). The sequence of 
PA12 is identical to that of angiotensin I (AngI) with an extended C-terminus, thus 
comprising Ang1-10-Leu11-Tyr12. To date, a single report has documented that PA12 
can constrict rat aorta in vitro and elevate blood pressure in anaesthetized 
normotensive Wistar rats in vivo (Nagata et al. 2006). Whether PA12 is present in 
human (or other mammalian) blood or tissue is unknown. It has been suggested the 
effects of PA12 are dependent upon both ACE1 and AT1R activities, and that PA12 
levels are elevated in hypertensive rat hearts (Jessup et al. 2008). However, whether 
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PA12 has direct cardiac actions is not known, nor whether PA12 can serve as a 
substrate for generation of AngII or other AngII-related peptides.  
 
Accordingly, we provide the first documentation of direct hemodynamic and 
endocrine effects of PA12 on the isolated, perfused rat heart, and report its effects in a 
model of cardiac ischemia-reperfusion (I-R) injury. We also provide the first evidence 
that PA12 is converted to AngII in vitro and ex vivo by enzymatic chymase activity, 
and provide a comparison with AngI under the same protocols. 
 
 
8.2   Materials and Methods 
 
8.2.1   Materials 
Male Sprague-Dawley (SD) rats weighing 300-400 g (60-75 days old) were obtained 
from the Christchurch Animal Research Facility, University of Otago, New Zealand. 
Rats were housed under controlled temperature (21 ºC), humidity (~40%) and natural 
day length with free access to standard rat chow and water. 
 
Synthetic rat PA12 was obtained from Phoenix Pharmaceuticals (Belmont, CA, 
USA), while angiotensin I and the angiotensin-converting-enzyme 1 antagonists 
Captopril and Ramipril, as well as the chymase inhibitor Chymostatin were all 
obtained from Sigma-Aldrich (St. Louis, MI, USA). The angiotensin II receptor type 
1 blocker, CV-11974 (Candesartan, 2-ethoxy-1-[[2′-(1H-tetorazol-5-yl)biphenyl-4-
yl]methyl]-1H-benzimidazole-7-carboxylic acid)h was a generous gift from Takeda 
Chemical Industries Ltd (Osaka, Japan). PA12 and captopril were diluted in distilled 
water, aliquoted and stored at -20 ºC prior to use. Ramipril and chymostatin were 
dissolved in DMSO, while CV-11974 was dissolved in 1 M Na2CO3 solution, 
aliquoted and stored at -20 ºC prior to use. 
 
8.2.2  Langendorff isolated rat heart perfusion 
Isolated rat heart perfusion was performed as previously described (Pemberton et al. 
2005; Prosser et al. 2006). Briefly, rats were anesthetized with sodium pentobarbital 
(50 mg/kg, i.p.). The heart was rapidly excised and mounted on the Langendorff 
apparatus, cannulated above the aortic valve and perfused at 12 ml/min (constant 
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retrograde flow) with perfusion buffer comprising (mmol/L): 123 NaCl, 22.0 
NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.1 MgSO4·7H2O, 1.5 CaCl2·2H2O and 11.0 glucose 
(final pH 7.40). Buffer was maintained at 37 ºC and oxygenated with 95% O2/5% 
CO2. The left atrium was removed allowing a 40% ethanol-filled balloon (attached to 
a pressure transducer) to be inserted through the mitral valve into the left ventricle 
(LV) enabling measurement of left ventricular hemodynamic contractile parameters. 
A side-arm cannula attached to a second pressure transducer was inserted into the 
aortic cannula above the heart to measure perfusion pressure (PP), an indirect measure 
of coronary arterial tone. Hearts were allowed to settle for 30 min before being paced 
at 320 bpm using an electrode attached to a Digimeter DS2A-Mk. II stimulator placed 
on the right atrium. Hearts were allowed a further 30 min to resettle before any 
experimental protocol was started. All data were recorded using a Powerlab Chart 5 
System (ADInstruments); see Appendix B.1 for supplementary information and 
methodology. Drugs were diluted using perfusion buffer to enable infusion of the 
drug or vehicle over 30 min at 0.5 ml/min using a syringe pump feeding directly into 
the perfusion line. This investigation was approved by the University of Otago 
Animal Ethics Committee and conforms with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996). 
 
8.2.3  Ischemia-reperfusion protocols 
All antagonist agents (100 µmol/L captopril, 100 nmol/L CV-11974, 100 nmol/L 
chymostatin, and 100 µmol/L and Ramipril) were co-infused with either 10 nmol/L 
PA12 or 10 nmol/L angiotensin I (AngI). Experiments were run in pairs: one heart 
infused with both the antagonist and PA12 or AngI, the other simultaneously infused 
only with PA12 or AngI from the same stock solution and same buffer reservoir 
providing a parallel control for each antagonist experiment. The heart given the 
antagonist was chosen at random. 
 
The doses of 10 nmol/L PA12, 10 nmol/L AngI, 100 nmol/L CV-11974, 100 µmol/L 
captopril and 100 nmol/L chymostatin administered were based upon preliminary 
dose-response studies or manufacturers recommendations (Appendix C, Figure C.2). 
After 30 min infusion of agents, perfusion was stopped and hearts underwent no-flow 
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Figure 8.1  Ischemia-reperfusion experimental protocol. Following a settling 
period, rat hearts underwent preconditioning infusion (30 min), no-flow global 
ischemia (45 min) and reperfusion with buffer only (105 min). Arrows indicate 
global ischemia for 45 min with pacing halted. Hearts were then reperfused with 
accompanying pacing for 105 min following ischemia (Figure 8.1). 
-10 0 10 20 30 75 90 120 180
Infusion Ischemia Reperfusion
Time (min)
 
 
 
8.2.4 Analysis of cardiac AngII, Atrial Natriuretic Peptide (ANP), 
Myocardial Creatine Kinase (CK), and Troponin I (TnI) release 
Perfusate samples were collected at specific time points after passing through the 
heart for hormonal and biochemical analysis (Figure 8.1). Samples of infusion 
solution from the syringe were also taken prior to passing through the heart. 
Angiotensin II (AngII) production was determined by extracting perfusate samples 
(collected into 500 IU Aprotinin/0.1% Triton X-100) through Bond Elut columns and 
measured using our previously described, specific radioimmunoassay (RIA) (Nicholls 
and Espiner 1976, refer Appendix D.1). This assay shows no detectable cross-
reactivity with PA12 or angiotensin I.  
 
ANP secretion was measured by RIA after extraction through SepPak columns as 
previously described (Yandle et al. 1986, refer Appendix D.2). Perfusate creatine 
kinase (CK) and troponin I (TnI) concentrations were measured using the Abbot 
Aeroset platform (Canterbury Health Labs, Christchurch, New Zealand). 
 
8.2.5  Ex vivo cardiac conversion of PA12 analysis 
To assess the ex vivo cardiac conversion of PA12, we employed reverse phase-high 
pressure liquid chromatography (RP-HPLC) coupled with specific RIA. RP-HPLC 
was carried out at 40ºC, with a gradient of 0-60% CH3CN / 0.1% TFA over 60 min, 
using a 22 cm Brownlee C18 RP-HPLC column. The gradient elution profile was 
calibrated with Ang(1-7), AngII, AngI and PA12 standard peptides. To assess 
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enzymatic cardiac conversion of PA12 after a single cardiac passage, 1ml samples of 
perfusate (during infusion of 10 nmol/L PA12) were collected into Aprotinin/Triton 
post-infusion and subjected to RP-HPLC as above, with fractions collected at 1 min 
intervals. Fractions were dried under air at 37ºC, reconstituted in AngII RIA buffer 
and subjected to AngII RIA, as described (Nicholls and Espiner 1976).  
 
8.2.6 In vitro conversion of PA12 by chymase – Tandem Mass Spectrometry 
analysis 
To confirm that chymase could generate authentic AngII from PA12, we employed in 
vitro incubation of PA12 with recombinant chymase. PA12 (12.72 µmol/L) was 
incubated either: a) alone; b) in combination with recombinant human chymase (3.33 
pmol/L); or c) in combination with both 3.3 pmol/L chymase and 33.4 µmol/L 
chymostatin. Incubations proceeded for 30 min at 37ºC in 50 µL PBS. Reactions were 
quenched by addition of 2 µL glacial acetic acid (final concentration of 0.6 mol/L), 
and the reaction products of each submitted to RP-HPLC using the gradient described 
above. Fractions were collected at 1 min intervals and portions submitted to AngII 
RIA analysis. The remainder of the RP-HPLC fractions were dried under air and those 
with AngII immunoreactivity and UV detection were submitted to Tandem Mass 
Spectrometry (MS/MS). 
 
8.2.7  Tandem Mass Spectrometry: 
Peptides were resuspended in 30% [v/v] acetonitrile and 0.1% [v/v] trifluoroacetic 
(TFA) acid in water. 1 µL of peptide solution was premixed with 2 µL of matrix (10 
mg/ml αcyano-4-hydroxycinnamic acid dissolved in 65% [v/v] aqueous acetonitrile 
containing 0.1% TFA and 10 mmol/L ammonium dihydrogen phosphate). 0.8 µL of 
sample/matrix mixture were spotted onto a MALDI sample plate (Opti-TOF 384 well 
plate, Applied Biosystems, MA) and air dried. 
 
Samples were analyzed on a 4800 MALDI tandem Time-of-Flight Analyzer (Applied 
Biosystems, MA). All MS spectra were acquired in positive-ion mode with 800-1000 
laser pulses per sample spot. The 6 strongest precursor ions of each sample spot were 
used for MS/MS collision-induced fragmentation (CID) analysis. CID spectra were 
acquired with 2000-4000 laser pulses per sample spot using the 2 kV mode and air as 
the collision gas at a pressure of 1x10-7 torr. 
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For protein identification MS/MS data was searched against the SWISS-PROT amino 
acid sequence database using the Mascot search engine (matrix science). The search 
was set up for full tryptic peptides with a maximum of 4 missed cleavage sites. 
Carboxyamidomethyl cysteine, oxidized methionine, and pyroglutamate (E, Q) were 
included as variable modifications. The precursor mass tolerance was 75 ppm and the 
maximum fragment mass error 0.3 Da. 
 
8.2.8  Statistical analysis 
All data are presented as mean +S.E.M. Analysis of changes in cardiac hormones and 
hemodynamics were performed on SPSS using a two-way ANOVA with repeated 
measure, with Bonferroni’s multiple comparison test, post hoc. Individual and 
cumulative data comparisons were made using a student’s T-test. In all statistical tests 
a value of P<0.05 was considered significant.  
 
 
8.3  Results 
 
8.3.1 PA12 Increases Coronary Perfusion Pressure (PP) pre and post 
cardiac ischemia 
PA12 dose-dependently increased PP indicating vasoconstriction of the coronary 
arteries. This effect was maximal at 10 nmol/L and sustained throughout the 30 min 
infusion period (Figure 8.2A). 1 and 10 nmol/L PA12 elevated PP by an average of 11 
± 0.7 and 32.3 ± 4.4 % (P<0.05, n=6 and P<0.0001, n=8) respectively, compared with 
vehicle infusion. PA12 had no significant effect on left ventricular developed pressure 
(DP), nor ±dP/dt (∆DP from 0 to 30 min was 8 ± 2.27 % and 9 ± 2.15 % for vehicle 
and PA12 respectively).  
 
Infusion of 10 nmol/L AngI significantly increased PP (P<0.05, n=5), comparable to 
that of 10 nmol/L PA12 (Fig 2E), and also showed no significant effects on DP or 
±dP/dt (∆DP from 0 to 30 min was 9 ± 1.30 and 9 ± 3.41 % for vehicle and AngI 
respectively). 
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Infusion of captopril alone (an ACE1 inhibitor) caused a significant drop in PP 
compared with vehicle (P<0.005, n=5). However, when co-infused with PA12, 100 
µmol/L captopril had no effect on PA12-induced increase in PP with levels 
comparable to that of PA12 infused alone (Figure 8.2B). This lack of response of 
PA12 to ACE1 inhibition was confirmed by infusion of a second ACE1 inhibitor 
Ramipril at a dose of 100 µmol/L (Appendix C, Figure C.3). Captopril abolished the 
AngI-induced elevation in PP significantly below both vehicle and AngI levels (both 
P<0.01, n=5, Figure 8.2E). The gradual increase in PP observed during the co-
infusion was equal to that of infusion of captopril alone (see Figure 8.2B). The AT1R 
antagonist, CV-11974, completely abolished PA12-induced elevations in PP 
(P<0.001, n=6), suggesting the AT1 receptor can mediate PA12 activity (Figure 8.2C).  
 
Infusion of the chymase inhibitor chymostatin at the dose employed had no effect on 
PP or LV contractility. However co-infusion of chymostatin with PA12 significantly 
attenuated PA12-induced increases in PP by an average of 63.9 ± 1.59 % (P<0.001, 
n=5, Figure 8.2D). In contrast, co-infusion of chymostatin with AngI caused minimal 
attenuation of AngI-induced increases in PP during infusion, remaining significantly 
above vehicle (P<0.003, Figure 8.2E). 
 
8.3.2  Ischemia-reperfusion 
With ischemia-reperfusion, hearts preconditioned with 10 nmol/L PA12 showed 
significantly elevated PP above vehicle levels throughout the reperfusion period 
(P<0.05, Figure 8.3A). Hearts preconditioned with 10 nmol/L AngI also showed 
elevated PP above vehicle levels, significant at 120 and 180 minutes (both P<0.05, 
n=5, Figure 8.3D). PA12 and AngI had no significant effect on DP, ±dP/dt, systolic 
or diastolic pressure during reperfusion.  
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Figure 8.2 PA12 elicited a dose-dependent increase in perfusion pressure (PP), significant 
at 1 and 10 nmol/L compared with vehicle (panel A, n=8). PA12 activity was unaffected 
by the ACE1 antagonist captopril (panel B, n=5), was abolished by the angiotensin II type 
1 receptor blocker CV-11974 (panel C, n=6), and was significantly attenuated by 
chymostatin (panel D, n=5). Infusion of 10 nmol/L AngI elevated PP equal to that of 10 
nmol/L PA12. AngI activity was significantly inhibited by captopril, while chymostatin 
caused minimal attenuation (panel E, n=5). Using a two-way ANOVA: **P<0.05, 
***P<0.005, bar indicates infusion of vehicle, PA12, CV-11974, chymostatin (all thatched 
bar) or captopril (solid bar). 
Figure 8.3 Perfusion pressure following global ischemia in isolated hearts 
preconditioned with 10 nmol/L PA12 (n=8) or 10 nmol/L AngI (n=5). 100 µmol/L 
captopril had no effect on PA12-induced elevations in PP during reperfusion (panel 
A), however 100 nmol/L CV-11974 (panel B) and 100 nmol/L chymostatin (panel C) 
both attenuated the PA12-induced increase. AngI caused minimal elevation of PP 
immediately following ischemia before rising above control levels (P<0.05 at 120 and 
180 min, panel D). Captopril significantly attenuated the AngI-induced elevation in 
PP throughout reperfusion; while chymostatin displayed minimal inhibitive potency, 
significant for the initial 10 min of reperfusion (panel D). +Individual data point 
comparison using student’s t-test P<0.05; **Data set comparison using a two-way 
ANOVA P<0.05. 
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Hearts preconditioned with captopril alone displayed significantly reduced PP 
throughout reperfusion (P<0.05, Figure 8.3A). Captopril attenuated PA12-induced 
elevations in PP immediately following ischemia, before antagonistic potency was 
lost and PP increased to equal PA12 alone (Figure 8.3A). In contrast, captopril 
significantly attenuated AngI-induced elevations in PP during reperfusion (P<0.05 
compared with AngI alone, Figure 8.3D). 
 
Co-infusion of CV-11974 with PA12 abolished PA12-induced increases in PP during 
reperfusion (P<0.005, Figure 8.3B). 
 
Figure 8.4 Cumulative CK release in PA12 preconditioned hearts was significantly 
higher compared with vehicle controls, an affect which was not attenuated by 100 
µmol/L captopril (panel A), but was significantly abolished by  100 nmol/L CV-11974 
(panel B) and 100 nmol/L chymostatin (panel C). Hearts preconditioned with 10 nmol/L 
AngI produced cumulative CK release significantly higher than vehicle controls (panel 
D); this increase was significantly attenuated by 100 µmol/L captopril, but not by 100 
nmol/L chymostatin. **P<0.05 compared with vehicle or PA12, as indicated by bars 
using a student’s t-test. 
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Chymostatin attenuated the PA12-induced increase in PP following ischemia, 
maintaining PP below that of hearts preconditioned with PA12 alone (P<0.05 at 120 
and 180 min, Figure 8.3C). Co-infusion of chymostatin with AngI saw a reduction in 
PP immediately following ischemia when compared with hearts preconditioned with 
AngI alone (P<0.05 at 77, 80 and 85 min, Figure 8.3D). 
 
 
 
Figure 8.5 Cumulative myocardial TnI release in PA12 preconditioned hearts was 
significantly higher compared with vehicle controls, an affect which was not 
attenuated by 100 µmol/L captopril (panel A), but was significantly abolished with 
100 nmol/L CV-11974 (panel B) and chymostatin (panel C). Hearts preconditioned 
with 10 nmol/L AngI produced cumulative TnI release significantly higher than 
control during reperfusion (panel D); this increase was significantly attenuated by 
100 µmol/L captopril, but not by 100 nmol/L chymostatin.**Using a student’s t-test 
P<0.05 compared with vehicle or PA12, as indicated by bars. 
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During reperfusion hearts preconditioned with 10 nmol/L PA12 or 10 nmol/L AngI 
released significantly more CK and TnI (both P<0.05) than control hearts, indicating 
greater myocardial injury (Figures 4 and 5).  The addition of captopril had no effect 
on PA12-induced CK or TnI release (Figure 8.4A and 8.5A); however, both CV-
11974 and chymostatin significantly blocked PA12-induced elevations in both CK 
and TnI (Figures 4B&C and 5B&C). In contrast to PA12, captopril significantly 
attenuated AngI-induced elevations in CK and TnI release when compared to hearts 
preconditioned with AngI alone (both P<0.05, Figures 4D & 5D), however 
chymostatin could not (both P>0.05, n=5, Figures 4D & 5D). 
 
8.3.3  Perfusate ANP levels during ischemia-reperfusion 
Hearts preconditioned with either 10 nmol/L PA12 or 10 nmol/L AngI showed no 
significant difference in perfusate ANP concentrations compared with vehicle 
throughout both infusion and reperfusion. Infusion of 100 µmol/L captopril alone 
reduced ANP secretion during infusion and significantly during reperfusion (P<0.05), 
as well as attenuating both PA12- and AngI-induced ANP release (P<0.05). CV-
11974 and chymostatin had no influence on ANP secretion with or without the 
presence of PA12 or AngI.  
 
8.3.4 PA12 is cleaved into angiotensin II during cardiac passage: 
dependence on chymase, but not ACE1 
An average of 457.2 ± 113.2 pmol/L and 651.3 ± 79.73 pmol/L IR-AngII was 
measured from perfusate samples collected at 10 minutes into infusion from hearts 
preconditioned with 10 nmol/L PA12 and 10 nmol/L AngI respectively, both 
significantly above that of vehicle (8.15 ± 7.75 pmol/L, P<0.001, Figure 8.6A & 
8.6B). PA12-derived AngII formation was not attenuated by captopril co-infusion 
(508.0 ± 169.5 pmol/L, P=NS vs. PA12 alone), but was almost completely abolished 
by chymostatin co-infusion (60.62 ± 8.71 pmol/L, Figure 8.6A), reducing IR-AngII 
by 87%. In contrast, both captopril and chymostatin significantly inhibited perfusate 
concentrations of IR-AngII collected from hearts infused with AngI by 92% and 81% 
respectively (P<0.001 vs. AngI alone, Fig 6B). (IR-AngII within the drug-infusion 
syringe was non-detectable).  
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Figure 8.6 Perfusate IR-AngII from rat hearts infused with 10 nmol/L PA12 (A) or 10 
nmol/L AngI (B), and effects of supra-added 100 µmol/L captopril and 100 nmol/L 
chymostatin. (C) Perfusate samples collected from hearts infused with PA12 + captopril 
were subjected to RP-HPLC (elution gradient 0-60 % CH3CN over 60 min (1 ml/min)). 
Eluted fractions were collected and measured for immunoreactive-AngII (IR-AngII) via 
specific RIA and overlapped with known elution times of angiotensin peptides (indicated 
by arrows; ***Using a students t-test P<0.005).
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The presence of authentic AngII within the cardiac perfusate was confirmed by 
subjecting perfusate samples to RP-HPLC / RIA. Hearts preconditioned with PA12 
alone and PA12 with captopril combined produced a peak of immunoreactive AngII 
that eluted consistent with synthetic standard (Figure 8.6C), indicating captopril was 
incapable of abolishing the conversion of PA12 to AngII in the heart. In contrast, co-
infusion of PA12 with chymostatin significantly attenuated AngII generation (Figure 
8.6A).  
 
 
8.3.5  Chymase converts PA12 to AngII in vitro – HPLC MS/MS analysis 
In vitro incubation of PA12 with chymase confirmed chymase is capable of 
converting PA12 into authentic AngII. Thus, 30 min incubation of PA12 alone in PBS 
yielded on RP-HPLC / UV a single peak corresponding with PA12 standard (Figure 
8.7A, solid line). Incubation of chymase with PA12 resulted in several UV peaks, 2 of 
which correlated exactly with AngII and PA12 standards (Figure 8.7B). A third minor 
peak also was observed at 27 min, consistent with Ang(1-7), (Figure 8.7B). The 
addition of chymostatin abolished all peaks bar PA12 on UV. RIA analysis of UV 
fractions from HPLC revealed that incubation of PA12 alone contained barely 
detectable IR-AngII (Figure 8.7A). In contrast, incubation of chymase with PA12 
produced significant IR-AngII (Figure 8.7B, dashed line). Addition of chymostatin 
abolished all IR-AngII (data not shown). MS/MS analysis of the IR / UV AngII peak 
in Figure 8.7B confirmed that it was authentic AngII, with a confirmed Mr of 
1046.4899 (Figure 8.7C). MS/MS analysis of a single UV peak in Figure 8.7A, gave a 
Mr of 1572.7407, identical with that of complete PA12 (Figure 8.7D). 
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Figure 8.7 RP-HPLC and MS/MS analysis of PA12 incubated with chymase at 37ºC for 30 
min in PBS. Each treatment: PA12 alone (panel A), and PA12 + chymase (panel B), 
underwent RP-HPLC with UV detection (solid line, right-hand axis), and specific AngII 
RIA for AngII (dotted line, left-hand axis). Arrow indicates AngII peak on the UV profile 
corresponding to the IR-AngII peak (B). Tandem Mass Spectrometry performed on 
treatment ‘PA12 + chymase’ confirmed the presence of both AngII (C) and PA12 (D). 
Chymostatin abolished all detectable AngII when incubated with PA12 and chymase 
combined (not shown). 
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8.4  Discussion 
 
PA12 is a newly isolated peptide, identified as a potential component of the RAS by 
Nagata and colleagues in late 2006, who reported that PA12 dose-dependently 
constricted rat aorta segments and significantly elevated blood pressure in vivo, via 
ACE1- and AT1 receptor-dependent mechanisms (Nagata et al. 2006). There have 
been no reports describing the direct cardiac actions of PA12, and only a single report 
has described the conversion of PA12 to AngII by the heart (Trask et al. 2008). 
Accordingly, we provide in this report the first evidence that: 
1) PA12 infusion induces potent, dose-dependent vasoconstriction in rat coronary 
arteries, without significant effect on LV contractility. 
2) PA12 significantly worsens ischemia-reperfusion injury.  
3) PA12 actions are blocked by AT1R and chymase inhibition, but not ACE1.  
4) Chymase effectively processes PA12 to authentic AngII ex vivo and in vitro.  
 
The cardiac vasoconstrictive actions of PA12 were approximately equal to that of 
AngII, and lasting the entire period of infusion and reperfusion. We observed no 
effects of PA12 upon LV contractility, nor any effect with infusion of 10 nmol/L 
AngI. This may suggest that PA12 actions are restricted to the vascular surface, and 
be minimal or absent in cardiac myocytes; or, that its effects were blunted in our 
single pass Langendorff setup. However, AngI also had no effects upon LV 
contractility and coupled with previous reports suggesting AngI and AngII exert 
inotropic effects in atrial but not ventricular myocardium (Holubarsch et al. 1993; 
Holubarsch et al. 1994), it is possible AngI and PA12 possess limited ability to 
contract LV tissue. 
 
In a model of ischemia-reperfusion injury, we found preconditioning the heart with 
PA12 significantly elevated coronary PP following ischemia, and increased both CK 
and TnI release. PA12 also maintained cardiac atrial natriuretic peptide (ANP) 
production slightly above that of hearts preconditioned with vehicle during both 
infusion and reperfusion. Taken together these results indicate PA12 impairs recovery 
from global ischemia in the rat heart by reducing coronary flow and causing increased 
myocardial damage. These results were comparative with hearts preconditioned with 
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AngI, however differed in that AngI exhibited slightly reduced potency immediately 
following ischemia when compared with PA12.   
 
Captopril, chymostatin and CV-11974 specifically inhibit ACE1, chymase and the 
AT1 receptor respectively (Feinstein et al. 1976; Patchett et al. 1980; Naka 1993). 
Blockade of the AT1 receptor abolished the PA12-induced vasoconstriction, revealing 
the AT1 receptor can mediate the response to PA12, indicating that either PA12 itself 
binds and activates AT1R, or PA12 is initially cleaved into fragments capable of 
binding and activating AT1R. To examine whether PA12 activity is dependent upon 
ACE1, captopril (and ramipril) were co-infused directly into the rat heart with PA12. 
Neither antagonist inhibited PA12-induced vasoconstriction in the isolated rat heart, 
nor had any effect on CK or TnI levels following ischemia. Analysis of perfusate 
samples collected after passing through the heart revealed an elevated presence of 
perfusate AngII from hearts infused with PA12, indicating PA12 was converted to 
AngII, not by ACE1, but by another cardiac enzyme. The concentrations of captopril 
and ramipril used in this study were relatively high (100 µmol/L), newly obtained and 
capable of causing significant vasodilation when infused alone, indicating potency 
and viability. These results contrast those of Nagata et al., which suggested PA12 
constriction of aortic strips and change in mean arterial pressure in vivo were 
dependent on ACE1 (Nagata et al. 2006). Differential tissue expression of chymase 
and ACE1 may underlie these discrepancies, as well as ex vivo versus in vivo 
methodological differences, but also the relative activities of chymase and ACE1 in 
the circulation to produce AngII from PA12 need to be clarified. 
 
The ‘normalized’ results observing PP would suggest that inhibition of ACE may, in 
fact, potentiate PA12 activity. This fit with the observed minor elevation in perfusate 
IR-AngII levels from hearts infused with PA12 + captopril compared with infusion of 
PA12 alone. There is little, if any, literature observing this phenomenon where 
inhibition of ACE stimulates upregulation of chymase and/or other enzymes capable 
of generating elevated vasoconstriction and AngII formation; as in all studies 
observing ACE versus chymase-induced AngII generation and vasoconstriction, AngI 
has been the substrate, which we and others (de Lannoy et al. 2001; Kokkonen et al. 
2003) have observed to have little dependence upon chymase activity. Wei et al. 
(2003) suggested an interaction between mast cells and Bradykinin (BK) in the 
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cardiac interstitium, whereby antagonism of the BK2 receptor significantly reduced 
mast cell density (Wei et al. 2003). Combining this latter report with knowledge that 
ACE1 inhibition increases BK2 activity (Minshall et al. 1997), leads to the hypothesis 
that ACE inhibition could theoretically increase mast cell density, providing a greater 
amount of chymase and other ACE-independent AngII-forming enzymes capable of 
generating AngII from PA12.  
 
Boucher et al. (1974) were the first to show enzyme(s) other than ACE are capable of 
converting AngI into AngII (Boucher et al. 1974). Indeed enzymes other than ACE1 
and ACE2 have been shown to convert angiotensinogen or AngI into smaller active 
peptides and/or inactive fragments, including carboxypeptidases and chymase 
(Robertson and Nicholls 1993). ACE1 inhibitors do not completely block AngII 
production and ACE1-independent pathways are present in many mammalian species 
(Gondo et al. 1989; Hoit et al. 1995; Urata et al. 1996; Shiota et al. 1997; 
Padmanabhan et al. 1999). Chymase, a serine protease, is synthesized and stored in 
granules of mast, endothelial, and mesenchymal cells widely expressed throughout 
mammalian tissues (Urata et al. 1994; Urata et al. 1996). Indeed, chymase is 
suggested to be the enzyme primarily responsible for AngII formation in tissue, while 
ACE1 is the dominant conversion mechanism within the circulation (Miyazaki and 
Takai 2006; Miyazaki et al. 2006). Accordingly, we employed chymostatin, a 
chymase inhibitor, to test whether chymase may be responsible for cardiac PA12 
conversion to AngII in our heart preparations. Chymostatin significantly inhibited 
PA12-induced vasoconstriction in the isolated rat heart during both infusion and 
reperfusion, as well as reducing the perfusate AngII concentrations by ~80%. In vitro 
analysis confirmed that chymase alone is capable of converting PA12 into AngII, and 
overall these results suggest that the cardiac conversion of PA12 to AngII is at least 
partially chymase-dependent.  
 
In contrast to PA12, generation of AngII from AngI was shown to be dependent upon 
ACE1 availability, consistent with prior reports (de Lannoy et al. 2001). The addition 
of chymostatin caused significant attenuation of AngI-induced AngII generation (as 
previously reported (Muller et al. 1998)), however exhibited minimal antagonism of 
AngI-induced vasoconstriction. This indicates chymase can convert AngI to AngII, 
and suggests that chymase (or other cardiac enzymes) may further cleave AngI or 
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AngII into AngIII (angiotensin-(2-8)) and/or AngIV (angiotensin-(3-8)), both shown 
to be potent vasoconstrictors (van Esch et al. 2008). If so, the current study could only 
observe perfusate AngII levels via RIA, explaining the discrepancy between the non-
significant reduction in PP and the significant reduction in AngII production from 
hearts receiving chymostatin + AngI. 
 
We cannot exclude ACE2-mediated conversion of PA12 to AngII and other related 
active peptides. For example, our HPLC profiles were consistent with some Ang(1-7) 
formation, and either chymase or ACE1 may further cleave AngII to AngIII or 
AngIV. The data also cannot rule out PA12 itself binding to AT1R, causing the 
hemodynamic effects observed. However, as chymostatin abolished PA12-induced 
vasoconstriction and severely reduced generation of AngII, it is likely that AngII is 
responsible for most of the observed bioactivity. 
 
PA12 is expressed in its highest levels within the small intestine (Nagata et al. 2006), 
where a close analogue of chymase, chymotrypsin, is also expressed in high amounts 
and secreted from the pancreas (Goldberg 2000). Bovine α-chymotrypsin is capable 
of hydrolyzing AngI into AngII, before degrading AngII into biologically inactive 
fragments (Trong et al. 1987). PA12 may also be converted into active AngII and 
have a specific role within the small intestine, possibly linking digestive and renin-
angiotensin systems. Thus, we extend these reports to identify PA12 as a potentially 
new precursor peptide specific for tissue-based generation of AngII. AngII blockade 
(by ACE or AT1R blockade) is a mainstay of treatment in hypertension, after ischemic 
cardiac events and in human heart failure. Breakthrough of AngII generation is known 
to occur over the weeks following initiation of ACE1 treatment and may contribute to 
alleviation of ACE1-related cardiovascular protection (Robertson and Nicholls 1993). 
Elucidation of alternative pathways of AngII generation enhances the understanding 
of cardiovascular pathophysiology and may lay the foundation for improved therapy. 
Furthermore, the high expression of PA12 within the gut combined with its potent 
vasoconstrictive properties observed in the heart raises the possibility that PA12 links 
gut processes with concurrent circulatory responses. It is yet to be reported whether 
PA12 levels in the gut and circulation correlate with each other and/or the effects of 
eating. 
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Whilst it is yet to be established whether ACE2 has any role in PA12 activity, (or 
whether PA12 is in fact present in humans or other mammalian species), we found 
this newly discovered peptide PA12 infused in isolated perfused rat hearts caused 
potent, sustained vasoconstriction and impaired recovery from ischemia. IR-AngII 
was significantly elevated in perfusate collected from hearts infused with PA12, 
indicating PA12 is converted into AngII. One enzyme responsible for the conversion 
of PA12 to AngII appears to be chymase, and the AT1 receptor was found to mediate 
PA12 activity, most likely binding PA12-derived AngII. Further studies identifying 
PA12 in humans and its role in control of the circulation are clearly required. 
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9. Vascular response to Proangiotensin-12 
(PA12) through the rat arterial system 
 
 
Abstract 
 
Proangiotensin-12 (PA12) is the most recent vasoactive peptide to be identified as a 
functional component of the renin-angiotensin system (RAS). Recent reports indicate 
PA12 may provide an alternate substrate to AngI in generating AngII. The vascular 
response to PA12, and conversion of PA12 to AngII have been reported as being both 
angiotensin-converting enzyme 1- (ACE1-) and chymase-dependent. The current 
study employs myography to determine the direct vascular effects of PA12 
administered to specific vessels isolated from the rat arterial system including the: 
right and left common carotid arteries, descending thoracic aorta, abdominal aorta, 
renal, mesenteric and femoral arteries. The dependence of PA12 upon ACE1 and 
chymase is revealed through the use of enzyme inhibitors, with AngII applied at the 
same dose providing a measure of comparison. PA12 caused significant constriction 
in 5 of 7 the vessels tested (all P<0.05), displaying no significant effect on the renal or 
femoral arteries (P>0.05). AngII significantly stimulated constriction in the same 
arteries (all P<0.05), paralleling PA12 vasoactivity. A potency gradient across the 
animal in response to PA12 was apparent, with vessels in closest proximity to the 
heart responding with the greatest constriction. Inhibition of ACE1 and chymase 
significantly attenuated PA12-induced constriction, with chymostatin displaying 
slightly reduced potency (although not significantly different). In sum, chymase and 
ACE1 regulated PA12-induced vasoconstriction throughout the rat arterial system. 
We postulate that ACE1 may primarily regulate RAS activity within the circulation, 
while chymase may have a greater role within local, tissue-based RAS activity.
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9.1   Introduction 
 
The most recent peptide to be identified within the renin-angiotensin system (RAS) is 
proangiotensin-12 (PA12), which comprises angiotensin I (AngI) with C-terminally 
extended -Leu11-Tyr12. PA12 was isolated from the rat small intestine, (the organ of 
highest gene and peptide concentrations, but PA12 is also found throughout the 
tissues of all major organs as well as being present in the circulation at approximately 
one third that of angiotensin II (AngII) (Nagata et al. 2006; Jessup et al. 2008). 
Because of its wide distribution it is desirable to identify the effects of PA12 
throughout the systemic and peripheral vasculature. As previously reported, PA12 
potently constricts isolated rat aortic strips and rat coronary arteries within an isolated 
heart preparation (Nagata et al. 2006). 
 
In the current study we sought to document any vasoactive properties of PA12 outside 
of the heart, employing myography to measure the response to PA12 in 7 different 
arteries from the rat vascular system: the left and right common carotid arteries 
(LCCA and RCCA respectively), descending thoracic aorta (DTA), abdominal aorta 
(AbA), mesenteric artery (Mes), renal artery (Ren) and femoral artery (Fem). The 
enzyme inhibitors chymostatin and captopril were employed to indicate whether 
chymase or ACE1 respectively, mediated PA12-induced activity in each vessel. 
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9.2  Materials and Methods 
 
9.2.1   Myography of rat vessels 
Male Sprague Dawley rats weighing 320-420g (60-75 days old) were obtained from 
Christchurch School of Medicine, Christchurch, NZ. Rats were housed under 
controlled conditions (21ºC, ~40% humidity, natural day length), and had free access 
to standard rat chow and water. Rats were anaesthetized by an intraperitoneal (IP) 
injection of sodium pentobarbital (50mg/kg). Once anaesthetized the head was 
guillotined and a t-incision made across the belly of the animal exposing the 
pericardium to the urethra. The rib cage was opened and the ribs cut on either side 
close to the vertebrae, fully exposing the heart and lungs. The initial ventral incision 
was continued transverse, across the animal, exposing all arteries to be excised. 
Sections of the left and right common carotid arteries, descending thoracic aorta, 
abdominal aorta (posterior to the renal arteries), mesenteric, renal and femoral arteries 
were all excised and immediately placed into individual, half-filled 20ml vials of ice-
cold rat buffer comprising (mM): 123 NaCl, 123 NaCl, 22.0 NaHCO3, 4.7 KCl, 1.2 
KH2PO4, 1.1 MgSO4·7H2O, 1.5 CaCl2·2H2O and 11.0 glucose (final pH 7.40). When 
required, vessels were cut to 2 mm lengths and placed into fresh rat buffer contained 
within the bath of a Mulvany Myograph (model 410A, JP Trading, Århus, Denmark) 
maintained at 37 ºC using a flow-through water heating system, and oxygenated with 
95% O2 / 5% CO2 (see Appendix B.2 for supplementary methods). Wires were 
inserted through the lumen, whilst avoiding endothelial damage, and attached to jaws 
on either side of the vessel. The vessel could then be tensioned in the radial plane by 
moving one jaw away from the other. The bath was drained and replaced with fresh 
buffer, removing any metabolic agents released during the excision process. Vessels 
were pretensioned and given at least 1 hr to reach their equilibrated resting tension. 
Two identical myographs were used, each with 2 sets of jaws with a dam inserted 
between them enabling experimentation of 4 vessels simultaneously. Both myographs 
contained buffer from the same stock solution, and the baths were maintained at equal 
temperatures providing identical media for all 4 vessels, and enabling application of 4 
different treatments. Changes in tension were recorded using Chart 4 software (AD 
Instruments).  
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One ‘control’ vessel was untouched throughout the experiment to allow measurement 
of any spontaneous changes in tension. The remaining 3 vessels were administered 10 
nM PA12 (obtained from Phoenix Pharmaceuticals, Belmont, CA, USA), followed by 
a wash out period, removing the media and replacing with fresh buffer at least 3 
times. Vessels were then allowed 20 min to resettle at their resting tension before 10 
nM AngII (obtained from Sigma-Aldrich, St. Louis, MI, USA) was administered 
directly into the bath and the response recorded for 25 min. At the end of the 
experiment each vessel was administered 120 mM KCl to obtain a close to maximal 
contraction and ensure viability. This process was repeated for each different vessel 
type. 
 
9.2.2  Antagonist protocol 
Vessels dissected from one animal were cut into 2 mm lengths to provide at least 2 
smaller sections of the same vessel. These sections were prepared as described above 
and held within each myograph separated by a dam. One section acted as the control 
receiving 10 nM PA12 alone, while the other received PA12 combined with 100 nM 
chymostatin, or preconditioned for 10 min with 100 µM captopril prior to the addition 
of 10 nM PA12 (both antagonists obtained from Sigma-Aldrich, St. Louis, MI, USA). 
Running the vessels in pairs enabled simultaneous recording of the effect of the 
antagonist against its parallel control vessel. This process was repeated for each 
different vessel type. The doses of antagonists applied were based on a previous 
report in isolated rat hearts (Prosser et al. 2009). 
 
9.2.3  PA12 peptide stability 
In order to determine the stability of PA12 within the rat buffer bath maintained at 37 
ºC over the duration of the time period, samples were taken at time 0 (immediately 
after adding PA12 to the bath), and again at 25 min from the same bath. The bath was 
maintained under the standardized conditions listed above, but held no vessel. 
Samples were subjected to Reverse Phase-High Pressure Liquid Chromatography 
(RP-HPLC) using the same C18 column and under the same elution gradient (0-60% 
CH3CN over 60 min). UV profiles were obtained to determine peptide degradation.   
 
9.2.4  Statistical analysis 
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All data are presented as mean +S.E.M. Analysis of changes in vessel tone were 
performed on SPSS using a two-way ANOVA with repeated measures, with 
Bonferroni’s multiple comparison test, post hoc. Individual data point comparisons 
were made using a Student’s T-test. In all statistical tests a value of P<0.05 was 
considered significant. 
 
 
9.3   Results 
 
9.3.1  Effect of PA12 on vessels throughout the rat arterial system 
PA12 potently constricted 5 of the 7 vessels measured (Figure 9.1), the most potent 
response observed in the left (n=7) and right (n=10) common carotid arteries, 
increasing tension by 174.5 ± 27.6 (P=0.004) and 181.7 ± 16.8 % (P=0.002) 
respectively. The descending thoracic aorta (n=10), mesenteric (n=10) and abdominal 
aorta (n=9) all responded positively to PA12, significantly elevating tension by 128.1 
± 6.4 (P=0.003), 118.9 ± 15.0 (P=0.049) and 115.0 ± 7.6 % (P=0.003) respectively. 
The renal (n=6) and femoral (n=7) arteries exhibited no significant response to PA12 
or AngII (both P>0.05), although the renal artery displayed minor constriction 
towards the end of the time period while the femoral exhibited minor dilation (Figures 
9.1F & G). 
 
9.3.2  Comparison with angiotensin II 
AngII significantly constricted the same 5 vessels as PA12 (all P<0.05), and similarly 
had no significant effect on Fem or Ren arteries (P>0.05, Figure 9.1). 
Compared with PA12, AngII elicited less vasoconstriction when administered to the 
RCCA, LCCA, and AbA, although did not significantly differ (P>0.05). The DTA 
and Mes arteries responded equally to both PA12 and AngII indicating approximately 
equal potency (Figure 9.1). 
 
PA12 constricted the RCCA, LCCA, DTA, AbA, Mes and Ren 90.9, 88.4, 62.5, 15.7, 
13.2 and 2.9 % of 120 mM KCl-induced constriction respectively (Figure 9.2). AngII 
elicited a similar pattern of response to PA12, although displayed slightly reduced 
potency in some vessels (Figure 9.2). AngII stimulated greater constriction of the 
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renal artery compared with PA12, and AngII stimulated minor constriction of the 
femoral artery, while PA12 caused minor dilation (Figure 9.1G & 9.2). 
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9.3.3  Antagonist Studies 
Preconditioning the vessels with 100 µM captopril significantly inhibited PA12-
induced constriction in all 5 vessels significantly responsive to PA12 (all P<0.05 vs 
PA12 alone), and abolished the minor PA12-induced vasoconstriction observed in the 
renal artery (Figure 9.3). The addition of 100 nM chymostatin to 10 nM PA12 also 
significantly inhibited PA12-induced vasoconstriction in 4 of the 5 vessel types 
significantly responsive to PA12, but with lower potency; and it abolished the minor 
PA12-induced constriction of the renal artery (Figure 9.3F). There was evidence of 
inhibition of PA12-induced vasoconstriction of the DTA by chymostatin, but this was 
not significant (P=0.674) (Figure 9.3A). 
 
Of note, chymostatin and captopril both attenuated the minor vasodilation observed in 
the femoral artery in response to PA12 (Figure 9.3G). However, this was not 
statistically significant as the femoral artery’s response to PA12 alone was not 
significantly different from vehicle levels (P>0.05). 
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Figure 9.1 PA12 and AngII potently constricted the rat vessels: descending thoracic 
aorta (A), right and left common carotid arteries (B and C respectively), abdominal 
aorta (D) and mesenteric artery (E). Both PA12 and AngII had no significant effect 
on the renal (F) or femoral arteries (G). Using two-way ANOVA with repeated 
measures: *P<0.05, **P<0.005 compared to control. 
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Comparing the two antagonists, captopril exhibited greater inhibitive potency than 
chymostatin in attenuating PA12-induced activity in all vessels tested and this was 
most pronounced in the DTA (Figure 9.3A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.3.4  PA12 Peptide Stability 
Samples obtained from a vessel-free bath infused with 10 nM PA12 at times 0 and 25 
min were subjected to RP-HPLC. The resulting UV profile displayed equal peak 
heights from both samples (Figure 9.4) indicating PA12 was stable within the rat 
buffer at 37 ºC throughout the experimental time period. 
 
 
Figure 9.2 The vasoconstrctive potency of PA12 and AngII 
represented as a % of maximal KCl-induced constriction in each 
vessel. A potency gradient is clearly apparent based on the vessels’ 
proximity to the heart for both PA12 and AngII.  
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9.4.   Discussion 
 
PA12 caused potent, significant vasoconstriction in 5 of the 7 vessels obtained from 
the rat arterial system. The vessels with closest proximity to the heart displayed the 
greatest response to PA12, while potency was reduced and eventually lost in vessels 
further from the heart. Thus, a potency gradient was observed in response to PA12 
with the order of greatest response to the least responsive being: 
RCCA>LCCA>DTA>Mes>AbA>Ren>Fem. AngII displayed a similar gradient of 
response as PA12, suggesting both peptides have primary roles within the central 
arteries immediately surrounding the heart, with less influence on peripheral arteries. 
To our knowledge, no one study has reported the effects of AngII on isolated vessels 
from localised points throughout the arterial system.  
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Figure 9.3. The effect of the ACE1 and chymase inhibitors captopril (100 µM) and 
chymostatin (100 nM) on PA12-induced vasoconstriction in the DTA (A), RCCA 
(B), LCCA (C), AbA (D) Mes (E), Ren (F) and Fem (G) arteries. Using a two-way 
ANOVA with repeated measures *P<0.05, **P<0.005 compared to 10 nM PA12 
alone. 
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UV profile of PA12 at 25 min
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Figure 9.4. UV profile of PA12 in rat buffer at 0 min (A), and after incubation at 37 
ºC for 25 min (B). Each sample was subjected to Reverse Phase-High Pressure 
Liquid Chromatography (RP-HPLC) using the same C18 column and under the same 
elution gradient (0-60% CH3CN over 60 min). Arrow indicates PA12 standard 
previously undergone RP-HPLC under the same conditions.
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However, compiling the current literature it is apparent AngII causes marked 
vasoconstriction of many arteries including those observed in the current study 
(Fisher et al. 1968; Gillespie and Rae 1972; Urabe M 1987; Chiba and Tsukada 1989; 
Merkel et al. 1990; Prins et al. 1992; Caputo et al. 1995). Interestingly, the effect of 
AngII on the femoral artery has been reported as both constrictive and dilative (Li and 
Zimmerman 1990), dependent upon the prostaglandins stimulated (Satoh et al. 1984; 
Yoshida et al. 1991). This provides possible explanation into why no constrictive 
effects were observed in response to.PA12 or AngII in the current study, and explains 
the minor reduction in tension observed in response to PA12 in the femoral artery. 
Whether AngII or PA12 stimulation of prostaglandins within the femoral artery is 
dependent upon the peptide warrants further research. Both chymostatin and captopril 
attenuated the minor PA12-induced vasodilation of the femoral artery, suggesting that 
ACE1 and chymase mediate this response. The renal artery exhibited no significant 
response to PA12 or AngII, although it did display minor vasoconstriction towards the 
end of the time period. Previous reports have all indicated AngII constricts the renal 
artery (Fisher et al. 1968; Cavarape et al. 2003; Zhong et al. 2007), although some 
have reported that there is a minor and short-lasting constriction in response to AngII 
(Lupu et al. 1968). 
 
The pattern of response to PA12 over the course of the time period following the 
bolus infusion was found to be similar in each vessel. PA12 caused immediate 
constriction rising to its maximum within 5-10 min. Maximal tension was retained for 
5-10 min then fell steadily over the course of the remaining recorded time frame. The 
gradient of both constriction and loss of tension was found to be somewhat vessel-
dependent. For example, PA12 caused rapid constriction of the Mes artery, reaching 
its maximum tension at 5 min before losing 73% of PA12-induced constriction over 
the following 20 min (Figure 9.1E); compared with RCCA which took longer to reach 
maximal constriction (at 10 min) but lost just 38% of its initial constriction over the 
remaining 15 min (Figure 9.1B). The response to AngII was parallel to that of PA12 
in all vessels observed, mirroring the rise and fall in tension. The vessel-dependent 
pattern in response to PA12 and AngII may be indicative of slight variations in the 
physiological role of each vessel, the distributive pattern of AT1R, and/or the 
composition of the vessel wall. This may afford a level of autonomy of vessels, 
despite central control.  
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The drop in constriction over the course of the time period following the bolus 
infusion could be indicative of the peptide becoming degraded in the solution over 
time. However, this theory was tested and disregarded as samples taken at time 0 and 
25 min from a water bath infused with 10 nM PA12 under the same standardised 
conditions found PA12 to be stable over the time period. This indicates the effect of 
PA12 and AngII are relatively short lasting, revealing the occurrence of 
tachyphylaxis, and possible loss of intracellular signalling. AngII has been previously 
reported to provoke tachyphylaxis (Aboulafia et al. 1989), suggested to be mediated 
by reductions in intracellular PLC/PKC/IP3 activity as well as reduced surface 
receptor availability (Pfeilschifter 1988; Ullian and Linas 1990; Feng et al. 1998). It 
was for this reason that vessels were exposed to only a single concentration of 
agonist. 
 
Our previous report (Prosser et al. 2009) observing PA12 activity in the isolated rat 
heart concurs with the current findings, where PA12 elicits potent constriction in the 
coronary arteries. Studies discovering the enzyme mediating PA12 activity and the 
conversion of PA12 to AngII have given mixed results, with one report indicating 
ACE1 is responsible for PA12 activity in vivo and ex vivo (Nagata et al. 2006), whilst 
our own research reported PA12 to be chymase-dependent ex vivo and in vitro 
(Prosser et al. 2009). The current study found inhibition of ACE1 and chymase 
attenuated constriction in vessels significantly responsive to PA12. Captopril was 
found to significantly reduce PA12 activity in all 5 vessels significantly responsive to 
PA12, while chymostatin significantly inhibited PA12 activity in 4 of the vessels, but 
only showed a non-significant inhibition of PA12 activity in the DTA. ACE1 
inhibition elicited slightly greater potency in attenuating PA12-induced constriction in 
all arteries tested, suggesting ACE1 possesses greater potency than chymase in 
controlling PA12 activity within the circulation. However, it must be noted that the 
concentration of captopril was 1000x greater than that of chymostatin, and had equal 
doses of the 2 antagonists been applied chymostatin may have become equally, or 
more, potent than captopril.  
 
Our results concur with previous reports indicating PA12 activity is mediated by both 
ACE1 and chymase activity. This would explain the ACE1-dependent results 
observed by Nagata et al. (2006) in live rats and aortic strips (Nagata et al. 2006). The 
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current report supports the ACE1-dependent activity of PA12 in the vascular system, 
and adds to it by reporting that inhibition of chymase also significantly reduces PA12 
activity throughout the rat arterial system. This is in line with our previously reported 
hypothesis, where combining the literature and our own studies, it appears ACE1 is 
the enzyme primarily responsible for AngII-generation in the circulation, while 
chymase may be the dominant AngII-producing enzyme within other tissues including 
the heart (Urata et al. 1996; Prosser et al. 2009). The tissue-based AngII-generating 
system is yet to be fully understood, however it is becoming increasingly evident that 
AngII-generation can occur within the tissue independent of the circulation. Brain, 
kidney, heart and vascular tissue all contain angiotensinogen, renin and ACE1 as well 
as their respective mRNAs, providing all the necessary agents required to produce 
AngII locally (Danser and Schalekamp 1996; Bader and Ganten 2008). Speculation 
has occurred as to the existence of tissue-based renin and renin mRNA, however it 
has been reported that renin can be released from mast cells, and cathepsin-D is also 
capable of converting angiotensinogen to AngI (Katwa et al. 1996; Mackins et al. 
2006). PA12 may represent another important agent within the tissue-based RAS, 
generating ACE1-independent AngII formation within cardiac tissue and potentially 
other organs as PA12 expression is vastly greater than that of AngI within the tissue 
of many central organs (Nagata et al. 2006). Taken together, these results, and those 
of our prior report (Prosser et al. 2009) indicate alternative mechanisms of angiotensin 
II synthesis within the cardiac tissue and arterial system exist and reinforce the need 
for novel therapeutic agents to block the tissue-based, ACE1-independent renin-
angiotensin system.  
 
It was hypothesized that the mesenteric artery should be highly responsive to PA12, 
and that chymostatin would abolish its activity. This hypothesis was based upon the 
report that the rat small intestine expressed the greatest amount of PA12 (Nagata et al. 
2006), as well as high levels of chymotrypsin, a potent analogue of chymase (Bacani 
and Frishman 2006). We found that the mesenteric artery was highly responsive to 
PA12, and AngII was similarly potent, but the proportional change in tension was less 
than in carotid arteries.  Our hypothesis was supported by the fact that chymostatin 
showed greater inhibition of PA12-induced vasoconstriction in the mesenteric artery 
than in any other artery tested. However, captopril displayed equal inhibitive potency, 
although was 1000 fold greater in concentration than chymostatin. This suggests 
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PA12 cleavage is not dependent upon chymase availability in the mesenteric artery as 
ACE1 can mediate PA12 activity.  
 
Based on these results and our previous report, chymase is beginning to emerge as a 
potentially important enzyme in the local, tissue-based RAS within the heart as well 
as in the vasculature. PA12 was found to be chymase-dependent within the isolated 
rat heart with ACE1 inhibition having little effect on PA12 activity (Prosser et al. 
2009). Within the circulation both ACE1 and chymase were shown to both be capable 
of mediating PA12 activity, with inhibition of ACE1 displaying slightly greater 
inhibitive potency. This was most evident in the DTA of our current report. The 
notion that the PA12-chymase pathway may be primarily involved in tissue-based, 
local AngII-generation is supported by the findings of Nagata et al. (2006) that PA12 
expression was significantly higher than that of AngI in the tissue of many organs 
throughout the rat, however AngI expression was greater than PA12 in the aorta and 
circulation (Nagata et al. 2006).  
 
It must be noted that the chymase inhibitor employed in the current study, 
chymostatin, is a non-specific chymotryptic inhibitor capable also of inhibiting 
cathepsin-G, an enzyme known to convert AngI to AngII (Owen and Campbell 1998; 
Belova 2000; Rykl et al. 2006). Therefore, it cannot be ruled out that cathepsin G is 
the active enzyme mediating PA12 activity, nor can we positively conclude whether 
PA12 itself can bind and activate AT1R or whether it first must be cleaved into AngII 
or other angiotensin fragments capable of activating the receptor. Thus, future studies 
employing more specific enzyme inhibitors are required to reveal which enzymes are 
primarily responsible for converting PA12 to AngII, and structure-activity studies are 
needed to observe whether PA12 can bind and activate the AT1 receptor directly.  
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10. Intracellular pathways stimulated in 
response to proangiotensin-12 (PA12) 
 
Abstract 
 
PA12 is a newly identified peptide within the renin-angiotensin system (RAS), 
recently reported to provide an alternate substrate for generation of angiotensin II 
(AngII) within the rat heart, and stimulate, either directly or indirectly, potent 
vasoconstrictor activity. PA12 expression has recently been reported to be elevated in 
spontaneously hypertensive rats, indicating a potential pathological effect, confirmed 
in a study reporting PA12 to promote and augment ischemic injury in the rat heart. 
The current study furthers exploration into PA12-induced activity by determining the 
intracellular proteins stimulated in response to PA12. Langendorff isolated rat hearts 
were infused with PA12 or angiotensin I (AngI) with or without antagonists for 
angiotensin-converting enzyme 1 (ACE1), chymase, or the angiotensin II type 1 
(AT1) receptor. Left ventricular heart tissue was removed and subjected to western 
blotting to determine the phosphorylation, and hence activation, of specific cytokines. 
PA12 and AngI caused phosphorylation of four cytokines: c-Jun N-terminal kinase 
(JNK), extracellular-regulated kinase p42/44 (ERK1/2), mitogen-activated protein 
kinase p38 (p38), and protein kinase C α/βII (PKCα/βII); but had no effect on PKC 
isoforms δ/θ. PA12-induced cytokine activity was mediated by the AT1 receptor. 
PA12-induced phosphorylation of JNK and PKCα/βII were found to be chymase-
dependent, while ERK1/2 was both chymase- and ACE1-dependent. Inhibition of 
chymase and ACE1 did not attenuate PA12-induced phosphorylation of p38. AngI-
induced phosphorylation of the cytokines was found to be dependent upon ACE1 
availability in all kinases investigated with the exception of JNK. That PA12 induced 
activation of these cytokines suggests PA12 stimulates cellular growth and 
differentiation, hypertrophy, apoptosis, inflammation and vasoconstriction within the 
cardiovascular system. The RAS is known for its potent pathological role in 
progressing vascular disease and hypertension, mediated by the AT1 receptor. This 
report is the first to reveal that PA12 acts through the AT1R stimulating pathways 
known to augment cardiovascular disease, however in contrast to AngI, PA12 activity 
can be independent of ACE1. 
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10.1  Introduction 
 
The renin-angiotensin system (RAS) has evolved to elevate blood pressure, 
maintaining it within homeostatic levels via a means of humoral and mechanical 
mechanisms. Since the initial discovery of renin in 1898 (Phillips and Schmidt-Ott 
1999), research into the RAS exploded to uncover a seemingly simple, linear cascade 
of enzymatic activity cleaving a primary peptide (angiotensinogen) into an inactive 
secondary (angiotensin I) and highly active tertiary peptide (angiotensin II), 
circulating within the blood. AngII produces a broad range of effects throughout the 
mammalian body including arteriolar vasoconstriction, stimulation of aldosterone 
secretion, increased tubular reabsorption of Na+ and Cl- while excreting K+ which 
increases water retention, and elicits the release of antidiuretic hormone (ADH) from 
the pituitary, which stimulates further water absorption at the kidneys, as well as 
reducing glomular filtration rate (Robertson and Nicholls 1993). However, with the 
recent discovery of a new enzyme, angiotensin-converting enzyme 2 (ACE2) 
(Crackower et al. 2002), and the identification and isolation of another potential 
product of angiotensinogen, proangiotensin-12 (PA12) (Nagata et al. 2006), it appears 
the RAS is not a simple linear process as once thought.  
 
We recently reported the physiological effects of PA12 in the isolated rat heart and 
showed that PA12 was converted to AngII during cardiac passage (Prosser et al. 
2009). Chymase was the enzyme found to be primarily responsible for mediating 
PA12 activity, as well as mediating the conversion of PA12 to AngII both in vitro and 
ex vivo; while angiotensin-converting enzyme 1 (ACE1) had little influence (Prosser 
et al. 2009). However, other reports have suggested PA12 activity is also ACE1-
dependent in the live rat and in strips of rat aorta (Nagata et al. 2006; Trask et al. 
2008).  The physiological effects of PA12 are reported to be mediated by the 
angiotensin II Type 1 receptor (AT1R), with blockade of this receptor abolishing 
PA12 activity (Prosser et al. 2009). 
 
In this report we further our study into the actions of PA12, observing the intracellular 
proteins activated in response to PA12 within the rat left ventricle. Additionally, we 
explore the effects of specific enzyme inhibitors and receptor blockade on PA12- or 
AngI-induced intracellular protein activity of the 3 classic mitogen-activated protein 
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kinase (MAPK) pathways: c-Jun NH2-terminal kinase (JNK), MAPK p38 (p38) and 
extracellular-regulated kinase p44/42 (ERK1/2), as well as different isoforms of 
protein kinase C (PKC).  
 
 
10.2  Methods 
 
10.2.1   Materials 
Male Sprague-Dawley (SD) rats weighing 270-400g (60-75 days old) were obtained 
from the Christchurch School of Medicine, Christchurch, New Zealand. Rats were 
housed under controlled temperature (21 ºC), humidity (~40%) and natural day length 
with free access to standard rat chow and water. 
 
Synthetic rat PA12 was obtained from Phoenix Pharmaceuticals (Belmont, CA, 
USA), while AngI and the ACE1 antagonist Captopril, as well as the chymase 
inhibitor Chymostatin were all obtained from Sigma-Aldrich (St Louis, MI, USA).  
The angiotensin II receptor type 1 (AT1R) blocker, CV-11974 (Candesartan, 2-
ethoxy-1-[[2’-(1H-tetorazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-
carboxylic acid) was a generous gift from Takeda Chemical Industries Ltd (Osaka, 
Japan). PA12, AngI and captopril were diluted in distilled water, aliquoted, and stored 
at -20 ºC prior to use. Chymostatin was diluted in DMSO, while CV-11974 was 
dissolved in 1 M Na2CO3 solution, aliquoted, and stored at -20 ºC prior to use. 
 
10.2.2  Langendorff isolated rat heart perfusion 
Isolated rat heart perfusion was performed as previously described (Pemberton et al. 
2000; Prosser et al. 2009). Briefly, rats were anesthetized with sodium pentobarbital 
(50 mg/kg, i.p.). The heart was rapidly excised and mounted on the Langendorff 
apparatus, cannulated above the aortic valve and perfused at 12 ml/min (constant 
retrograde flow) with perfusion buffer comprising (mmol/L): 123 NaCl, 22.0 
NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.1 MgSO4·7H2O, 1.5 CaCl2·2H2O and 11.0 glucose 
(final pH 7.40). Buffer was maintained at 37 ºC and oxygenated with 95% O2/5% 
CO2. Hearts were allowed to settle for 30 min before being paced at 320 bpm using an 
electrode placed on the right atrium and attached to a Digimeter DS2A-Mk. II 
stimulator. Hearts were allowed a further 30 min to resettle before any experimental 
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protocol was started; see Appendix B.1 for supplementary information and methods. 
Drugs were diluted using perfusion buffer to enable infusion of the drug or vehicle 
over 30 min at 0.5 ml/min using a syringe pump feeding directly into the perfusion 
line above the heart. This investigation was approved by the University of Otago 
Animal Ethics committee. 
 
10.2.3  Heart Infusion Protocol 
All antagonist agents (100 µmol/L captopril, 100 nmol/L CV-11974, 100 nmol/L 
chymostatin, and 100 µmol/L and Ramipril) were co-infused with either 10 nmol/L 
PA12 or 10 nmol/L angiotensin I (AngI). Experiments were run in pairs: one heart 
infused with both the antagonist and PA12 or AngI, the other simultaneously infused 
only with PA12 or AngI from the same stock solution and same buffer reservoir. The 
heart given the antagonist was chosen at random. 
 
The concentrations of 10 nmol/L PA12, 100 µmol/L captopril and 100 µM ramipril 
were based on prior dose-response studies (see Figure 8.2A and Appendix C, Figures 
C.2 and C.3, respectively). 100 nmol/L CV-11974 and 100 nmol/L chymostatin were 
administered based upon manufacturers’ recommendations. The dose of 10 nmol/L 
AngI was chosen to provide a cirect comparison with PA12. 
 
10.2.4  Western Blotting 
10.2.4.1 Tissue preparation and cellular protein extraction 
Upon completion of the 30 min infusion rat hearts were rapidly removed from the 
perfusion apparatus and a section of the left ventricular free wall was obtained, 
wrapped in aluminum foil, snap frozen in liquid nitrogen and stored at -80 ºC.  
 
When required, frozen heart tissue was combined with 2 ml cell lysis buffer 
comprising: Tris (pH 8.0) 10 mM, EDTA (pH 8.0) 1 mM, NaCl 150 mM, IGEPAL 
CA-630 0.5%, Na3VO4 1 mM, and inhibitor cocktail 1 µg/ml, (all obtained from 
Sigma, St. Louis, MI, USA). The tissue was homogenized in the lysis buffer (using an 
IKA-Ultra Turrax T25, Janke & Kunkel Labortchnik) then incubated on ice for 30 
min before being centrifuged at 15,000 rpm for 5 min at 4ºC. The cytosolic 
supernatant was removed and stored at -80 ºC. Measurement of viable protein 
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concentration was performed using Bradford’s protein assay (Refer Appendix A for 
Bradford’s protein assay methods).  
10.2.4.2 Gel Electrophoresis 
Gels and protein samples were prepared as previously described (Sambrook et al. 
1989) (refer Appendix A). The proteins to be determined in the current report were 
between 42 and 82 kD requiring an acrylamide concentration of 10 % (Sambrook et 
al. 1989). Using 2 BioRad mini-gels a total of 20 wells were available per run. Protein 
samples comprising 35% protein, laemmli dye and Tris-buffered saline (TBS) were 
loaded into each well having been incubated at 95 °C for 8 min, and underwent 
electrophoresis at 100V for 2 hours at room temperature using a BioRad PowerPac-
200. 
 
Protein transfer onto nitrocellulose membranes was then accomplished using a 
BioRad PowerPac-200 run at 80V for 1.5 hrs at 4 °C. Membranes were checked for 
protein staining using Ponceau S dye before being rinsed in TBS + 1% Tween 
(TBST) and incubated in 4% milk solution for 1 hour at room temperature using a 
plate mixer.  
 
10.2.4.3 Antibody Incubation 
The primary antibodies specific for phosphorylated: ERK1/2 (p-ERK1/2), SAPK/JNK 
(p-JNK), p38 (p-p38), PKCα/βII (p-PKCα/βII), and PKCδ/θ (p-PKCδ/θ) were all 
obtained from Cell Signal Technologies Inc, MA, USA. All primary antibodies were 
diluted 1:1000, with the exception of β-actin which was diluted at 1:1500 Ab:TBST. 
Membranes were left to incubate overnight using a platform mixer at 4 ºC. 
 
Membranes were repeatedly rinsed prior to being incubated with secondary antibody 
(horseradish peroxidase (HRP)–linked anti-rabbit IgG (Cell Signaling Technology, 
USA), diluted 1:2000 in TBST for 2 hours at room temperature using a platform 
mixer. 
 
10.2.4.4 Protein Detection 
Detection solution was made from scratch combining Luminol, p-courmic acid and 
H2O2 in 100 mM Tris-HCl solution (refer Appendix A). Membranes were bathed in 
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detection solution, blotted dry and exposed to x-ray film (Kodak BioMax XAR) or 1-
10 minutes. The film was moved directly into an Autotank automatic x-ray film 
processor (Fischer Industries Inc., Geneva, IL, USA). 
 
The density of the protein bands were quantified using Bio-Rad Quantity One 
software (Bio-Rad laboratories, Hercules, USA), and reported as intensity / mm2. β-
actin was used as an internal control in all incubations 
 
10.2.5  Statistical Analysis 
All data are presented as mean + S.E.M. Original data were log10-transformed to 
‘normalize’ the data, enabling a paired Student’s t-test to be performed comparing 
protein expression of each kinase between the different treatment groups. In all 
statistical tests a value of P<0.05 was considered significant; n=3 for all treatments. 
 
 
10.3  Results 
 
10.3.1 Effect of PA12, AngI and specific enzyme antagonists on cytokine 
phosphorylation 
 
ERK1/2: Phosphorylated ERK1/2 (p-ERK1/2) expression was significantly elevated 
in LV heart tissue infused with PA12 and AngI (P<0.05 vs vehicle, Figure 10.1). Co-
infusion of the enzyme inhibitors captopril and Chymostatin significantly attenuated 
the PA12- and AngI-induced phosphorylation of ERK1/2 (all P<0.05 vs PA12 and 
AngI respectively, Figure 10.1).  
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g
Figure 10.1. The effect of PA12 and AngI with or without specific inhibitors 
upon phosphorylated ERK1/2 (p-ERK1/2) is evident in the raw, developed 
film (B). Repeating the experiment in three rat hearts revealed p-ERK1/2 was 
elevated significantly in cardiomyocytes within the LV of rat hearts in 
response to infusions of PA12 or AngI (A). The enzyme antagonists captopril 
and Chymostatin significantly attenuated both PA12- and AngI-induced 
increases in p-ERK1/2 (A). CV-11974 also abolished PA12-induced p-ERK1/2 
expression.  
Data in (A) represented as fold change in p-ERK1/2 compared with vehicle, 
n=3. Using a student’s t-test P<0.05 for PA12 or AngI vs vehicle (#); P<0.05 
for PA12 or AngI vs PA12 or AngI + their respective antagonist (*). Western 
blott (B) displays 42/44kDa. 
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JNK: Phosphorylated JNK (p-JNK) expression was significantly elevated in response 
to infusion of PA12 or AngI when compared with vehicle (Figure 10.2). Chymostatin 
also reduced p-JNK expression, significantly attenuating PA12- and AngI-induced 
JNK phosphorylation (both P<0.02 vs PA12 and AngI respectively, Figure 10.2). 
However, reductions in both the PA12- and AngI-induced increases in p-JNK 
expression in the presence of captopril, did not reach significance (both P>0.05 vs 
PA12 and AngI respectively). 
           g
Figure 10.2 Phosphorylated JNK (p-JNK) expression in hearts infused with 
PA12 or AngI with or without specific antagonists. (B) represents an example of 
a raw film developed displaying p-JNK expression (46/54 kDa) in LV rat heart 
tissue from the different treatments in line with the bar graph above (A). PA12 
and AngI elevated p-JNK expression that was found to be chymase-dependent 
and mediated by the AT1 receptor. 
Data represented as fold change compared to vehicle; lines indicate significant 
differences between treatment groups using a student’s t-test (P<0.05, n=3).  
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p38:  PA12 and AngI significantly elevated phosphorylated p38 (p-p38) expression 
(Figure 10.3). The ACE1 inhibitor captopril significantly attenuated AngI-induced p-
p38 expression (P<0.05), but did not significantly inhibit PA12-induced p38 
phosphorylation (P>0.05). Co-infusion of chymostatin with PA12 and AngI had no 
inhibitive effect on attenuating p-p38 expression (Figure 10.3). 
         g
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Figure 10.3 Phosphorylated p38 (p-p38) expression in response to PA12 or 
AngI infusions with or without enzyme inhibitors or AT1R blockade. As 
clearly shown in the raw developed film displaying 43 kDa (B), PA12 and 
AngI increased p-p38 expression in the rat heart LV (A), which was found to 
be mediated by AT1R. Captopril significantly attenuated the AngI-induced 
increase in p-p38 expression but displayed no inhibitive effect on PA12. 
Chymostatin had no effect on either peptide’s activity. 
Data represented as mean + SEM (n=3), fold change in p-p38 expression 
compared with vehicle. Lines indicate significant differences between 
treatment groups using student’s t-test, P<0.05. 
B 
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PKCα/β: Phosphorylated PKCα/β (p-PKCα/β) expression was significantly elevated 
in response to infusion of PA12 or AngI in the LV of the rat heart (Figure 10.4). 
Captopril significantly attenuated the AngI-induced increase in p-PKCα/β (P<0.05), 
however had little influence on PA12 activity (P>0.05). Chymostatin had the opposite 
effect to captopril, significantly inhibiting the PA12-induced elevation in p-PKCα/β 
expression (P<0.05), while having little effect on AngI activity (P>0.05).  
       g 
Figure 10.4 Phosphorylated PKCα/βII expression (p-PKCα/βII) in response to 
PA12 or AngI with or without specific antagonists. As displayed in the raw 
developed film at 80-82 kDa (B), infusion of PA12 or AngI into isolated rat 
hearts stimulated an elevation in p-PKCα/βII expression. AngI-induced 
increase was attenuated with captopril, while the PA12-induced increase was 
attenuated with chymostatin or CV-11974, indicating PA12 and AngI were 
dependent upon chymase and ACE1 respectively in phosphorylating PKCα/βII 
(A). Data represented as fold change in p-PKCα/βII expression compared with 
vehicle (mean + SEM), n=3. Lines indicate significant differences between 
treatment groups using student’s t-test (P<0.05). 
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PKCδ/θ: Infusion of PA12 or AngI into rat hearts displayed no effect on altering 
PKCδ/θ phosphorylation (Figure 10.5). Addition of ACE1 and chymase inhibitors or 
AT1 receptor blockade with PA12 or AngI did not uncover any PA12- or AngI-
induced PKCδ/θ phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10.3.2  Effect of AT1 receptor blockade on cytokine phosphorylation 
 
Infusion of the AT1 receptor blocker, CV-11974 in combination with PA12 
significantly attenuated PA12-induced JNK, ERK1/2, p38 and PKCα/β 
phosphorylation (Figures 10.1 - 10.4), indicating the AT1 receptor mediated PA12 
phosphorylation of the intracellular proteins measured. CV-11974 did not reveal any 
effect of PA12 on PKCδ/θ phosphorylation (Figure 10.5). 
 
 
 
Figure 10.5. Developed film displaying phosphorylated 
PKCδ/θ expression from hearts treated with PA12 or AngI 
with or without antagonists. PA12 and AngI had no effect on 
PKCδ/θ phosphorylation. Co-infusion of captopril, 
chymostatin or CV-11974 had no effect on altering PA12- or 
AngI-induced p-PKCδ/θ expression. 
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10.4  Discussion 
 
Two reports now reveal PA12 can be converted to AngII by rat cardiac tissue (Trask 
et al. 2008; Prosser et al. 2009). This conversion is reported to be both ACE1- and 
chymase-dependent. However, Prosser et al. suggest chymase to be the primary 
enzyme responsible for mediating PA12 activity, including the conversion of PA12 to 
AngII, at least within localised rat cardiac tissue (Nagata et al. 2006; Prosser et al. 
2009). Whether PA12 itself can bind to the receptor or must initially be cleaved into 
smaller active peptides, including AngII, is yet to be established, however reports 
concur that PA12 activity is mediated by the AT1 receptor (Nagata et al. 2006; 
Prosser et al. 2009).  
 
The AT1R activates many intracellular pathways (Figure 10.6) stimulating 
serine/threonine kinases including PKC isoforms, as well as the classic 3 mitogen-
activated protein kinase (MAPK) pathways: JNK, p38, and ERK1/2 (Mehta and 
Griendling 2007). These pathways are known to regulate vasoconstriction, cellular 
growth, proliferation, migration and differentiation, inflammation and apoptosis, and 
hence are tightly regulated (Su and Karin 1996; Higuchi et al. 2007; Mehta and 
Griendling 2007). However, in patients with an overreactive RAS, or chronically 
elevated AngII, the above pathways can become overstimulated, inducing 
maladaptive, pathological cardiovascular remodelling and augmenting vascular 
diseases such as atherosclerosis, and progressing hypertension (Wen et al. 1997; 
Suzuki et al. 2005; Hunyady and Catt 2006; Otis and Gallo-Payet 2007).  
 
 
Figure 10.6. AngII binding to 
AT1R triggers the activation 
of many intracellular 
pathways. The downstream 
effector agents of these 
pathways stimulate cellular 
survival, growth, hypertrophy 
and contraction. Figure 
modified from Mehta and 
Griendling 2007. 
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The current report explored the intracellular pathways stimulated by PA12, recently 
identified as a component of the RAS, and proposed as a potential alternate substrate 
to AngI in the rat (Trask et al. 2008; Prosser et al. 2009). Western blotting was 
employed to determine the amount of phosphorylation, and hence level of activation, 
of each of the cytosolic proteins: p38, ERK1/2, JNK, and PKC isoforms α/βII and δ/θ.  
 
We found that infusion of PA12 or AngI into isolated rat hearts stimulated the 
phosphorylation of all 3 classic MAPK pathways: ERK1/2, JNK, and p38, as well as 
phosphorylating PKCα/βII in the left ventricle of the rat, indicating elevated activity 
of these cytokines. Increased activity of the same kinases in response to PA12 or AngI 
also supports the theory that PA12 can act as an alternate peptide to AngI in 
stimulating cardiac RAS activity. Furthermore, activation of the intracellular proteins 
responsive to PA12 were all found to be dependent upon AT1 receptor binding, 
supporting our previous report that the AT1 receptor mediates PA12-induced 
physiological effects within the rat heart (Prosser et al. 2009).  
 
 
10.4.1  PA12 activation of ERK1/2 
 
PA12 and AngI significantly elevated ERK1/2 phosphorylation, mediated by the AT1 
receptor. This is consistent with our prior report indicating PA12 to be AT1R-
dependent, and is in agreement with prior reports indicating AngI-derived AngII-
induced activation of the AT1R stimulates ERK1/2 (Mazak et al. 2004). ERK1/2 is 
widely reported as a stimulating pro-mitogenic, anti-apoptotic and vasoconstrictive 
intracellular pathways within cardiomyocytes (Baines and Molkentin 2005; Mehta 
and Griendling 2007). As previously reported, PA12 potently constricted rat coronary 
arteries and aortic strips (Nagata et al. 2006; Prosser et al. 2009). The current findings 
suggests this observed constriction may, at least in part, be mediated by PA12-
induced phosphorylation of ERK1/2. The constrictive effects of ERK1/2 are 
reportedly caused by ERK1/2-induced increases in Ca2+ availability within the cell 
(Touyz et al. 2001).  
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AT1R-induced ERK1/2 activity has also been reported to: inhibit apoptosis (Barki-
Harrington et al. 2003), promote cellular growth and protein synthesis (Rocic et al. 
2003), as well as stimulate cell differentiation and migration through activation of c-
Fos and c-Jun (Touyz 2004) (Figure 10.6); suggesting that PA12-induced ERK1/2 
activity may also stimulate these pro-mitogenic effects. Blockade of the AT1 receptor 
has been shown to significantly attenuate cardiovascular remodelling (van Eickels et 
al. 1999; Azuma et al. 2000; Tamura et al. 2000; Bai et al. 2004), while more specific 
inhibition of AngII-induced ERK1/2 activity attenuates maladaptive vascular 
remodelling in spontaneously hypertensive rats (Touyz et al. 2002). Taken together 
these studies indicate that inhibition of PA12 activity may also attenuate pathological 
cardiovascular remodeling.  
 
Inhibition of the proteolytic enzymes ACE1 and chymase effectively inhibited PA12-
induced ERK1/2 activity, either via attenuating the conversion of PA12 to its active, 
effector peptide(s), or through captopril or chymostatin stimulating intracellular 
proteins antagonising ERK1/2 activity. This is yet to be determined, however our 
findings do reveal that administering ACE1 or chymase inhibitors, or blocking the 
AT1 receptor, may significantly attenuate pathological effects stimulated by the 
PA12-ERK1/2 pathway. 
 
 
10.4.2  PA12 activation of JNK and p38 
 
MAPK p38 and JNK share many characteristics as both kinases are activated in 
response to cellular stress such as increased ROS expression within the cell (Ohtsu et 
al. 2005; Chen and Mehta 2006; Liu et al. 2008). JNK and p38 influence vascular 
remodeling, primarily promoting apoptosis and inflammation (Force et al. 1996; 
Ohtsu et al. 2005). AngII is known to stimulate ROS production (Griendling et al. 
1994) and stimulate JNK/p38 proteins (Mehta and Griendling 2007). In this report we 
observed the effect of PA12 on JNK and p38 activity. PA12 and AngI significantly 
elevated JNK and p38 phosphorylation indicating activation of these proteins and 
subsequent downstream JNK/p38-activated pathways. JNK has been reported to 
activate many pro-apoptotic effector proteins including bad, bim, bid, bmf, cyt-c and 
c-Jun, as well as stimulating PKCδ causing the activation of further cell-death 
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pathways (Baines and Molkentin 2005; Mehta and Griendling 2007). However, p38 
has been reported to possess protective mechanisms including attenuating apoptosis, 
enhancing cardiomyocyte survival (Kang et al. 2000), and stimulating downstream 
proteins Akt and heat shock protein 27 (HSP-27) which stabilizes intracellular 
proteins and stimulates protein synthesis (Stokoe et al. 1992; Taniyama et al. 2004). 
In contrast, JNK has been reported to phosphorylate just one potential cell survival 
protein, Bcl-2 (Fan et al. 2000) which is capable of stimulating both pro- and anti-
apoptotic effects (Chao and Korsmeyer 1998). p38 is also suggested to stimulate 
cyclooxygenase-2, activating inflammatory prostaglandins, causing vascular damage 
(Scheuren et al. 2002). Taken together PA12-induced activation of JNK and p38 
potentially stimulates pro-apoptotic, inflammatory factors promoting deleterious 
cellular effects and potentially progressing cardiovascular disease (Figure 10.7). 
AngII-induced activation of JNK is reported to progress CHF (Mehta and Griendling 
2007; Liu et al. 2008). However another study indicated activation of p38 negatively 
regulated AngII-induced ERK1/2 activity, supporting AT1R as a regulator of vascular 
remodelling (Kintscher et al. 2003) (Figure 10.7). In the diseased state stimulation of 
AT1R-induced pathways can become unbalanced and unregulated resulting in AT1R 
promoting pathogenesis, for example JNK activity is significantly elevated while 
ERK1/2 activity is unchanged in a rat model of hypertension (Vogel et al. 2001). 
 
 
10.4.3  PA12 activation of PKC  
 
There are 11 isoforms of PKC identified to date, grouped into three main groups 
based on their factors required for activation. The classical group containing α, βI, βII 
and γ require Ca2+ and diacylglycerol (DAG) for activation, while the novel isoforms 
δ, ε, η and θ require DAG alone. The third atypical PKC group does not require Ca2+ 
or DAG to stimulate their activity (Mellor and Parker 1998). The current report 
observed the effect of PA12 on stimulating two of the PKC groups: PKCα/βII and 
PKCδ/θ, which are reported to cause contrasting cellular effects as described below. 
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Prostaglandins 
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Figure 10.10.7. Schematic overview detailing the activity of the cyotosolic proteins 
observed in the current study. PA12-induced activation of the AT1R can stimulate 
cellular survival and growth (green pathways), inflammation (orange pathways), 
contraction (blue pathways) and cell death (red pathways), indicating the receptors 
broad regulatory influence on the vasculature. During the diseased state the AT1R 
can become overstimulated resulting in unregulated activation of these pathways 
causing maladaptive vascular remodeling, hypertension, and endothelial 
dysfunction; ultimately progressing atherosclerosis and cardiovascular disease. 
(PA12 did not phosphorylate PKCδ/θ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
g 
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PKCα/βII are reported to promote cell survival and stimulate vascular constriction 
(Cross et al. 2000; Mehta and Griendling 2007). PKCα/β-induced cell survival is 
promoted through inhibiting apoptosis (potentially via stimulation of Bcl-2 (Ito et al. 
1997; Ruvolo et al. 1998), as well as promoting cellular growth through activating the 
ERK1/2 pathway (Braz et al. 2002; Greco et al. 2003; Vijayan et al. 2004). However, 
PKCα expression is elevated in many cancers, indicating that chronic activation of 
PKCα can cause unregulated, pathological cellular growth (Lord and Pongracz 1995). 
Activation of PKC also stimulates sustained vasoconstriction, with AngII-induced 
PKC activity suggested to play a potential pathological role in the progression of 
hypertension and promote ROS production (Figure 10.6) (Baines et al. 1996; Touyz et 
al. 2001). In contrast, the PKC isoforms δ/θ are reported as pro-cell death, pro-
apoptotic isoforms in both cardiac and non-cardiac cells (Heidkamp et al. 2001; 
Brodie and Blumberg 2003), and progress cardiac injury during times of stress. For 
example, PKCδ was reported to exacerbate ischemic injury in rat cardiomyocytes, 
while inhibition of PKCδ attenuated the injury (Chen et al. 2001). PKCδ/θ’s pro-
apoptotic effects are suggested to be stimulated through activation of downstream 
kinases including JNK and p38, as well as activating caspase-3 (Heidkamp et al. 
2001). One report indicated caspase-3 can also activate PKCδ, potentially providing a 
positive feedback loop for PKCδ-induced apoptosis (Datta et al. 1997; Basu and 
Akkaraju 1999) (Figure 10.7).  
 
Results from the current study support previous reports indicating that activation of 
the AT1 receptor stimulates PKCα/β activation (Higuchi et al. 2007; Mehta and 
Griendling 2007) as PA12 and AngI significantly elevated p-PKCα/βII expression, 
which was abolished by the AT1R blocker CV-11974. PA12 and AngI displayed no 
effect on phosphorylating PKCδ/θ, suggesting PA12 and AngI stimulate PKC 
isoforms promoting cellular growth and inhibiting apoptosis. PA12-induced activation 
of PKCα/βII also conforms with the physiological response to PA12 as a potent 
chymase-dependent, ACE1-independent vasoconstrictor (Prosser et al. 2009), as PKC 
is known to stimulate Ca2+-dependent vasoconstriction (Mehta and Griendling 2007). 
The response to the enzyme inhibitors employed in the current report also correlate 
with the vasoconstrictive activity of PA12 previously reported; indicating that AngI is 
dependent upon ACE1 availability, while PA12 is chymase-dependent, with ACE1 
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having little influence on PA12’s constrictive potency (Prosser et al. 2009), or 
PKCα/βII activation as evidenced in the current study.  
 
Chymase-dependent PA12-induced PKCα/β stimulation may also develop a positive 
feedback system if unregulated, as both the RAS and chymase are reported to be 
elevated during times of vascular stress, promoting hypertension and the resultant 
vascular diseases (Shiota et al. 1993; Shiota et al. 1997; Takai et al. 1997a; Takai et 
al. 1998; Guo et al. 2001; Ju et al. 2001). Combining these findings with reports 
indicating PKC increases mast cell number and can trigger mast cell degranulation 
(Peng and Beaven 2005; Palaniyandi et al. 2008) suggests PA12 may be involved in 
initiating a positive feedback mechanism within the cardiovasculature, progressing 
pathological remodeling and cardiac dysfunction.  
 
It must be noted that the chymase inhibitor used in the current study, chymostatin 
obtained from Sigma Aldrich (St Louis, MI, USA), is a non-specific chymotryptic 
inhibitor, capable of inhibiting chymases as well as cathepsin-G. It would be of 
interest to employ inhibitors with greater specificity in future studies, in order to 
reveal whether chymase or cathepsin-G is the primary enzyme in converting PA12 to 
AngII in rat cardiac tissue.  
 
Inhibition of the RAS is commonly used to ameliorate hypertension and inhibit 
pathological vascular remodelling through the use of ACE1, renin and/or AT1R 
antagonists (Yang et al. 1996; Kim et al. 1998; Al Khalaf et al. 2009). The current 
report indicates that PA12 is an active component of the RAS and the PA12-chymase 
pathway may potentially provide an alternate therapeutic target in ameliorating RAS 
activity, and thus attenuate RAS-induced cardiovascular disease.  
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10.4.4   Summary 
 
In summary, PA12 and AngI were found to stimulate ERK1/2, JNK, p38 and 
PKCα/βII phosphorylation. These MAPKs are known to regulate cellular growth, 
apoptosis, cell differentiation, hypertrophy, inflammation and muscle contraction. Our 
results concur with our previous report observing the physiological effects of these 
peptides on the isolated rat heart (Prosser et al. 2009). PA12-induced stimulation of 
the intracellular cytokines JNK, ERK1/2 and PKCα/βII were found to be dependent 
upon chymase, while ERK1/2 was the only intracellular kinase to be inhibited by 
captopril when co-infused with PA12, significantly attenuating the PA12-induced 
increase in p-ERK1/2. All PA12-induced cytokine activity was found to be mediated 
by the AT1 receptor, indicating PA12 can potentially stimulate both pro-apoptotic, 
cell death pathways (p38 and JNK), as well as anti-apoptotic, cell survival, 
hypertrophic pathways (ERK1/2, p38 and PKCα/βII) as displayed in Figure 10.7. The 
RAS is known for its pathological role in progressing vascular disease and 
hypertension, mediated by the AT1 receptor. This report is the first to reveal that 
PA12 acts through the AT1R, stimulating pathways known to augment cardiovascular 
disease, but differs from AngI in that its activity is suggested to be independent of 
ACE1. 
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11. Concluding Summary and Discussion 
 
 
There have been few reports determining the hemodynamic and humoral functions of 
URP and PA12 within the cardiovasculature, while studies observing the function of 
UII have reported highly contradictory findings. All three peptides are low molecular 
weight proteins, with wide tissue expression, including the cardiovascular system, and 
are reported to be elevated in patients suffering cardiovascular disease, indicating a 
potential pathological role in the mammalian cardiovascular system. It is, therefore, of 
importance to define the role of these three peptides within the mammalian 
cardiovascular system in both the healthy and diseased states in order to enable 
therapeutic manipulation of their effects, be they pathogenic or beneficial. The current 
thesis approached this task in a logical, methodical manner, with experiments building 
upon previous ones to produce a solid foundation for continuing investigations into 
the role and effects of UII, URP and PA12 in the cardiovascular system, as well as 
reveal some of the mechanisms regulating their responses.  
 
Initial studies identified UII to be highly species specific (while the URP sequence is 
the same across all known species), as non-native species-forms of UII either severely 
attenuated, or stimulated opposite effects when compared to application of its native 
form. This specificity was evident in both salmon and rat coronary arteries, indicating 
that species-dependence was conserved over evolution. The results from this study 
also provided some explanation into the contrasting results reported in response to 
UII, as commonly the species form of UII administered was not native to the animal 
subject. UII and URP were found to stimulate potent vasodilation within the rat and 
salmon coronary vasculature, in contrast to many reports suggesting UII to be a potent 
vasoconstrictor. The essential difference being that the current study used UII native 
to the appropriate species (i.e. administering rat UII into the rat, and salmon UII into 
salmon), providing the same vasodilatory effect in both species, indicating UII’s 
form-function to be highly conserved. UII/URP-induced nitric oxide production and 
and elevated cyclooxygenase activity were suggested to mediate the vascular response 
to UII and URP, stimulating relaxation of VSMCs.  
 
 154
 
Infusion of PA12 to rat hearts caused potent, sustained vasoconstriction of the 
coronary arteries but had little influence on altering left ventricular contractile 
parameters. This study was the first to report the direct effects of PA12 on an isolated 
mammalian heart, and its effects were shown to be similar to that of angiotensin I 
(AngI), although displaying reduced potency. As the amino acid sequence of PA12 is 
AngI-Leu11-Tyr12-C’ the vasoconstrictive effects, although novel and important to 
report, were not surprising. Again as with AngI, PA12 activity was shown to be 
mediated by the AT1 receptor. The enzyme mediating AngI activity is primarily 
ACE1 (Robertson and Nicholls 1993), but inhibition of ACE1 failed to attenuate 
PA12-induced vasoactivity, while significantly attenuating AngI-induced 
vasoconstriction. The enzyme found to be responsible in mediating PA12 activity was 
chymase, a carboxypeptidase capable of cleaving angiotensin peptides into smaller 
active and/or inactive fragments.  
 
Chymase is contained with mast cells and displays high species-specificity, with rat 
chymase initially reported only to degrade angiotensins into inactive fragments. 
However, with the identification of a novel chymase isoform within rat VSMCs, it 
was evident that chymase could, in fact, convert AngI to the potent, effector peptide 
AngII. We found that chymase mediates PA12 activity in the rat heart and was 
responsible for converting PA12 to AngII both in vitro and within rat cardiac tissue. 
These studies have opened up a potentially novel, alternate pathway within the RAS, 
independent of both AngI and ACE1. This new PA12-chymase pathway is an 
important discovery as it a) presents a novel AngII-generating pathway within the 
cardiac tissue, and b) may provide an alternate target in reducing RAS activity, 
helping to ameliorate hypertension, atherosclerosis, and other cardiovascular diseases 
of which the RAS is implicated.  
 
As UII, URP and PA12 are elevated in patients suffering cardiovascular diseases and 
in spontaneously hypertensive rats (Douglas et al. 2002; Richards et al. 2002; Lapp et 
al. 2004; Jessup et al. 2008; Mori et al. 2009), it was necessary to investigate the role 
of UII, URP and PA12 in a model of heart disease. Using a rat heart model of 
ischemia-reperfusion, UII, URP and PA12 were administered prior to ischemia, in 
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order to simulate patients expressing elevated circulating levels of these peptides prior 
to an ischemic event.  
 
UII and URP were both found to significantly alleviate ischemic injury during 
reperfusion, dilating the coronary arteries, reducing the release of biomarkers of 
myocardial damage, and reducing ANP release. Only UII had mild negative inotropic 
effects, potentially reducing cardiac energy requirements following ischemia. A 
further study simulating administering UII or URP to a patient following a cardiac 
ischemic event indicated that despite endothelial damage sustained during ischemia, 
UII and URP maintained their vasodilative, cardioprotective effects. These studies 
suggest that patients with elevated circulating UII levels should have a better outcome 
following ischemia, a finding supported by some reports (Khan et al. 2006; Zoccali et 
al. 2006), with contrasting studies indicating beneficial effects of UII receptor 
blockade (Tzanidis et al. 2001; Tzanidis et al. 2003; Bousette et al. 2006a; Bousette et 
al. 2006b). The current thesis examined blockade of the UII receptor in a model of 
ischemia-reperfusion employing the UII receptor blocker Palosuran. We reported that 
Palosuran itself acted as a mild agonist of the UII receptor, suggesting that not only is 
UII species specific, but receptor differences between species may also alter ligand 
binding, activation and the resultant effects. This was previously reported for another 
UII receptor blocker, SB-710411, in monkeys and rats where it antagonised UII-
induced activity at the rat UII receptor, but functioned as an agonist at the monkey UII 
receptor (Behm et al. 2004). This indicates that a) synthetically manufactured receptor 
blockers may need to be designed for each individual species, and b) the use of these 
UII receptor blocking agents employed in studies observing UII’s pathogenic effects 
may, in fact, be reporting false results due to the receptor blocker itself stimulating 
activity. 
 
In contrast to UII and URP, infusion of PA12 prior to ischemia worsened recovery 
during reperfusion, causing greater myocardial damage and constricting the coronary 
arteries. As observed in healthy hearts, PA12 activity was mediated by chymase 
activity, with inhibition of ACE1 having no influence. This finding is of great 
importance as currently millions of hypertensive patients as well as others suffering 
from the detrimental effects of an overactive RAS are administered ACE1 inhibiting 
drugs. However, it is noted by cardiologists that ACE1 inhibition may not be 
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sufficient in alleviating hypertension, while causing adverse side effects in some 
patients (Yusuf et al. 2008; Sealey and Laragh 2009), and thus a ‘perfect treatment’ in 
reducing RAS activity is yet to be established. The chymase-activated PA12 pathway 
provides a novel target in alleviating RAS activity, as inhibition of chymase has been 
reported to prevent cardiac fibrosis and dysfunction in rats and dogs (Matsumoto et al. 
2003; Kanemitsu et al. 2005), and to significantly attenuate pathological cardiac 
remodelling, aiding myocardial function in a rat model of hypertension-induced heart 
failure (Palaniyandi et al. 2008).  
  
However, the findings obtained from observing the effect of PA12 on the rat arterial 
system suggests that ACE1 can also alter PA12 activity within the circulation. PA12 
activity was found to be both ACE1 and chymase-dependent, with inhibition of ACE1 
attenuating PA12-induced vasoconstriction with greater potency than chymase. This 
suggests that ACE1 may be primarily responsible for mediating PA12 (and AngI) 
activity within the circulation, while chymase plays a greater role in tissue-based, 
local RAS activity, including regulating PA12-derived generation of AngII.  
 
To further explore the pathways stimulated by PA12, western blotting was employed 
to ascertain whether the 3 classical MAPK pathways (ERK1/2, JNK and p38), as well 
as PKC isoforms were activated. PA12-induced effects are suggested to be entirely 
mediated through the AT1 receptor. The intracellular pathways stimulated by the AT1 
receptor are well defined, providing the basis to suggest that PA12 may also stimulate 
these same cytosolic pathways. Indeed analysis of heart tissue infused with PA12 
revealed that PA12 stimulated ERK1/2, p38, JNK and PKC activity, as in AngI-
infused heart tissue. These pathways are known regulators of cellular proliferation, 
growth, differentiation, apoptosis, inflammation and vasoconstriction (Mehta and 
Griendling 2007). Therefore, it could be postulated that PA12 induces pro-mitogenic, 
pro-apoptotic, hypertrophic, constrictive and inflammatory effects. The PA12-
chymase pathway may provide an alternate target in inhibiting RAS activity and 
attenuate hypertension, atherosclerosis and other cardiovascular diseases promoted by 
the RAS. 
 
The contrasting effects of UII and PA12 also suggests that in vivo UII and PA12 may 
be antagonistic. For example, UII stimulation of PGE2 activity has been shown to 
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attenuate AngII-induced oxidative stress, and inhibit hypertension (Jia et al. 2008). 
Furthermore, AngII is reported to decrease NO synthase expression, limiting UII-
induced NO production (Ramseyer and Garvin 2008). Due to the intracellular 
pathways activated by UII and AngII, there are possible circumstances where UII and 
AngII may work in additive, or synergistic ways, rather than opposing each other’s 
actions. These pathways and their effects require defining, specifically with regard to 
the development and progression of cardiovascular disease.  
 
The current thesis has provided much needed information extending the knowledge of 
the UII/URP and PA12 systems, and has provided key reasons explaining the large 
amount of discrepancy in the literature concerning the cardioprotective versus 
pathological effects of UII. In our hands UII and URP were found to provide 
significant cardioprotection following ischemia provided the native form was 
administered. In contrast, PA12 was found to augment ischemic injury and cause 
further myocardial injury. The key finding that PA12 elicits its effects independent of 
ACE1, and rather, is dependent upon the presence of chymase in cardiac tissue 
illustrates a potentially new target for alleviating RAS-induced hypertension at the 
local, tissue level, and may provide some explanation into the reason why ACE1 
inhibitor therapy loses potency over time. Therefore, the current thesis provides a 
solid foundation for further intracellular, molecular and in vivo work to be performed 
on both stimulating UII/URP production and inhibiting PA12 activity in order to 
provide cardioprotection for at risk patients and attenuate cardiovascular disease.  
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APPENDIX A 
 
WESTERN BLOTTING PROTOCOL 
 
 
A.1  Bradford’s protein assay  
A stock solution of Bradford reagent was made by dissolving 0.2 g Coomassie 
Brilliant Blue G-250 (BDH Laboratories, England) into 200 ml 85% (w/v) phosphoric 
acid and mixing the dye until completely dissolved. The solution was then made up to 
1 litre with distilled water, and filtered through 0.45µM filter paper (Lewis 1998). 
 
Bovine Serum Albumin (BSA) was made to 1 mg/ml with distilled water and 0.1% 
sodium azide added. 2 ml distilled water was pipetted into each tube and the 
appropriate measure of BSA pipetted into its correlate tube to produce known protein 
concentrations of 0.5, 1, 1.5, 2, 2.5, 4, 6 and 8 µg/µL. 10µL of ‘unknown’ cytosolic 
samples were added to their correlate labelled tubes. Two tubes had no protein added 
to provide blank controls. 2 ml Bradford’s reagent was then added to all tubes, which 
were vortexed and allowed to incubate for 5 min at room temperature.  
 
The spectrophotometer (Helios Epsilon visible spectrometer, Thermo Spectronic, 
Cambridge, UK) was allowed to warm to running temperature and stabilize before 
being programmed to read the single absorbance wavelength of 595 nm.  
 
Aliquots of each tube were placed into quartz cuvettes for precise measurement within 
the spectrophotometer. The spectrophotometer was zeroed using the two blank tubes 
prior to measuring the standards and samples. 
 
A.2  Calculation of results 
The protein concentration of the known BSA standards were plotted against their 
measured absorbance to produce a standard curve. Using the regression equation of 
the standard curve, the samples containing unknown concentrations of viable protein 
were calculated. 
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A.3  Gel Electrophoresis 
 
1. Prior to beginning gel electrophoresis stock solutions were prepared/obtained 
as follows: 
 
Separating buffer (4x): 1.5 M Tris (90.8 g / 500 ml ddH2O) 
    0.4 % SDS (2.0 g / 500 ml ddH2O) 
    pH adjusted to 8.8 
 
Stacking buffer (1x):  0.139 M Tris (8.4 g / 500 ml ddH2O) 
    0.11 % SDS (0.55 g / 500 ml ddH2O) 
    pH adjusted to 6.8 
 
Acrylamide solution: Purchased from Sigma as ready-made 29:1 
acrylamide:Bisacrylamide solution 
 
AMPS (10%): Freshly prepared each time with 
Ammoniumperoxidisulphate (AMPS) diluted in ddH2O 
 
TEMED: N’-N’-N’-N’-Tetramethylethylenediamine purchased 
from Sigma as ready-made solution 
 
Laemmli dye (1x):  50 mM Tris·Cl (pH 6.8) 
    100 mM dithiothreitol 
    2 % SDS 
    0.1 % bromophenol blue 
    10 % glycerol 
 
Running buffer (10x):  144 g glycine 
    30 g Tris 
    10 g SDS 
    Make up to 1L ddH2O, pH 8.3 
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% Gel 10 % 
dd H2O 6.25 ml
Separating gel buffer 3.75 ml
Acrylamide solution (1:29) 5.0 ml 
10% AMPS 75 µl 
TEMED 7.5 µl 
 
 
2. The glass plates were clamped into their vice and separating gel poured 
between them. 1 cm of isopropanol was poured on top of the gel to ensure the 
gel set with a level surface. The gel polymerized after 30-60 min enabling the 
isopropanol to be poured off and the gel rinsed with ddH2O several times prior 
to adding the stacking gel.  
 The percentage of acrylamide used was based on the weight of the proteins to 
 be determined. The proteins to be determined in the current report were 
 between 42 and 82 kD requiring an acrylamide concentration of 10 % 
 (Sambrook et al. 1989). 
 
Gel Size 2x BioRad Minigels, 0.75 mm thick 
Stacking gel buffer 4.25 ml 
Acrylamide solution 0.75 ml 
10 % AMPS 25 µl 
TEMED 2.5 µl 
 
 
3. The stacking gel (see Table 10.2 for ingredients) was added on top of the 
separating gel and combs inserted with their tips 2 mm above the separating 
gel layer. It was ensured that no air bubbles were present anywhere within the 
gel. 
 
 
 
 
Stacking gel 
composition 
sufficient for 2 
BioRad Minigels 
Seperating gel ingredients 
comprising 10% acrylamide 
solution 
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A.4 Loading protein samples 
4. Using 2 BioRad minigels a total of 20 wells could be loaded per run. Thus, 
20x 1 ml centrifuge vials were numbered and a total of 17 µL protein solution 
was added to each, comprising 4 µL Laemmli dye, 35 µg protein sample, and 
the difference made up to 17 µL with Tris-buffered solution (TBS), 
comprising 2.42 g Tris-HCl + 8.0 g NaCl dissolved in 1 L ddH2O (pH 7.6).  
 
5. Once all agents were added each vial was centrifuged for 1 min at 5000 rpm, 
vortexed, and incubated at 95 ºC for 8 min before being placed on ice and 
centrifuged for 3 min at 5000 rpm ensuring all liquid was collected at the 
bottom of each vial. Two vials of 17 µL of protein marker (purchased from 
Cell Signal Technology) also underwent the same process. All samples were 
then loaded into the wells under the ‘wet condition’ with the running buffer 
submerging the wells prior to loading.  
 
6. Gel electrophoresis was conducted at a constant 100 V for 2 hours at room 
temperature until the dye reached the bottom of the plates. 
 
 
A.5  Protein transfer and staining 
 
Transfer buffer (1x):  14.4 g glycine 
  3.0 g Tris 
    200 ml 100% methanol 
    Made up to 1L with ddH2O 
 
Ponceau S dye (10x):  0.2 g Ponceau S (Sigma) 
    3.0 g Trichloroacetic acid 
    3.0 g Sulfosalicylic acid 
    Made up to 10 ml with dd H2O 
 
TBST (1x): Dissolve 2.42 g Tris-HCl + 8.0 g NaCl into 800 ml 
ddH2O and pH at 7.6. Make up to 1 L with ddH2O and 
gradually add 1 ml Tween-20 under constant stirring. 
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7. The transfer ‘sandwich’ was prepared as detailed below: 
 
 Positive electrode (+) 
****************************  **  Sponge 
------------------------------------------  ---  Whatman paper 
      Nitrocellulose membrane 
=========================  ==  Gel membrane 
------------------------------------------   
****************************   
 Negative electrode (-) 
 
All layers were maintained submerged in transfer buffer prior to use. 
 
8. Protein transfer was achieved using a BioRad PowerPac-200 at a constant 80V 
for 1.5 hours at 4 ºC. 
 
9. The nitrocellulose membrane was removed and placed into a bath of Ponceau 
S dye (1x) where the transferred protein bands appeared under gentle 
agitation. Ponceau S was salvaged and the membrane was then rinsed 
repeatedly in TBST until the run-off became clear and no dye was present on 
the membrane. The membranes were then incubated in 4 % skim milk in 
TBST for 1 hour at room temperature using a plate mixer.  
 
A.6  Antibody incubation 
10. Following the milk blocking incubation, membranes were incubated in 
primary antibody diluted in TBST. The primary antibodies specific for 
phosphorylated: ERK1/2 (p-ERK1/2), SAPK/JNK (p-JNK), p38 (p-p38), 
PKCα/βII (p-PKCα/βII), and PKCδ/θ (p-PKCδ/θ) were used (all obtained from 
Cell Signal Technologies Inc, MA, USA). All primary antibodies were diluted 
1:1000, with the exception of β-actin which was diluted at 1:1500 Ab:TBST. 
The membranes were left to incubate overnight using a platform mixer at 4 ºC. 
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11. The next day, membranes were washed 3 times (5-10 min per wash) with 
TBST using a platform mixer. 
 
12. The membranes were then incubated with secondary antibody (anti-rabbit IgG, 
horse radish peroxidase (HRP) –linked antibody, (Cell Signaling Technology, 
USA) diluted in TBST alone (1:2000). The membrane was incubated with the 
secondary Ab for 1-2 hours at room temperature using a platform mixer. 
 
13. The membranes were then washed as above - 3 times in TBST for 5-10 min 
each wash. 
 
 
A.7  Protein Detection System 
Homemade detection solution was made immediately prior to use, comprising of 
stock chemiluminescence solution combined with H2O2 in a 1:1 ratio. 
 
Chemiluminescence Solution:  100 µL 250 mM Luminol (in DMSO) 
44 µL 90 mM p-coumaric acid (in DMSO) 
10 ml 100 mM Tris-HCl, pH 8.5 
 
Oxidation solution:   6.1 µL of 30 % H2O2  
10 ml 100 mM Tris-HCl, pH 8.5 
 
14. The membranes were bathed in the detection solution for 5-10 min, ensuring 
the protein-primary antibody-secondary antibody-HRP-bound surface was 
facing upwards, and that the solution completely covered the membrane. The 
membranes were removed and placed on glass plates within a film cassette 
and carefully blotted dry. Plastic wrap was placed over the membranes and all 
bubbles trapped between the layers removed using clean tissues. 
 
15. In a dark room under red light only, Kodak BioMax XAR film was cut to 
shape and placed over the plastic wrap-covered membranes, and sealed within 
the film cassette. The film was left for the appropriate amount of time 
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depending upon the primary Ab being measured, and the effectiveness of the 
detection solution (30 sec - 15 min). 
 
16. Again under red light, the cassette was opened and the film moved directly 
into an Autotank automatic x-ray film processor (Fischer Industries Inc., 
Geneva, IL, USA), developing the visible bands where the HRP-linked 
antibodies were present. 
 
17. The density of the protein bands were quantified using Bio-Rad Quantity One 
software (Bio-Rad laboratories, Hercules, USA), and reported as intensity 
(INT) / mm2. β-actin was used as an internal control in all incubations to 
ensure gel electrophoresis and antibody incubation were successful. 
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APPENDIX B 
 
THE LANGENDORFF ISOLATED, PERFUSED HEART APPARATUS AND THE 
MULVANY MYOGRAPH. 
 
 
B.1  The Langendorff isolated rat heart system 
 
The Langendorff isolated perfused heart technique is described in detail by Sutherland 
& Hearse (Sutherland and Hearse 2000; Hearse and Sutherland 2000). In order to 
measure the specific cardiac effects of new peptides or drugs, including their potential 
role in cardiovascular disease, experimental animal models are required. These 
models must balance their reproducibility and quality of data with its representation of 
the natural in vivo setting and clinical relevance of the model. The Langendorff 
isolated, perfused heart model provides a good compromise to this balance, showing 
good reproducibility, providing physiological, biochemical and pharmacological 
characteristics to be measured and recorded easily (Figures B.1 and B.2). The 
apparatus delivers perfusate either under ‘constant flow’ or ‘constant pressure,’ 
depending upon the requirements for the experiment. Constant flow delivers perfusate 
to the heart at a rate controlled by the researcher and this flow does not alter despite 
the heart undergoing hemodynamic changes. This is the method the current thesis 
employed (Figure B.1). Constant pressure requires a more complex system whereby 
perfusate flow is adjusted accordingly to maintain constant pressure within the heart. 
The perfusate expelled from the heart is easily collected into vials containing 
aprotinin and triton-X for analysis of specific factors at a later date. It must be noted 
that this model is constantly deteriorating as it has been removed from the body and 
this must be taken into consideration, especially for longer experiments. Once 
attached to the Langendorff apparatus, the hearts can also be manipulated to simulate 
cardiac dysfunction, most commonly ischemia, as it is simple to induce. Ischemia can 
be initiated either globally by halting perfusion through the heart (as conducted in 
Chapters 5 and 6 of the current thesis), or locally by surgical ligation of an artery. 
These techniques combined with easy infusion of any desired agents enable simple 
and quick measure of their role in heart disease and dysfunction. 
 214
 
 
 
Figure B.1. Two constant flow Langendorff isolated heart systems side by side 
feeding from the same perfusion solution (A), maintained at 37°C by a water heater 
within a water bath (B). The two perfusion lines feeding from the buffer reservoir are 
attached to individual peristaltic pumps (C) before trailing into waterbaths containing 
the isolated rat hearts (D). Cardiac parameters are recorded via pressure transducers 
supplying data to an ADInstrumants powerlab (E) that conveys the data to Chart 5 
software on a single PC in real time (F). Lamps are placed in from of the hearts to 
maintain them at 37°C (G) and stimulators (H) maintain a constant heart rate via 
pacing electrodes. The constant flow system provides a single pass of perfusing 
solution through the heart with the perfusate collected (I) and either discarded or held 
for further analysis. Syringe pumps (J) provide a method of infusing drugs or agents 
at a specific rate over time. 
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Figure B.2. The isolated, perfused rat heart. The heart is perfused with modified 
Krebs buffer through the perfusion line (A) in a single pass system with perfusate 
collected after passing through the heart (B). Heart rate is maintained at a constant 
rate using a pacing electrode (C), while coronary artery pressure is measured using a 
cannula inserted into the perfusion line (D), which is attached to a pressure 
transducer. Left ventricular contractility is determined through the insertion of an 
ethanol-filled balloon (E) attached to a pressure transducer. Infusion of agents is 
achieved by inserting a line directly into the perfusion line above the heart (F). 
 
 
B.2  The Mulvany myograph 
 
The Langendorff isolated, perfused heart system provided an ideal method for 
determining the role of UII, URP, PA12, and their respective antagonists on the rat 
heart as it provided a measure of both coronary artery activity and LV contractility. 
However, in order to provide a comparative measure of the vascular effects of UII and 
URP between salmon and rat hearts, myography had to be employed as attaching a 
salmon heart to the Langendorff system does not provide a measure of coronary artery 
E 
D 
F A 
B 
C 
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activity. The Mulvany myograph technique also enabled direct measurement of drug 
effects on specific vessels isolated from throughout the rat (Figure B.3). 
The Mulvany myograph technique provides a measure of vessel activity via an 
increase or decrease in tension in response to infusion of vasoactive agents. Vessels 
are removed from the animal, stored in ice-cold buffer, before being cut transversely 
to 2 mm lengths when required. Two wires are threaded through the lumen of the 
artery before each wire is attached to opposing jaws within a bath of solution specific 
for the vessel type, fastening the vessel between the two jaws. This bath is maintained 
at the temperature required via a simple flow-through water system pumped from a 
separate waterbath maintained at the desired temperature. The jaws are spread apart 
using micromanipulators, stretching the vessel to provide some tension as it would 
have experienced was it still within the live animal. Vessels are then allowed at least 1 
hour to settle to their resting tension. Each myograph bath can hold two vessels and a 
dam can be placed between the two, enabling vessels to be run in pairs providing a 
direct control for drug effects. A lid is placed over the bath, maintining the bath at 
temperature and enabling the bath to be gassed with 95% O2 / 5% CO2. Agents are 
administered directly into the bath where diffusion occurs rapidly and drug effects are 
recorded on Chart 4 software via an ADInstruments powerlab. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.3. Schematic 
representation of the two vessels 
held between the two sets of 
jaws (grey) within the bath of 
the myograph. The vessel (red) 
is held between the jaws by 
wires (green) fastened to screws 
(open circles). The two vessels 
can be divided by a dam (striped 
bar) enabling the effects of drug 
and control to be measured 
simultaneously.  
The top vessel is fully attached 
and stretched to achieve a resting 
level of activity. The lower 
vessel has only one wire 
attached, with the other threaded 
through the lumen. 
 217
 
 
 
F A CE
G D 
Figure B.4. The Mulvany myograph system. Vessels are held within a 10 ml bath of Krebs 
buffer (A) (see Figure B.3. for enlargement of the bath). Vessels are stretched or relaxed 
using micromanipulators (B), and the bath is maintained at the desired temperature using a 
flow-through recirculating water system (C) sourced from a water bath (out of view). 
Vessels are attached to the jaws under a dissection microscope (D) and changes in vessel 
tension are recorded via the myograph data interpretor (E) and amplified using a Powerlab 
(F) before being viewed and recorded on Chart 4 software (G). 
B
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APPENDIX C 
 
GRAPHS OMITTED FROM PUBLISHED PAPERS 
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Figure C.1. The effect of URP, native (rUII) and non-native UII on left 
ventricular contractility (DP) in the isolated, perfused rat heart. UII or URP 
had no significant effect on DP compared with vehicle (P>0.05). Grey bar 
indicates infusion period. 
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Figure C.2. Dose response of the ACE1 antagonist captopril on PA12-
induced elevation in PP of the isolated, perfused rat heart. Captopril was 
infused alone for an initial 10 min (solid black bar) before 10 nM PA12 was 
co-infused for a following 30 min (thatched bar). Captopril had no significant 
effect on altering PA12-induced activity at any dose administered. 
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Figure C.3. The ACE1 inhibitor ramipril infused alone for 10 min (solid 
black bar) reduced PP but had no effect on altering PA12-induced activity on 
PP in the isolated, perfused rat heart when 10 nM PA12 and 10 µM Ramipril 
were co-infused for 30 min (thatched bar). 
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APPENDIX D 
 
MEASUREMENT OF ANGII AND ANP 
 
 
D.1  Angiotensin II 
 
Perfusate samples collected after passing through the heart were analysed for 
immunoreactive AngII (IR-AngII). 1 ml of each perfusate sample was passed through 
individual Bond Elut columns containing carbon18 cartridges. Protein bound to the 
columns was eluted using 100 % ethanol and collected into glass tubes containing 500 
IU Aprotinin/0.1% Triton X-100. Samples were dreid down under air held in a 
waterbath maintained at 37°C. Dried samples were reconstituted with 2 ml AngII-
specific buffer, thus diluting each sample 2 fold.  
100 µL of each sample was subjected to RIA in duplicates. The AngII assay was an 
in-house assay with a sensitivity of 1.4 pmol/L; interassay variability of 11.5%, and 
an intra-assay variability of 4.8%. 
 
 
D.2  Rat ANP 
 
 Perfusate samples collected after passing through the heart were analysed for 
immunoreactive rat ANP (IR-ANP). 10 ml of each perfusate sample was passed 
through individual SepPak columns containing carbon18 cartridges. Protein bound to 
the columns was eluted and collected into plastic tubes containing 0.1% Triton X-100. 
Samples were dreid down under air held in a waterbath maintained at 37°C. Dried 
samples were reconstituted with 1 ml K+-buffer, thus concentrating each sample 10 
fold.  
50 µL of each sample was subjected to RIA in duplicates. The rat ANP assay was an 
in-house assay with a sensitivity of 1.2 pmol/L; interassay variability of 6.8%, and an 
intra-assay variability of 3.6%. 
 
 
